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 This dissertation contributes to the literature on arsenic and health, 
identifying four areas for specific investigation.  Chapter 1 addresses arsenic in 
the environment examining its impact on public health in high and low exposure 
populations.  Chapter 2 examines possibilities for ameliorating the toxicity of 
arsenic in real world contexts. This chapter is published in the Journal Toxics 
(doi:10.3390/toxics5040038). Chapter 3 investigates the association between 
metabolic syndrome and arsenic methylation capacity in a low exposure 
population, showing a positive association between methylation capacity and 
metabolic syndrome in a sample drawn from the U.S. National Health and 
Nutrition Examination Survey (NHANES) population. This chapter is under 
preparation for journal submission.  Chapter 4 experimentally assesses the 
differential toxicity of trivalent inorganic arsenic (iAs(III)) and the metabolite 
trivalent monomethylarsonous acid (MMA(III)) in vascular smooth muscle cells, 
and our data show increased toxicity of MMA(III) relative to iAs(III) in VSMCs 
with mitochondrial dysfunction as a central component of toxicity.  This chapter 
is published in the journal Toxicology in Vitro 









(https://doi.org/10.1016/j.tiv.2016.06.006). Chapter 5 provides a summary, 
conclusions, and recommendations for future research. 
 Methodologically, this dissertation is composed of a review and synthesis 
of published data, a secondary data analysis from an epidemiology perspective, 
and an original study of experimental data.  Each chapter addresses gaps in the 
current literature pertaining to various aspects of arsenic and cardiovascular 
disease. The dissertation as a whole contributes to our understanding of a 
significant and ubiquitous environmental toxin. 
 This research is important and innovative because it applies diverse 
methodologies to study arsenic and cardiovascular disease. The selected 
methodologies are relevant in the fields of environmental science and 
epidemiology.  This research has implications for millions of individuals exposed 
to arsenic through contaminated ground water around the world as well as 
among select arsenic-exposed populations in the U.S., and provides the 
foundation for future exploration of the selective toxicity of arsenic and its 
metabolites to mitochondria, the relevance of arsenic methylation capacity as a 
risk factor for the health effects of arsenic, and a framework for developing 









antioxidant solutions to the global problem of arsenic induced cardiovascular 
toxicity.   
 In chapter 2 we reviewed 25 studies that assessed the effects of non-
enzymatic antioxidants against arsenic exposed mitochondria and/or 
cardiovascular cells and tissues. We report that arsenic impairs all aspects of 
mitochondrial function and mitigates apoptosis by elevating reactive oxygen 
species (ROS). The antioxidants presented in this review largely prevented 
arsenic-induced pathology in vivo and in vitro. Compared to arsenic treatment 
alone, co-treatment with phytonutrient antioxidants restored cardiac function, 
reduced ROS levels, restored antioxidant activities, reduced apoptosis, reduced 
calcium overload, restored ATP content, and restored the activity of 
mitochondrial complexes. We suggest that future studies directly compare 
antioxidant compounds against arsenic-induced cardiovascular dysfunction, and 
we encourage the development of mitochonrially targeted antioxidant 
nanoformulations to improve antioxidant bioavailability.  
 In chapter 3 we report a positive association between increased arsenic 
methylation and metabolic syndrome in women with normal BMI, and among 
obese women after controlling for statistically significant and literature justified 









covariates. Our data suggest that gender and BMI modify the association 
between arsenic methylation and metabolic syndrome. Additionally, we report 
that arsenic methylation patterns in our sample are similar to reports of 
methylation capacity in populations with significantly higher arsenic exposure. 
Based on these results, we suggest that future studies evaluate the effectiveness 
of the current maximum contaminant level (MCL) for arsenic on preclinical 
biomarkers for cardiovascular disease in a model that establishes causality.  
In chapter 4 we demonstrate increased toxicity of the arsenic metabolite 
MMA(III) relative to iAs(III) in VSMCs.  We report for the first time that 
MMA(III) promotes mitochondrial dysfunction and oxidative stress in VSMCs, 
and that these deficits stem from the generation of mitochondrial and non-
mitochondrial ROS following exposure to MMA(III). This work warrants future 
studies that probe for molecular mechanisms by which MMA(III) selectively 
targets mitochondria and elicits the release of superoxide in VSMCs. 
 The results from chapter 4 (increased toxicity of methylated arsenic 
species) support our results from chapter 3, in which we demonstrate that 
increased arsenic methylation is associated with increased odds of metabolic 
syndrome, presumably due to the elevated presence of toxic methylated species 









that result from increased arsenic methylation. Data from chapters 3 and 4 
support the premise that increased arsenic methylation increases the 
concentrations of toxic methylated arsenic species in the body, resulting in 
increased rates of ROS production, and contributing to disease status. Our results 
from chapter 2 (antioxidant amelioration of arsenic-induced cardiovascular 
dysfunction) provide recommendations for future research on the prevention of 
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Chapter 1. Arsenic: geographical distribution and health implications 
i. Arsenic in the environment 
 Arsenic is a metalloid with possible oxidation states -3, 0, +3 and +5, 
primarily found as inorganic arsenite (iAs(III)) in reducing conditions and 
inorganic arsenate (iAs(V)) under oxygenated conditions. Inorganic arsenic 
compounds can be trivalent (arsenic trioxide, arsenic trichloride, sodium 
arsenite, and arsenic disulfide) or pentavalent (arsenate and arsenic pentoxide) 
(Figure 1). In nature, arsenic primarily occurs in sulfide form complexed with 
one of over 200 mineral species [1].  
 
Figure 1. Trivalent and pentavalent arsenic species 
i.i. Arsenic in Groundwater 
 The release of arsenic to groundwater varies as a function of the 





surrounding area. Geologic formations that contain arsenic include sulfide 
minerals, iron oxides, felsic volcanic rock, and shale [2]. These formations can 
release arsenic to groundwater in the presence of elevated pH, oxic or sulfidic 
redox conditions, naturally occurring or applied phosphate, and geothermal 
waters [2]. Catalyzing bacteria and intense evaporative conditions can further 
concentrate arsenic in groundwater sources [2]. 
 Human activities such as mining, phosphate fertilizer application, and 
improper disposal of arsenical waste can increase regional arsenic 
concentrations. Perhaps the largest anthropogenic impact on arsenic availability 
occurs through the mismanagement of water resources. Global water demands 
continue to rise in proportion to growing populations, resulting in decreased 
surface water supplies and a growing dependence on groundwater [3]. As 
shallow aquifers are tapped beyond replacement levels, arsenic concentrates in 
groundwater basins. Attempts to tap deeper aquifers can result in drawdown in 
which arsenic infiltrates previously uncontaminated groundwater [4].  
 
i.ii. Global distribution 
 There are many past and present instances of arsenic exposure throughout 





within the range of 200 to 300 ppb, and has been documented in excess of 1,000 
ppb, continuing to expose about 50 million residents [5]. Water in Antofagasta, 
Chile containing 470 to 770 ppb of arsenic was supplied from the Andes 
Mountains via the Tocance River from 1959 to 1970, exposing 130,000 inhabitants 
until a water treatment plant was installed [1]. The Cordoba Provence in 
northern Argentina has reported water ranging from 100-3,810 ppb arsenic 
resulting from volcanic conditions and thermal springs [6]. Other notable 
instances of arsenic exposure have occurred in Taiwan, Japan, West Bengal, 
Mexico, and various regions of the Western United States [7].  
 
i.iii. United States 
 Pockets of arsenic-endemic groundwater are present throughout the 
United States (U.S.). Although inorganic arsenic levels are regulated in municipal 
waters by the U.S. Environmental Protection Agency (U.S. EPA) at 10 parts per 
billion (ppb), exposure to higher concentrations of arsenic still occur among U.S. 
populations reliant on well water. For example, a survey of 102 homes using 
domestic wells in rural areas of Nevada found an average of 356 ppb arsenic pre-
treatment and 87 ppb arsenic following reverse osmosis treatment [8], and 





reservation lands in Arizona [9]. Additionally, researchers found that a 
population of 250 was drinking well water containing between 180 and 210 ppb 
inorganic arsenic in Millard County, Utah [10], and residents of Lane County, 
Oregon consumed well water that ranged from 5 to 1,700 ppb arsenic due to 
underlying sedimentary and volcanic rock [11].  
 
ii. Health effects of arsenic 
ii.i. Arsenic bioavailability and metabolism 
 Bioavailability refers to the percentage of the external dose that is 
absorbed and reaches systemic circulation. Studies conducted on human 
volunteer subjects reveal that between 80% and 90% of a single dose of ingested 
arsenite or arsenate is absorbed by the human GI tract [12-14]. However, arsenic 
absorption varies at the individual level and is affected by the presence of food, 
stomach acidity, and GI tract flora [15-17].  
 Ingested arsenic enters circulation, travels to organs and tissues, and 
accumulates in the kidneys, liver, hair, skin, and nails [18,19]. Inorganic arsenic is 
reduced from arsenic (V) to arsenic (III) in blood plasma and arsenic 
methyltransferase enzymes in the liver mediate the methylation process with S-





sequentially added to inorganic arsenic species forming the organic arsenic 
species monomethyarsonous acid (MMA) and dimethylarsonous acid (DMA) 
(Figure 2). 
  Arsenic methylation capacity can be measured as the proportion of 
methylated arsenicals in urine or as a ratio of MMA:iAs (termed primary 
methylation index or PMI) and ratio of DMA:MMA (termed secondary 
methylation index or SMI). Average relative distribution of urine metabolites is 
10-30% inorganic arsenic, 10-20% MMA, and 60-80% DMA [20]. However, urine 
arsenic distribution varies somewhat as a function of genetic polymorphisms 
controlling methyltransferases [21].  
 Arsenic methylation facilitates urinary excretion, yet it also increases the 
bioavailability of toxic methylated arsenicals [22-27]. Indeed, arsenic (III) species 
are more toxic than arsenic (V) species, and the metabolites MMA(III) and 
DMA(III) have been shown to be 26 and 100 times more toxic to certain cell types 
compared to iAs(III), respectively [26]. The elevated toxicity of trivalent and 
methylated arsenicals is primarily a function of their increased reactivity with 
biological molecules.   






Figure 2. Arsenic biomethylation 
ii.ii. Toxicity  
 
 Both acute and chronic arsenic toxicity manifest in virtually all body 
systems. The acute lethal dose of arsenic in humans is approximately 0.6 
mg/kg/day [28]. Acute arsenic exposure results in vomiting, abdominal colic, and 
diarrhea [16]. In rare cases, arsenic poisoning can cause death through massive 
fluid loss due to secretions from the gastrointestinal tract, which in turn cause 
severe dehydration, reduced blood volume, and circulatory collapse [28]. 
Prolonged exposure to non-lethal doses of arsenic can cause thickening of the 
skin of the palms (keratosis), skin pigmentation (melanosis), and systemic 
disease of the liver, kidney, nervous system, and cardiovascular systems, as well 





 Arsenic species are known to inhibit more than 200 enzymes [29]. Arsenic 
(III) interferes with enzyme systems by binding to –SH and –OH groups [30], and 
an affinity for sulfur allows arsenic to accumulate in keratin tissue [18]. Arsenic 
species can compete with phosphate, uncoupling oxidative phosphorylation and 
disrupting ATP production [31]. Arsenic may also replace phosphorus in DNA, 
inhibit DNA repair mechanisms [32] and interfere with selenium in human 
metabolism [33].  
 
ii.iii. Mortality and cancer 
 Chronic exposure to arsenic can result in increased overall mortality and 
risk of cancer, diabetes, organ toxicity and cardiovascular disease.  A prospective 
cohort study in Bangladesh assessed all cause and chronic disease mortality 
among over 11,000 subjects at the individual level. Exposures in this population 
were often in the range of 200 to 300 ppb. Argos et al. (2010) reported that 21.4% 
of all deaths and 23.5% of deaths associated with chronic disease could be linked 
to arsenic exposure in drinking water [34]. Dose response mortality patterns have 
been seen at the ecological level for cancers of the lung, skin, bladder, and kidney 





 In addition to cancer mortality, the incidence of lung, bladder, kidney and 
liver cancers, as well as basal cell and squamous cell carcinomas have been 
linked to arsenic exposure in highly exposed populations of Taiwan, Japan, West 
Bengal, Bangladesh, Chile, and Argentina [1,39-41]. 
 
ii.iv. Diabetes and organ toxicity 
 Elevated diabetes risk has been demonstrated among arsenic-exposed 
populations of Bangladesh [42,43], and diabetes has been observed at a two-fold 
increase in arsenic-exposed areas compared to the rest of Taiwan [44]. Arsenic 
accumulates in the liver and can contribute to cirrhosis, portal hypertension, fatty 
degeneration, and jaundice [45-47]. The kidneys, the major site of arsenic 
excretion, accumulate arsenic where it damages capillaries, tubules, and 
glomeruli, and increases the risk of renal failure [48].  
 
ii.v. Cardiovascular disease 
 Epidemiological studies have convincingly established an association 
between arsenic exposure above 50 ppb and hypertension [43], atherosclerosis 
[49], and ischemic heart disease [50]. Blackfoot disease, a peripheral vascular 





resulting in amputation, has been linked to arsenic exposure in regions of 
Taiwan [51]. Additionally, carotid atherosclerosis increases dose dependently 
with arsenic exposure [49]. Furthermore, high pulse pressure, an indicator of 
arterial stiffness and risk factor for atherosclerosis, is significantly higher among 
arsenic exposed compared to unexposed subjects in Bangladesh [52].  
 The cardiovascular effects of arsenic are not limited to highly exposed 
populations. Indeed, a prospective cohort study in the U.S. compared the hazard 
ratios of cardiovascular disease (CVD) and coronary heart disease incidence 
among low (5.7 ppb) to moderately (15.7 ppb) arsenic exposed subjects [9]. The 
authors report hazard ratios of 1.32 (95% CI: 1.09 -1.59) for incident CVD and 1.30 
(95% CI: 1.04 -1.62) for incident coronary heart disease [9]. Statistically significant 
hazard ratios were also reported for CVD, coronary heart disease, and stroke 
mortality among moderate compared to low exposure subjects [9].  
 
ii.vi. Metabolic syndrome 
 Metabolic syndrome is a risk factor for cardiovascular disease and 
diabetes. Metabolic syndrome is defined as the presence of at least 3 out of 5 
components including elevated fasting glucose, hypertension, elevated 





(2007) demonstrated that inorganic arsenic exposure was associated with a 
clinical diagnosis of metabolic syndrome, elevated plasma glucose, and elevated 
blood lipids among residents of an industrial region of Taiwan exposed to 
arsenic both occupationally and through water sources measured up to 16 ppb 
[49]. Additionally, Chen et al. (2012) reported that a high proportion of urine 
DMA was associated with increased risk of metabolic syndrome among a 
population in Taiwan exposed to median arsenic concentrations of 700-930 ppb 
[53]. Elevated blood pressure was positively associated with elevated urine 
concentrations of DMA in the U.S. NHANES 2009-2012 population [54], and 
large waist circumference was associated with a high proportion of urine DMA 
among participants of the Strong Heart Study, a rural cohort from the southwest 
U.S. [55].  
 
ii.vii. The role of mitochondria in cardiovascular disease and metabolic disorder  
 The cardiovascular toxicity of arsenic is mediated, in part, through mitochondrial 
dysfunction. Due to high-energy demand, cardiovascular tissues are heavily enriched 
with mitochondria and are thus particularly susceptible to mitochondrial toxins [56]. 
The respiratory chain is a critical mitochondrial mechanism by which toxic agents act 





transmembrane potential, and increased reactive oxygen species (ROS) [56]. Arsenic has 
exhibited toxic effects in the mitochondria of vascular smooth muscle [57], myocardial 
cells [58], and vascular endothelial cells [59]. Arsenic is associated with mitochondrial 
dysfunction through mechanisms such as elevated ROS, induction of apoptosis, and 
Ca2+ overload [60].  
 
ii.viii. Arsenic as cancer treatment and the role of antioxidants 
 Arsenic is a recognized carcinogen. Arsenic-induced ROS cause genetic 
mutations and cancer through DNA damage, activation of oncogenic kinases, and 
activation of lipids and proteins that inactivate DNA repair mechanisms [61,62]. 
Paradoxically, arsenic trioxide has been used as a therapeutic agent in the treatment of 
acute promyelotic leukemia (APL). APL is a subtype of acute myeloid leukemia (AML) 
that is genetically characterized by a specific chromosomal translocation that yields the 
promyelotic leukemia/retinoic acid receptor alpha (PML/RARA) fusion gene - a DNA-
binding transcription factor. Arsenic targets the PML moiety of PML/RARA and 
disrupts PML unclear bodies, which regulate stem cell self-renewal [63]. Specifically, 
arsenic was found to bind to protein kinase M2 (PKM2), located on the surface of 
PML/RARA. PKM2 promotes aerobic glycolysis (“Warburg effect”) leading to 





inhibiting cancer cell growth [64].  
 Despite the benefits, the clinical use of arsenic trioxide is severely limited due to 
arsenic’s severe cardiovascular side effects. A growing body of evidence suggests that 
antioxidant compounds may ameliorate arsenic’s toxicity to the cardiovascular system. 
Antioxidant phytonutrients are naturally occurring chemicals in plants such as 
vegetables, grains, legumes, seeds, fruits, leaves, flowers, and bark. Polyphenols are a 
major class of phytochemicals that have non-enzymatic antioxidant activities and 
scavenge free radicals and oxidants such as superoxide (O2 .), peroxynitrite (ONOO-), 
and hydrogen peroxide (H2O2) [65]. As ROS are a major contributor to arsenic-induced 
toxicity, it is possible that polyphenols and other antioxidants could be employed 
against the deleterious effects of arsenic in the cardiovascular system.  
 
iii. Addressing gaps in the literature 
 Despite a growing body of evidence on the hazards of arsenic exposure, there are 
several important gaps in the literature. No systematic review has explored the 
protective actions of food-based antioxidants against arsenic-induced mitochondrial 
toxicity. Therefore, chapter 2 reviews the available literature on in vivo and in vitro 
studies using antioxidants to counteract arsenic-induced cardiovascular toxicity. We 





employed against arsenic-mediated toxicity in cardiovascular cells and tissues, and 
suggest future directions for research aimed at ameliorating the harmful effects of 
arsenic in a real-world context.  
 In light of arsenic-induced cardiovascular dysfunction and evidence that 
methylation capacity contributes to arsenic’s toxicity, chapter 3 investigates the 
association between arsenic methylation capacity and metabolic syndrome. While 
arsenic methylation capacity is known to be associated with a diagnosis of metabolic 
syndrome in high exposure populations, it is unknown if arsenic methylation 
contributes to metabolic syndrome in a low exposure population. To answer this 
question we conducted a secondary data analysis using data from the U.S. National 
Health and Nutrition Examination Survey (NHANES). Chapter 3 reports a positive 
association between arsenic methylation capacity and metabolic syndrome in a 
population with low arsenic exposure represented by the U.S. NHANES population. 
Methylation capacity contributes to the extent to which toxic arsenic metabolites enter 
and remain in systemic circulation. Arsenic metabolites are hypothesized to be major 
contributors to disease, however, many of the mechanisms pertaining to the toxicity of 
different arsenic species remains to be elucidated. Chapter 4 experimentally assessed 
the differential toxicity of iAs(III) and the metabolite MMA(III) in VSMCs. This cell type 





dysfunction. Therefore, in chapter 4, we report increased toxicity of MMA(III) relative 
to iAs(III) in VSMCs with mitochondrial dysfunction as a central component of toxicity. 
This outcome adds to the growing body of literature on mechanistic differences 
between arsenic species.  
 
iv. Methodology 
 This dissertation uses three different methodological approaches. Chapter 
2 is a review and synthesis of published data. We conducted a literature search of 
MEDLINE, web of science, and Google scholar for the terms and relevant 
variations of “mitochondria” “toxicity” “cardiovascular” “arsenic” and 
“antioxidant.” We excluded reviews and publications not available in English. 
This chapter tested the hypothesis that food-based antioxidants are highly 
effective against arsenic induced mitochondrial toxicity in cardiovascular cells 
and tissues. The selected 25 studies assessed the effects of non-enzymatic 
antioxidants against arsenic exposed mitochondria and/or cardiovascular cells 
and tissues.  
 Chapter 3 is a secondary data analysis using U.S. NHANES data to 
draw epidemiological conclusions. NHANES uses a complex, probability 





participate in each 2-year cycle. NHANES personnel collected demographic 
information via survey, and a physical examination was performed on all 
subjects. Biological samples were collected by NHANES personnel from 
nationally representative subsamples. In our study, we included a total of 957 
subjects over the age of 20 who had complete data on all relevant variables.  
 We used logistic regression to assess the relationships between measures 
of methylation capacity with metabolic syndrome. Covariates were evaluated in 
the literature and statistically using Mann-Whitney-U test, Kruskal Wallace test, 
χ2 test, or student-t test, and statistically relevant or biologically justified 
covariates were included in the final adjusted model.  We report a positive 
association between arsenic methylation and metabolic syndrome in women 
with normal BMI and obese women, and that both gender and BMI modify the 
effect of arsenic methylation on metabolic syndrome.   
 Chapter 4 is an experimental laboratory study of the differential toxicity of 
iAs(III) and MMA(III) on VSMCs. We used a variety of methodological 
approaches to assess cell viability, cell death, mitochondrial respiration, 
mitochondrial ATP levels, reactive oxygen species (ROS), and mitochondrial 
morphology and content. We report increased toxicity of MMA(III) relative to 





 In summary, this dissertation is composed of a review and synthesis of 
published data, a secondary data analysis from an epidemiology perspective, 
and original experimental data, all of which address gaps in the literature 
pertaining to various aspects of arsenic and cardiovascular disease. We conclude 
with a short chapter summarizing our findings with recommendations for future 
research pertaining to the selective toxicity of arsenic and its metabolites to 
mitochondria, the relevance of arsenic methylation capacity as a risk factor for 
the health effects of arsenic, and a framework for developing antioxidant 











Chapter 2. Antioxidants protect against arsenic induced mitochondrial cardio-toxicity 
 
i. Abstract 
 Arsenic is a potent cardiovascular toxicant associated with numerous 
biomarkers of cardiovascular diseases in exposed human populations. Arsenic 
is also a carcinogen, yet arsenic trioxide is used as a therapeutic agent in the 
treatment of acute promyelotic leukemia (APL). The therapeutic use of arsenic 
is limited due to its severe cardiovascular side effects. Many of the toxic effects 
of arsenic are mediated by mitochondrial dysfunction and related to arsenic’s 
effect on oxidative stress. Therefore, we investigated the effectiveness of 
antioxidants against arsenic induced cardiovascular dysfunction. A growing 
body of evidence suggests that antioxidant phytonutrients may ameliorate the 
toxic effects of arsenic on mitochondria by scavenging free radicals. This review 
identifies 22 antioxidants that can effectively reverse mitochondrial dysfunction 
and oxidative stress in cardiovascular cells and tissues. In addition, we propose 
that antioxidants have the potential to improve the cardiovascular health of 
millions of people chronically exposed to elevated arsenic concentrations 
through contaminated water supplies or used to treat certain types of leukemia. 
Importantly, we identify conceptual gaps in research and development of new 





improve bioavailability of antioxidants and distribution to target tissues in 
order reduce arsenic-induced cardiovascular toxicity in a real-world context.  
 
ii. Introduction 
ii.i. Arsenic and cardiovascular disease 
 Exposure to arsenic through contaminated ground water is widespread in 
certain regions of many countries including Bangladesh, India, and China [18]. 
Arsenic is a potent cardiovascular toxicant; epidemiological evidence has linked 
arsenic exposure to ischemic heart disease, cerebrovascular disease, 
atherosclerosis, and hypertension in exposed human populations [50,66,67].  
Arsenic has been characterized as a strong carcinogen [36]. Arsenic-induced 
reactive oxygen species (ROS) cause genetic mutations and cancer by promoting 
DNA damage, activating oncogenic kinases, and activating lipids and proteins 
that inactivate DNA repair mechanisms [61,62]. Paradoxically, arsenic trioxide 
has been used as a therapeutic agent in the treatment of acute promyelotic 
leukemia (APL). APL is a subtype of acute myeloid leukemia (AML) that is 
genetically characterized by a specific chromosomal translocation that yields the 
promyelotic leukemia/retinoic acid receptor alpha (PML/RARA) fusion gene - a 





PML/RARA and disrupts PML nuclear bodies, which regulate stem cell self-
renewal [63]. Specifically, arsenic was found to bind to cysteine thiols on 
pyruvate kinase M2 (PKM2), located on the surface of PML/RARA [64]. PKM2 is 
a glycolytic enzyme that promotes aerobic glycolysis (the “Warburg effect”) 
leading to tumorigenesis and cancer cell proliferation. Arsenic reduces PKM2 
activity, thus inhibiting cancer cell growth [64].  
Arsenic also prevents cancer cell proliferation in human breast MCF-7 cancer 
cells by binding to thioredoxin reductase (TrxR) in the thioredoxin (Trx) system 
[68]. The Trx system, which contains NADPH, TrxR and Trx, is an important 
thiol-dependent electron donor system in the cell that regulates numerous cell 
functions including cell viability and proliferation [69,70]. As Trx and TrxR are 
overexpressed in many aggressive tumors, the Trx system has become an 
important target for cancer drug development [71,72]. Lu et al. (2007) 
demonstrated that arsenic trioxide irreversibly inhibits mammalian TrxR by 
binding at the N-terminal redox–active dithiol and the C-terminal selenothiol-
active sites [68]. Despite the benefits, the clinical utility of arsenic trioxide is 
limited due to arsenic’s severe cardiovascular side effects such as QT-






ii.ii. Mitochondria in cardiovascular disease 
 The cardiovascular toxicity of arsenic is mediated, in part, through 
mitochondrial dysfunction. Due to their significant energetic requirements, 
cardiovascular tissues generally have high mitochondrial densities and are thus 
particularly susceptible to mitochondrial toxins [56]. The electron transport 
system (ETS) is a critical mitochondrial mechanism. Components of the ETS are 
particularly susceptible to the toxic effects of arsenic, leading to decreased ATP 
production, reduced mitochondrial transmembrane potential, and increased ROS 
[56].  
 
ii.iii. Oxidative stress 
 ROS cause oxidative modifications of cellular macromolecules including 
proteins, lipids, and polynucleotides. ROS include superoxide radical (O2 .) which 
is converted into hydrogen peroxide (H2O2) spontaneously or via dismutation 
catalyzed by superoxide dismutase (SOD) [76]. O2 . also reacts with nitric oxide 
(NO) to generate peroxynitrite (ONOO-), an oxidant and reactive nitrogen 
species. Electron leakage from the mitochondrial electron transport chain (ETC) 





(NADPH, oxidases, lipoxygenase, cyclooxygenase, cytochrome P450s, and 
xanthine oxidases (XOs)) also participate in ROS generation [77,78].  
Intrinsic antioxidants such as SOD, catalase, and glutathione peroxidase 
(GPx) are the first line of defense against oxidative stress. Excessive ROS or 
diminished innate antioxidant capacity result in increased oxidative stress and 
are associated with a multitude of downstream effects as well as disease 
initiation and progression [79]. 
 
ii.iv. Antioxidant phytonutrients 
 A growing body of evidence demonstrates the mitochondrial toxicity of 
arsenic in cardiovascular tissues. Importantly, antioxidant phytonutrient 
compounds counteract the toxic effects of arsenic on mitochondria [80]. 
Antioxidant phytonutrients are naturally occurring chemicals in plants such as 
vegetables, grains, legumes, seeds, fruits, leaves, flowers, and bark. Polyphenols 
are a major class of phytochemicals that have non-enzymatic antioxidant 
activities and scavenge free radicals such as O2 ., and H2O2 [65]. 
The present review focuses on in vivo and in vitro studies of arsenic on 
cardiovascular tissues and cells in which the mitochondrial endpoints of 





antioxidant content and activity were analyzed. In particular, we reviewed a 
comprehensive list of antioxidant phytonutrients used to counteract 
mitochondrial toxic (mito-toxic) effects of arsenic. The antioxidants discussed 
here may have a therapeutic value for both individuals chronically exposed to 
arsenic through groundwater sources as well as patients who require arsenic 
trioxide therapy for APL. Importantly, we suggest future directions for research 
and clinical interventions applying antioxidant therapy to revert mitochondrial 
dysfunction, oxidative stress and cell death of cardiovascular tissues in humans 
exposed to high levels of arsenic trioxide. 
 
ii.v. Mitochondria  
ii.v.i. Energy production 
 The primary function of mitochondria is to produce energy in the form of 
ATP through oxidative phosphorylation [81]. Glucose is broken down into 
pyruvate to generate NADH, which is oxidized in the presence of oxygen 
(aerobic respiration) or in limited oxygen conditions (anaerobic fermentation) 
[56]. Pyruvate is actively transported through the inner mitochondrial membrane 
into the matrix where it is oxidized and combined with coenzyme A to generate 





oxidized to generate CO2, NADH and FADH2, which donate electrons for the 
electron transport chain, and ATP. NADH and FADH2 are also produced via 
glycolysis in the cytosol and imported to the mitochondrial matrix [56]. Electrons 
from NADH and FADH2 are used in the process of oxidative phosphorylation to 
donate electrons for the respiratory chain during oxidative phosphorylation [56].  
The respiratory chain consists of 5 large protein complexes called NADH-Q 
oxidoreductase, Q-cytochrome c oxidoreductase, cytochrome c reductase, 
cytochrome-c-oxidase, and ATP synthase (complexes I, II, III, IV, and V) [56]. The 
transfer of electrons sets up an electron gradient used to pump protons across the 
inner membrane space. Protons move down their concentration gradient back to 
the matrix, where they combine with O2 to form H2O and serve to power ATP 
synthase (Complex V) to facilitate the generation of ATP from ADP and 
inorganic phosphate [81].  
Despite the overall efficiency of the respiratory chain, a small amount of 
electron leakage occurs at mitochondrial complexes I and III. This charge leakage 
can reduce oxygen to form reactive oxygen species such as O2 ., H2O2, and -OH 
[56]. Deficiencies in mitochondrial energy production can be demonstrated in an 





mitochondrial complexes, and elevated ROS, particularly mitochondrial 
superoxide, suggesting decreased respiratory chain efficiency [56].  
 
ii.v.ii. Calcium storage 
 In addition to other intracellular storage deposits, calcium is transiently stored 
in the mitochondria and used for signal transduction and regulation of intracellular 
reactions. Calcium is taken up into the mitochondrial matrix by the calcium uniporter 
in the inner mitochondrial membrane, which is driven by mitochondrial membrane 
potential [83]. Calcium can later be released via a sodium-calcium exchange protein or 
by a change in the membrane potential [83]. Dysfunction in mitochondrial calcium 
status, such as Ca2+ overload, can result in elevated oxidative stress through Ca2+-
stimulated NO production, Ca2+-induced cardiolipin peroxidation, Ca2+- induced 
mitochondrial permeability pore opening with consequent release of cytochrome c 
and GSH-antioxidative enzymes, and activation of Ca2+-calmodulin dependent protein 
kinases [83]. Additionally, the rise in mitochondrial ROS can alter Ca2+ dynamics and 
increase Ca2+ surge. Thus the reciprocal interaction between Ca2+ induced ROS increase 








 Mitochondrial-mediated apoptosis is an important mechanism of 
programed cell death. Pro-apoptotic proteins on the surface of mitochondria 
detect mitochondrial damage and activate BAX proteins, which “punch” pores in 
the outer mitochondrial membrane, allowing cytochrome c to be released into 
the cytoplasm, where it binds to apoptotic protease activating factor-1 (Apaf-1) 
[82,84]. The interaction of these proteins forms apoptosomes, which bind and 
activate caspase-9, and subsequently cleave mitochondrial membrane proteins 
and result in phagocytosis [82,84]. Elevated levels of BAX, Apaf-1, and caspases 
3, 8, and 9 all suggest an increase in apoptosis. Other biomarkers of apoptosis 
include upregulation of TGF-β, a profibrogenic cytokine that indicates repressed 
cell proliferation and apoptosis, and phosphorylation of the NF-κB pathway.  
 
ii.v.iv. Membrane potential 
 Mitochondria closely regulate membrane potential, which is critical for 
mitochondrial functions including the electron transport chain and calcium 
homeostasis [56]. A significant loss of membrane potential depletes the cell of 
ATP and results in cell death [85]. Dysfunctional membrane potential can be 





specific dye JC-1, and by measuring the membrane pore permeability and Na+/K-
ATPase activity.  
Protein kinases are translocated to mitochondria in response to oxidative 
stress, where they regulate membrane potential, impact growth factors, and lead 
to phosphorylation of respiratory chain proteins. The mitogen-activated protein 
kinase (MAPK) cascade includes the subfamilies p38 mitogen-activated protein 
kinase (p38 MAPK), c-Jun N-terminal kinase (JNK), and extracellular signal-
regulated kinase (ERK). p38 MAPK signaling regulates cell death, in part, by 
initiating the translocation of BAX from the cytosolic to mitochondrial 
compartments [85]. Activated JNK stimulates apoptosis by inhibiting the anti-
apoptotic Bcl-2 and Bcl-xl, leading to cytochrome c release and subsequent 
induction of apoptosis. Increased ERK1/2 activity leads to ERK1/2 colocalization 
to the mitochondria where it promotes autophagy and mitochondrial 
degradation [86]. This creates a self-amplifying loop of mitochondrial 
dysfunction in which mitochondrially-derived ROS activates ERK1/2, which 
translocates to the mitochondria where it damages ATP synthase function, 
reduces mitochondrial membrane potential, and causes cytochrome c release, 






ii.v.v. Source of ROS 
 Mitochondria are an important source of ROS, which play a significant 
role in cell signaling [56]. As previously mentioned, some ROS are produced as a 
result of electron leak that occurs due to the incomplete flow of electrons in 
complex I and in complex III. ROS levels are typically low and are maintained in 
balance through the activity of intrinsic antioxidants, which scavenge for ROS. 
For example, superoxide dismutases (SODs) convert O2- to H2O2, and catalase 
subsequently converts H2O2 to water. Another endogenous antioxidant is 
glutathione reductase (GSH), which donates a reducing equivalent (H+ + e-) to 
neutralize ROS. By donating an electron, GSH becomes reactive and binds to 
another reactive GSH to form glutathione disulfide (GSSG). Oxidized glutathione 
can be converted back to its reduced state using NADPH as an electron donor, 
and the ratio of GSH/GSSG is often used as a measure of oxidative stress [87]. 
Glutathione S-transferase (GST) utilizes GSH as a substrate and participates in 
the metabolism of xenobiotics [88], and glutathione peroxidase (GPx) and 
thioredoxin reductase (TR) catalyze interconversion and equilibrium among 
reduced/oxidized species [78].  
Excessive ROS or decreased content/activity of endogenous antioxidants 





have used a variety of methods to assess oxidative stress. A direct measure of 
ROS can be obtained by measuring the fluorescence of 2’,7’-dichlorofluorescin 
diacetate (DCFH-DA) to 2-, 7’-dichlorofluorescein (DFA) [89]. DCFH-DA readily 
diffuses into cells, is hydrolyzed to H2 DCF (which is not membrane permeable), 
and then is oxidized by H2O2 and other ROS to the fluorescent compound DFA. 
The fluorescence of DFA is proportional to the intracellular concentration of 
combined H2O2, ONOO-, and OH- [90].   
 
ii.v.vi. Arsenic and cysteine thiol binding 
Arsenic is considered a "sulfhydryl-reactive metalloid" [91]. The affinity of 
arsenic for free sulfhydryl groups results in certain mechanisms of toxicity, 
including binding and depletion of GSH pools, as well as binding and 
inactivation of sulfhydryl-rich proteins [88]. This cysteine thiol binding-mediated 
inactivation of specific proteins is central to the ability of arsenic to both induce 
metallothionein biosynthesis [92] and elevate ROS generation via inhibition of 
the antioxidant enzyme thioredoxin reductase [68]. The depletion of GSH titers 
by arsenic may also influence arsenic methylation rates, leading to variable rates 
of metabolic activation in certain tissues [93]. Protein cysteine thiol binding in 





antioxidant activity, leading to accumulation of ROS and attendant pathological 
consequences [94-97].  
 
ii.v.vii. ROS and the Nrf2 pathway 
 Arsenic’s affinity for sulfhydryls also contributes to the activation of 
Nuclear factor erythroid 2-related factor (Nrf2) [89]. Kelch ECH (Keap-1) anchors 
Nrf2 in the cytoplasm in quiescent conditions. Arsenic binds to Keap-1 cysteine 
residues, leading to Nrf2 dissociation and translocation to the nucleus [98,99]. 
Nrf2 activation results in a coordinated antioxidant and anti-inflammatory 
response in which phase II detoxification enzymes are activated. Nrf2 regulates 
GPx, GST, SOD, and TR (all discussed above) as well as glucose-6-phosphate 
(G6PD)-which provides NADPH to glutathione reductase, heme oxygenase-1 
(HO-1)- which generates antioxidant molecules and regulates apoptosis, 
glutathione reductase (GR)- which catalyzes the reduction of GSSG to GSH, and 
NAD(P)H:quinone dehydrogenase (NQO1)-a FAD-binding protein [98].  
 
ii.vi. Arsenic-induced mitochondrial toxicity 
 Arsenic, a recognized cardiovascular toxicant, has exhibited mito-toxic 





endothelial cells [59]. Arsenic is associated with mitochondrial dysfunction 
through mechanisms such as elevated ROS, induction of apoptosis, and Ca2+ 
overload. In the heart, arsenic causes QT prolongation by altering L-type calcium 
channels [60]. As previously noted, GSH is also consumed during metabolism of 
arsenic and in response to arsenic-induced ROS. Indeed, GST utilizes GSH as a 
substrate and participates in the xenobiotic metabolism of arsenic and other 
compounds [88] and GPx catalyzes the reduction of H2O2 to H2O with GSH as a 
substrate [88,100]. Furthermore, decreased availability of GSH due to arsenic 
toxicity further contributes to ROS accumulation [101].  
The pathological effects of ROS are widespread for the cell.  For example, 
lipid peroxidation is a common feature of oxidative stress that has also been 
attributed to arsenic exposure. In this process, free radicals cause cell damage by 
sequestering electrons from the lipids in cell membranes [102]. Additionally, 
arsenic may decrease membrane-based enzyme activity through the generation 
of ROS [88]. For instance, ROS inhibit the activity of Na+/K+ ATPase resting 
membrane homeostasis, which is critical for maintaining mitochondrial 
transmembrane potential [103].  
In light of arsenic’s demonstrated cardiovascular toxicity and the association 





mechanisms of arsenic toxicity and the protective action of food-based 
antioxidants, many of which work by scavenging antioxidants. We hypothesize 
that studies provide sufficient proof-of-concept that antioxidant formulations can 
protect against arsenic-induced mitochondrial dysfunction in cardiovascular 
cells and tissues. 
 
iii. Methods 
 We conducted a literature search by screening MEDLINE, Web of Science, 
and Google Scholar for the terms “mitochondria” “mitochondrial” “toxicity” 
“toxic” in combination with “heart” “cardiac” “cardiovascular” “myocardial” 
“myocardium” “arsenic” “ATO” or “arsenic trioxide” and “antioxidant.” We 
limited our results by eliminating reviews and publications that were not 
available in English. We had two primary objectives. The first was to test the 
hypothesis that non-enzymatic antioxidants are highly effective against arsenic-
induced cardiovascular toxicity, and may be employed to protect mitochondria 
in cardiovascular cells and tissues. The second objective of this review was to 
identify a series of food-based antioxidants that could be supplemented to the 





developed into commercial formulations to include in clinical trials involving 
arsenic trioxide.   
Appropriate hits were analyzed in detail and reference lists were screened 
for additional appropriate studies. Our initial search returned 308 potential 
studies to include. One hundred and nineteen studies were eliminated because 
they were focused on the effects of arsenic on cancer cells, 99 focused on non-
cardiovascular cell or tissue types (10 blood, 37 liver/kidney, 16 brain and 
nervous system, 8 reproductive system, and 28 other), 60 did not investigate the 
restorative effects of a non-enzymatic antioxidant, 3 had an environmental focus, 
and 2 were epidemiological studies (Figure 1). The remaining 25 articles were 
included in the present review. We assessed the quality of the studies analyzed 
in this review in terms of clarity of purpose, experimental design, 
appropriateness of statistical methods used, thoroughness of data reporting, and 
impact of primary research article and journal in which the article was published. 
No additional studies were collected from Web of Science or Google Scholar. We 
included animal model investigations and cell culture studies in this review. Our 
search yielded studies investigating isolated heart mitochondria, 







Figure 1: Schematic of selected references 
iv. Results 
iv.i. Arsenic 
iv.i.i. Dose and duration 
 Dose selection justifications varied between studies, but generally, in vivo 
doses were selected based on the literature [89,104-107]. For example, as a 
fraction of the lethal dose [108], or experimentally as the minimum dose that 
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significant detrimental effects on cell viability and/or cell death and were further 
stratified by exposure duration (Table 1). The studies presented in this review 
utilized arsenic trioxide (As2O3) [58,88,105,106,109-118] or sodium arsenite 
(NaAsO2) (Figure 2) [101,107,108,119-123] at in vivo doses ranging from 
0.8mg/kg/day to 5mg/kg/day administered intravenously or 2mg/kg/day to 
50mg/kg/day administered orally for durations of 6 to 56 days. Experimental 
animals included Sprague Dawley rats [101,107,122], Wistar rats [111,119], 
BABL/c mice [124], APO E-/- mice [123], and guinea pigs [110]. In vitro exposures 
ranged from 1μM to 20μM arsenic at exposure durations of < 3 to 72 hrs. Cell 
types included neonatal ventricular cardiomyocytes (NRLVM) [116], rat 
embryonic cardiomyocytes (H9c2) [114], primary cardiomyocytes isolated from 
Albino Wistar rats [121], and primary guinea pig cardiomyocytes [110]. Although 
not the focus of the present review, one study also utilized human promyelotic 










Table 1. In vivo and in vitro study design 
In vivo studies stratified by arsenic exposure duration 
Duration Arsenic Dose            Type Method Model Citation 
2 hours 
 
0.15μM, 1.5μM, 5μM    









6-10 days 0.8 mg/kg               
1 mg/kg                
3 mg/kg                 
10 mg/kg               





















10-29 days 1 mg/kg                 
2.5 mg/kg                
5 mg/kg                 
5 mg/kg                 
5 mg/kg 

























30-56 days 2 mg/kg                
4 mg/kg                
4 mg/kg                  
4 mg/kg                  
5 mg/kg                  
10 mg/kg                



















SD rat  
SD rat  








In vitro studies 
  1μM                      
1μM, 2μM                  
2μM/mL                   
4μM                       
5μM                        
5μM                        
5μM                       
5μM                       
5μM, 7.5μM, 10μM           
5μM, 6μM, 12μM            
10μM                       





































1intravenous, 2intraperitoneal, 3Sprague Dawley, 4H9c2-rat heart cardiomyocyte cells,  







Figure 2. Arsenic species 
 
iv.i.ii. Cardiovascular structure and function 
 In vivo, increased arsenic exposure increased arsenic deposition in the 
heart [105], caused QT interval prolongation [122], increased QTc interval [106], 
induced ST-T wave change [114], prolonged PQ interval [111], increased RR and 
QRS interval [122], inhibited IKS current [110], reduced IK amperage [110] 
decreased heart rate [122], decreased cardiac output [116], and decreased 3′-5′-
cyclic adenosine monophosphate (cAMP), an intracellular messenger that 
mediates catecholaminergic control of heart rate and contractility [126]. Arsenic 
exposure increased triglycerides [107], total cholesterol [119], and LDL 
cholesterol [122], and decreased HDL cholesterol in blood plasma [120]. Arsenic 
decreased phospholipids, increased free fatty acids (FFA) [108], and increased 
lipase activity in heart tissues [115].  Arsenic also increased atherosclerotic 
plaque formation in the aortic arch and aortic sinus [123], and decreased 





Arsenic significantly elevated Creatine Kinase (CK) [114] and Creatine 
Phosphokinase (CPK) [120], which indicate stress to the heart, and elevated 
Creatine Kinase from muscle and brain (CK-MB) [122], as well as levels of serum 
troponin [106], which are cardiac markers used to diagnose acute myocardial 
infarction. Arsenic increased inflammation, measured with C-reactive protein 
(CRP) [115], and increased the activities of cardiac enzymes lactate 
dehydrogenase (LDH) [107,122], aminotransferase (AST) [108], alkaline 
phosphatase (ALP) [108,122], and aspartate aminotransferase (ALT) [108,122], all 
of which indicate necrotic damage to the heart [127].  Furthermore, arsenic 
caused notable changes in cardiac structures including cytoplasmic 
vacuolization, myofibrillar loss, and cardiomyocyte necrosis [124].   
 
iv.i.iii. Cardiac Nrf2 
Several in vivo studies reported downregulation of cardiac Nrf2 following 
arsenic exposures ranging from 8-28 days [122], as well as upregulation of Keap-
1 [108]. However, Hu et al. (2016) reported an increase in Nrf2 activity after 
exposing H9c2 cardiomyocytes to 2μM/ml arsenic for 24-hours. Based on 
arsenic’s affinity for sulfhydryls, we expected to see arsenic-induced Nrf2 





apparently contradictory results suggest a short term upregulation of the Nrf2 
pathway in which Nrf2 is modestly activated because cardiomyocytes have a 
weak ability to excrete arsenic into the extracellular space [133]. This is 
presumably followed by a more permanent repression of Nrf2 [133].  
Since Nrf2 activation stimulates expression of phase II detoxification 
enzymes, Nrf2 repression should decrease the innate antioxidant response. 
Indeed, arsenic decreased the activity of enzymes in the Nrf2 pathway including 
SOD [122], TR [58], GPx [119], GR [108], GST [119], G6PD [108], and 
hemeoxygenase 1 (HO-1) [122]. Again Hu et al. (2016) had contradictory 
findings, reporting elevated HO-1 expression, and an increase in NQO1 that 
likely resulted from short-term elevation in Nrf2.  
 Arsenic exposure decreased catalase activity [119], decreased GSH levels [120], 
and decreased GSSG levels and/or GSH/GSSG ratio [119]. In one study, GSH level 
was elevated at 6 hours following 5μM arsenic exposure [118], but this trend reversed 
at 12 and 24 hours [118], a result that is consistent with other studies. This observation 
suggests that arsenic may induce a short-term, compensatory but unsustainable 
increase in GSH activity. As previously mentioned, GSH is used in the 
biotransformation of inorganic arsenic to methylated arsenic species, and a temporary 






 In addition to measuring antioxidant activity, many studies have reported 
ROS levels induced by arsenic exposure. Indeed, cells exposed to arsenic 
demonstrated an elevation of several ROS and oxidants including H2O2 [112,115], 
mitochondrial superoxide [101,112], ONOO-, and OH- [122]. Arsenic increased 
lipid peroxidation -measured as malondialdehyde (MDA) [88]- and increased 
thiobarbituric acid reactive substances (TBARS), a byproduct of lipid 
peroxidation [119]. Arsenic also increased xanthine oxidase (XO) [118] and 
increased NOX enzyme activity-an important source of ROS [108]. Interestingly, 
one study detected a significant increase in nitric oxide (NO) following exposing 
rats to 5mg/kg/day sodium arsenite for 28 days [122], and one study found that 
NO changes were not significant following 3mg/kg arsenic exposure in mice on 4 
alternate days over an 8-day period [89]. NO is a second messenger involved in 
the process of blood vessel vasorelaxation, and decreased NO in endothelial cells 
is associated with elevated blood pressure. Paradoxically, low dose arsenic 
exposure has been shown to increase NO in endothelial cells, whereas higher 
dose arsenic exposure decreases NO [134]. Thus, reports of increased NO in 
response to arsenic exposure likely result from arsenic’s non-linear effects based 






 As expected, arsenic elevated lactate dehydrogenase (LDH) release at 
various doses and exposure times [89,101,124] and consistently decreased cell 
viability [112]. Apoptosis was detected via DCFH-DA fluorescence, flow 
cytometry profile, physiological characteristics (shrinkage, blebbing and 
rounding up), DNA fragmentation, and/or increased micronuclei frequency 
[122]. Arsenic also decreased cell growth via DNA synthesis [112].  
Arsenic increased caspase-3 cleavage [101], activated caspase-3 [112], 
caspase-8 [113], and caspase-9 [114], and increased cytochrome c levels in the 
cytosol [121]. Arsenic increased the level of proteolysis of poly (ADP-ribose) 
polymerase (PARP) (downstream of caspase-3 activation) [121], increased 
expression of pro-apoptotic proteins BAX [112], Bad [121], and p53 upregulated 
modulator of apoptosis (PUMA) [112], and decreased expression of anti-
apoptotic proteins Bcl-2, Bcl-xL [112], Survivin [112], X-linked inhibitor of 
apoptosis protein (XIAP) [112], cellular inhibitor of apoptosis protein-1 (CIAP1), 
and the ratio of phosphorylated to total anti-apoptotic kinase (AKT) [114]. 
Arsenic also decreased Bcl-2/BAX protein ratio in one study [114]. Arsenic up 
regulated TGF-β and Smad3 [122], which both indicate apoptosis (TGF-β triggers 





kappa-light-chain-enhancer of activated B cells (NF-κB) pathway [121]. When 
phosphorylated, NF-κB translocates to the nucleus and induces the transcription 
of anti apoptotic proteins such as XIAP1 and Survivin, thus, decreased NF-κB 
activity has a pro-apoptotic effect.  Interestingly, one study reported decreased 
activity of NF-κB, which is generally considered an anti-apoptotic event [112]. 
This contradiction may stem from the fact that NF-κB has both inflamatory and 
anti-inflamatory properties, and apoptosis is an essential mechanism that 
prevents prolonged inflammation. Thus, increased and decreased NF-κB may 
reflect different states of cellular stress [135].  
It is also worth noting that although a majority of studies have reported on 
arsenic’s ability to induce apoptosis in various cell types including aortic, 
coronary, and mesenteric smooth muscle cells [136,137], several past studies have 
also reported that exposure to inorganic arsenic results in necrosis whereas the 
metabolite monomethylarsonous acid (MMA) primarily results in caspase-
dependent apoptosis in vascular smooth muscle cells [57] and other cell types 
[138-140]. Variations in the method of cell death may result from differences in 
the arsenic dose, duration, and cell type (vascular smooth muscle vs. 
cardiomyocytes). In the present review, we report that among cardiomyocytes, 





iv.i.vi. Calcium overload 
Arsenic increased Ca2+ content [88],  increased Cav 1.2 protein expression 
[116], and decreased Ca-ATPase [88]. Calcium overload results in collapsed 
mitochondrial transmembrane potential. Indeed, arsenic consistently decreased 
mitochondrial transmembrane potential [116], a sign of decreased mitochondrial 
health. Arsenic also decreased Na+/K+ ATPase activity, which regulates 
mitochondrial transmembrane potential [88,108], and elevated phosphorylation 
of JNK and p-38 MAPK, which mediate mitochondrial membrane collapse [116]. 
 
iv.i.vii. Mitochondrial function 
 Arsenic decreased the activity of mitochondrial complexes I [58], II [122], 
III [58], and IV [58], decreased steady-state levels of ATP [58], decreased 
Mg2+ATPase, [108], and increased the level of mitochondrial superoxide [112]. 
Arsenic caused mitochondrial swelling, mitochondrial pore opening [58], and 
other alterations in mitochondrial morphology [122]. In one study, arsenic 
decreased the activities of heart mitochondrial enzymes including isocitrate 
dehydrogenase (ICDH), succinate dehydrogenase (SDH), malate dehydrogenase 
(MDH), and NADH dehydrogenase [108]. Arsenic also decreased the activity of 





enzyme in the citric acid cycle that converts citrate into iso-citrate [141]. Arsenic 
increased autophagy in cardiomyocytes, as measured by assaying for the level of 
the autophagic markers microtubule-associated protein 1A/1B-light chain 3-
phosphatidylethanolamine conjugate (LC3-II)/ microtubule-associated protein 
1A/1B-light chain 3 (LC3-I) [117]. In the process of autophagy, LC3 is conjugated 
with phosphatidylethanolamine to form LC3- phosphatidylethanolamine 
conjugate (LC3-II), which is recruited to autophagosomal membranes in 
autophagic vacuoles. The autophagosomes subsequently fuse with lysosomes to 
form autolysosomes, thus contributing to autophagic cell death [142].  
This data is consistent with previous studies showing that arsenic induces 
widespread mitochondrial dysfunction via loss of mitochondrial membrane 
potential, generation of ROS, diminution of cytochrome-C oxidase function, 
ROS-dependent activation of autophagy, and suppression of oxygen 
consumption via depletion of mtDNA copy number [143,144]. In addition, a 
recent study found that inorganic arsenic and/or methylated arsenicals decrease 
ATP content, increase the level of hydrogen peroxide and mitochondrial 
superoxide, cause aberrant nuclear clustering of mitochondria and decrease 





The studies reviewed here clearly demonstrate that arsenic impacts all 
aspects of mitochondrial function including energy production, calcium storage, 
ROS, and activities of mitochondrial-regulated cell death signaling pathways.  
 
iv.ii. Antioxidants 
 The studies selected for this review analyzed the abilities of antioxidants 
to counteract the toxic effects of arsenic on mitochondria in cardiovascular 
tissues and cells (Table 3). It is worth noting that the majority of these 
antioxidants were phenolic compounds. Polyphenolic compounds belong to a 
heterogeneous group of chemicals that contain one or more aromatic rings and 
one or more hydroxyl groups. Polyphenols have non-enzymatic antioxidant 
activities that scavenge free radicals and oxidants such as O-, ONOO- and H2O2. 
Oxidants are deactivated by polyphenolic antioxidant (POH) donation of a 
hydrogen atom, forming a phenoxyl radical (PO), which is then stabilized 







Figure 3: Polyphenolic neutralization of ROS  
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Polyphenols can be subcategorized as flavonoids, stilbenes, phenolic acids, 
and lignins (Table 2). Flavonoids are subcategorized as isoflavones, flavonols, 
flavones, flavanols, proanthocyanidins, and anthocyanins [145].  
Table 2. Antioxidant classification and source 
Polyphenolic Antioxidants  Classification Source 
Biochanin A [107] Flavonoid Cabbage, alfalfa 
Boerhavia diffusa [125] Flavonoid B. diffusa 
Ellagic acid [106]  Phenol Berries, walnuts 
EGCG [101] Catechin Green tea 
Eugenol [88] Phenol Clove 
Genistein [117]  Flavonoid Soy 
Grape seed and skin extract [115] Flavonoid, stilbene Grapes 
Imperatorin [113] Flavonoid Radix Saposhininkovaie  
Sec-o-glucosylhamandol [113] Flavonoid Radix Saposhininkovaie  
Malus domestica apple peel [118] Flavonoid Apples 
Naringin [122] Flavonoid Citrus fruit 
Phloretin [58] Flavonoid Apples 
Resveratrol [89] Stilbene Red wine 
Silybum marianum [108]  Flavonoid Milk thistle 
Sorbus phnuashanesis (Hante) Hedl[114]Flavonoid Chinese herb 
Trichosanthes dioca [120]  
 
Flavonoid T. dioica  
Other antioxidants Type Source 
α-lipoic acid [111] Organosulfur compound Spinach, broccoli  
Flax seed oil [105] α-linoleic acid  Flax seeds 
Morphine [112] Opioid  Poppy seeds 
Omega-3 fatty acid [109] Polyunsaturated fatty acid Fish oil 
Selenium [123] 
Taurine [121] 
Essential trace element 
Sulfonic acid  
Lentils 











Table 3. Arsenic induced effects and antioxidant restoration 
Arsenic induced effect Restored with antioxidant Citation 
Heart 
Arsenic deposition in heart Eugenol 
Grape seed & skin extract 
EGCG 
Omega-3 


























ST-T wave change Sorbus phnuashanesis [114] 
Increased RR interval Naringin [122] 
Increased QRS interval Naringin [122] 
Inhibited IKS currents α-lipoic acid [110] 
Reduced amperage of IK α-lipoic acid [110] 






Decreased cardiac output Genistein [116] 
Decreased CAMP Resveratrol [89] 
Structural changes in cardiac tissue Naringin 
Eugenol 
Ellagic acid 
Grape seed & skin extract1 
EGCG 
Omega-3 














Atherosclerotic plaque formation Selenium                                   [123] 







Elevated triglycerides Biochanin A 







Increased total cholesterol Naringin 
T. dioica root 
T. dioica fruit 
Taurine 
Silybum marianum 













Decreased HDL cholesterol T. dioica root 
T. dioica fruit 
[120] 
[119] 






Increased cardiac risk ratio Biochanin A [107] 
Increased free fatty acids Silybum marianum [108] 
Increased lipase activity GSSE [115] 
Increased CPK T. dioica root 
T. dioica fruit 
[120] 
[119] 


















Increased serum troponin Ellagic acid [106] 
Elevated LDH Naringin 
T. dioica root 



































Silybum marianum [108] 
Increased ALP activity Silybum marianum [108] 
Increased CRP Grape seed & skin extract [115] 





Downregulated NRf2 Naringin 













Upregulation of Keap-1 Silybum marianum (liver) [108] 
Decreased SOD activity Naringin 
T. dioica root 






Grape seed & skin extract 
EGCG 
Omega-3 
Flax seed oil 
Boerhavia diffusa 





















Decreased TR activity Phloretin [58] 
Decreased GPx activity T. dioica root 




Grape seed & skin extract 
EGCG 
Omega-3 
Flax seed oil 

















Increased GPx activity Ellagic acid [106] 





T. dioica fruit 
Taurine 
Silybum marianum 





Decreased GST activity 
 
 
T. dioica root 













Decreased G6PD activity Silybum marianum [108] 
Downregulated HO-1 Naringin 















Decreased catalase activity T. dioica root 




Grape seed & skin extract 
Omega-3 
Flax seed oil 
Boerhavia diffusa 

























T. dioica root 




















No significant change in GSH Ellagic acid [106] 
Short term GSH elevation 
followed by decrease 






Increased GSSG Selenium 
T. dioica root 









Elevated H2O2 Grape seed & skin extract [115] 




























































Elevated TBARS T. dioica root 
T. dioica fruit 
Silybum marianum 













No change in NO Resveratrol [89] 
















































































DNA fragmentation Morphine 
T. dioica root 












































Elevated caspase-8 activity Sorbus phnuashanesis [114] 
Elevated caspase-9 activity Sorbus phnuashanesis [114] 
Elevated cytochrome-c Taurine [121] 







Increased Bad Taurine [121] 
Increased PUMA Morphine [112] 








Decreased Bcl2/BAX ratio Sorbus phnuashanesis [114] 
Decreased CIAP1, CIAP2, XIAP Morphine3 [112] 
Decreased Survivin Morphine [112] 
Decreased P-Akt/Akt Sorbus phnuashanesis [114] 
Upregulated TGF-β Naringin [122] 
Increased SMAD3 Naringin [122] 
Calcium and Membrane potential 
Decreased NF-κB activity Morphine [112] 
Phosphorylated NF-κB Taurine [121] 


























Increased in Cav1.2 Genistein [116] 































Elevated phosphorylation of JNK 






Decreased activity at mito. 











Decreased ATP content Phloretin [58] 










Decreased OCR Phloretin [58] 
Mito. swelling and pore opening Phloretin [58] 











1 partially restored, 2 further increased, 3 not restored 
Several studies investigated non-polyphenolic compounds. These included 
taurine, a sulfonic acid derivative of the amino acid cysteine; omega-3 fatty acid, 
which is found in fish oil and contains eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA); flax seed oil, an alpha-linoleic acid; and the 







Figure 4. Polyphenolic antioxidant structures 
 
iv.ii.i. Polyphenols (Figure 4) 
•  Biochanin A  
 Biochanin A (BCA) is found in red clover, cabbage, and alfalfa. BCA is a 
flavonoid polyphenol that scavenges free radicals and chelates and mobilizes 
toxins due to the presence of methoxy substitutions [107,146]. BCA is initially 
metabolized into genistein, but if excess BCA is available it is metabolized into 





poor antioxidant properties and can induce oxidative stress by generating free 
radicals [107].  
Sprague Dawley rats were orally treated with sodium arsenite at a 
concentration of 10mg/kg/day or co-administered arsenic with BCA at 10, 20, or 
40mg/kg/day for 6 weeks [107]. BCA was unable to restore arsenic-induced 
elevations in MDA [107]. BCA at the 20μM concentration significantly reduced 
SOD but was incapable of restoring GSH and catalase in heart tissue [107]. 
BCA significantly restored triglyceride levels, LDL and V-LDL cholesterol, 
atherogenic coefficient (AC)- a ratio of non-HDL cholesterol to HDL cholesterol, 
and cardiac risk ratio (CRR)- a ratio of non-HDL cholesterol to total cholesterol 
[107]. No pathological signs of arsenic toxicity were detected in heart tissues 
[107]. It is worth noting that although BCA was not effective at restoring all 
parameters, BCA alone had no negative effects on any variables in normal rats. 
The authors observed that BCA was only moderately effective at restoring 
arsenic-induced damages in cardiovascular tissues because of the pro-oxidative 
properties of the metabolite daidzein [107]. 
Although not the focus of the present study, BCA at 20mg/kg and 40mg/kg 
restored renal dysfunction, measured with urinary urea, creatinine, and BUN 





activity in kidney tissues and protected kidney architecture compared to arsenic-
exposed tissue [107].  
 
• Boerhavia diffusa  
 Boerhavia diffusa (BDE) is a potent antioxidant that contains biologically 
active polyphenols including retinoids and flavonoids as well as amino acids, 
lignins, saponins, b-sitosterols, and tetracosanoic, eicosanoic, stearic, and 
ursolic acids [125,147].  
 H9c2 cardiomyocytes were treated with 5μM, 7.5μM, and 10μM arsenic in 
the presence or absence of 20μg/mL BDE for 24-hours. BDE reversed many of 
the effects of arsenic in H9c2 cardiomyocytes, particularly at the lower doses 
of arsenic tested. BDE (20μg/mL) prevented alterations in morphology and 
cell viability caused by 5μM and 7.5μM arsenic [125]. BDE also increased the 
uptake of neutral red (NR) a supravital dye that viable cells incorporate in the 
lysosome- which had been reduced with 5μM arsenic, and significantly 
rescued LDH release from cells treated with all arsenic concentrations [125]. 
BDE reduced ROS and oxidants (H2O2, OH-, ONOO-), and reduced 
morphological aberrations of apoptosis caused by exposure to 5μM [125]. 





exposure to 5μM and 7.5μM arsenic. Additionally BDE reversed alterations in 
lysosome, ER, and contractile protein morphology in cells exposed to 5μM 
and 7.5μM arsenic, and maintained ER integrity in cells exposed to 5μM 
arsenic [125]. 
 
• Ellagic acid 
 Ellagic acid is a phenolic compound found in blackberries, raspberries, 
strawberries, cranberries, grapes, pomegranate, and walnuts [148]. Ellagic acid is 
considered a potent antioxidant and exhibits antibacterial, antiviral, anti-
inflammatory, anti-fibrotic, anti-atherogenic, anti-mutagenic, and 
immunoregulatory properties [149]. The authors orally administered 30mg/kg of 
ellagic acid to Wistar rats, followed one-hour later by an intraperatonial injection 
of 5mg/kg arsenic for 10 days. Ellagic acid co-treatment increased QTc interval 
and decreased the cardiac biomarkers troponin-I and CK-MB [106]. Ellagic acid 
co-treatment significantly decreased GPx activity, and significantly decreased 
lipid peroxidation in the heart tissue of experimental animals [106]. Ellagic acid 
also prevented arsenic-mediated myofibrillar loss and myofibrillar coagulative 







 (-)-Epigallocatechin-3-gallate (EGCG) is a catechin and the most abundant 
flavonoid found in green tea [101]. EGCG has potent antioxidative activity 
because of the two triphenolic groups in its molecular structure [101] and has 
been used for the treatment of cancer, cardiovascular diseases, and autoimmune 
disease [150,151]. 
Sun et al. (2016) exposed Sprague-Dawley rats to sodium arsenite at a 
concentration of 50mg/kg/day alone or in combination with EGCG at a 
concentration of 50mg/kg/day for 30 days. Additionally, H9c2 cardiomyocytes 
were treated with 1μM arsenic alone or with 1μM EGCG for 24 hours.  
EGCG fully reversed morphological changes in the myocardium including 
necrosis, intracellular edema, myofibrillar derangements, swollen and damaged 
mitochondria, and wavy degeneration of muscle fibers [101]. EGCG significantly 
reduced arsenic accumulation in the hearts of experimental rats and significantly 
inhibited arsenic-induced elevations in the activities of the cytoplasmic enzymes 
LDH, CK-MB, and AST in tissue [101].  
EGCG co-treatment significantly reduced apoptosis, significantly increased 
the catalytic activities of SOD, catalase, and GPx, significantly decreased lipid 





treatment significantly decreased LDH release, increased cell viability, and 
decreased apoptosis, caspase-3 activity, and the level of cleaved caspase-3. 
Additionally, EGCG significantly inhibited arsenic mediated mitochondrial ROS 
[101].  
 
• Eugenol  
 Eugenol is a phenolic monoterpene and member of the allylbenzene 
chemical class of compounds. Eugenol is extracted from clove and has 
antioxidant activity attributed to its methoxyphenolic structure [88].  
Binu et al. (2017) orally exposed Wistar rats to 4mg/kg arsenic with or 
without 5mg/kg eugenol for 30 days. Electrocardiograph (ECG) readings 
performed on anesthetized rats demonstrated that arsenic prolonged QT interval 
and caused low heart rate, while co-treatment with eugenol significantly 
corrected these measures [88]. Eugenol co-treatment significantly decreased 
sodium and calcium tissue electrolytes, and increased potassium tissue 
electrolytes compared to arsenic exposed rats [88].  
Eugenol significantly increased Ca2+-ATPase activity and decreased Na+/K+-





eugenol also significantly decreased levels of the cardiac markers CK-MB and 
LDH, and increased GSH content, GST activity, and GPx activity [88].  
Lipid peroxidation was significantly elevated in the arsenic treated group, 
and significantly restored from eugenol co-treatment. Eugenol co-treatment also 
significantly decreased arsenic deposition in the heart and restored structural 
abnormalities in the myocardium of arsenic treated rats to near normalcy [88]. 
Although the mechanism is not fully elucidated, the authors suggest that eugenol 
may trap free radicals to protect the myocardium from oxidative injury [88].  
 
• Genistein 
  Genistein is a natural biologically active flavonoid found in soy that has 
anti-cancer, anti-inflammatory and antioxidant properties [116]. Wistar rats were 
intravenously administered saline or genistein (10, 50, or 100mg/kg/day) for 7 
days, after which arsenic trioxide (0.8 mg/kg/day) was co-administered for 
another 7 days. Additionally, primary neonatal rat ventricular cells (NRVCs) 
were exposed to 10, 50 or 100μM genistein for 1-hour followed by incubation 
with 5μM arsenic for various time points.   
Pre-treatment with genistein (10, 50, 100μM) attenuated apoptosis in NVRCs 





induced up-regulation of JNK phosphorylation, phosphorylation of 38-MAPK 
(p38-MAPK), and cleaved caspase-3 in vivo and in vitro from exposure to 5μM 
arsenic for 24-hours [116]. In NVRCs, genistein dose-dependently attenuated the 
collapse of mitochondrial membrane potential induced with 12-hour exposure to 
5μM arsenic, and DNA fragmentation induced with 24-hour exposure to 5μM 
arsenic [116]. In addition, pretreatment with genistein was effective against 
intracellular Ca2+ overload in NVRCs induced with 6-hour exposure to 5μM 
arsenic, and up-regulation of Cav1.2 (an alpha1 subunit of L-type calcium 
channel carrying IcaL) in vivo and in NVRCs following 6-hour exposure to 5μM 
arsenic.  
In vivo, genistein dose-dependently shortened arsenic-induced QT interval 
prolongation, and improved cardiac function impairment, including arsenic-
induced reduced heart rate and reduced cardiac output in Wistar rats [116].  
 
• Grape seed and skin extract  
 Grape seed and skin extract (GSSE) is a polyphenolic mixture containing 
flavonoids, stilbenes, proanthocyanidins, and other polyphenols [115]. The 
antioxidative effects of GSSG may be due to flavonoid components such as 





resveratrol, a stilbene found in GSSE, or due to a synergism between 
polyphenols [115]. 
Wistar rats were exposed to 2.5mg/kg of arsenic trioxide in the presence or 
absence of 4g/kg GSSE for 21 days. Arsenic did not significantly alter body mass 
or heart mass of experimental animals, nor were total cholesterol or triglyceride 
levels affected. Alternately, arsenic exposure did provoke myocardial 
inflammation (measured with plasma CRP and LDH) and led to significantly 
elevated arsenic concentrations in plasma and heart tissue, while GSSE co-
treatment significantly corrected the above disturbances to near control levels 
[115]. GSSE counteracted arsenic-induced increases in lipid peroxidation, 
carbonylation and non-protein sulfhydryl (NPSH) in the heart, all of which are 
promoted by ROS [115]. GSSG-co treatment also rescued catalase activity, GPx 
activity, and SOD activity to near control levels.    
Interestingly, expression of the Cu/Zn SOD isoform was highly depressed in 
this study, while the Mn SOD isoform was unchanged. Thus the authors 
investigated the effect of arsenic on transition metals and determined that arsenic 
depleted copper in the heart, slightly increased zinc level in the heart, and had no 
effect on heart manganese [115]. In agreement with these findings, arsenic 





zinc containing enzyme), and had no effect on the manganese-dependent 
glutamine synthase [115]. Heart copper deficiency is a recognized cause of 
myocardial fibrosis and heart failure. Copper deficiency has also been linked to 
cardiomyopathy, decreased cytochrome-c oxidase activity, hydrogen peroxide 
generation, and calcium dysregulation [153]. The authors suggest that the effect 
of arsenic on transition metal distribution (i.e. copper depletion and iron 
overloading), could be an initiation point of arsenic induced oxidative stress 
[115]. Importantly, GSSE significantly counteracted the effects of arsenic on 
transition metals and enzyme activities [115].  
Compared to arsenic exposed rats, GSSE significantly decreased 
triglycerides, cholesterol, and lipase activity in the hearts of co-treated rats [115]. 
GSSE-co treatment also significantly decreased hydrogen peroxide, free iron, 
ionizable calcium, and calpain activity (a calcium dependent protease) [115]. 
GSSE was partially effective at correcting arsenic-induced effects on myocardial 
architecture such as decreased myocardial size, cytoplasmic vacuolization, 








• Imperatorin and sec-O-glucosylhamaudol 
 Radix Saposhnikoviae is a traditional Chinese medicine from the root of 
Saposhnikovia divaricata (Turcz.) Schischk that contains the flavonoid components 
imperatorin and sec-O-glucosylhamaudol [113].  
These two extracts were compared at a variety of concentrations for their 
ability to counteract the toxic effects of arsenic trioxide on cardiomyocytes. Hu et 
al. (2016) administered antioxidants 1-hour prior to exposing cardiomyocytes to 
2μM/mL arsenic for 24 hours. Both imperatorin (20, 30, 40 up to 90μg/ml) and 
sec-O-glucosylhamaudol (60, 70, 80μg/ml) protected against arsenic-induced cell 
death [113]. Fifty micrograms per milliliter of imperatorin or 50μg/ml sec-O-
glucosylhamaudol prevented LDH release. Imperatorin (100μg/ml) and sec-O-
glucosylhamaudol (50μg/ml) prevented apoptosis, however, neither antioxidant 
decreased caspase-3 activity. Imperatorin (50 and 60μg/ml) reduced ROS and 
oxidants (H2O2, HO-, and ONOO-), but sec-O-glucosylhamaudol failed to 
suppress ROS. Neither imperatorin nor sec-O-glucosylhamaudol significantly 
restored arsenic induced elevations in cellular calcium levels [113]. 
Compared to control cells, single exposure to arsenic, imperatorin, or sec-O-
glucosylhamaudol increased mRNA expression of Nrf2, NQO1, and HO-1. 





arsenic exposure led to a further significant increase in mRNA levels of Nrf2 
compared to arsenic treated cells. Additionally, pre-treatment with imperatorin 
(100μg/mL) or sec-O-glucosylhamaudol (50μg/mL) followed by arsenic exposure 
further significantly increased the expression levels of NQO1 mRNA [113]. In 
contrast, Imperatorin pre-treatment (50μg/mL) significantly decreased HO-1, yet 
sec-O-glucosylhamaudol had no significant effect on HO-1 in combination with 
arsenic.  
In agreement with the effects of these antioxidants on mRNA expression, co-
exposure to arsenic and imperatorin or sec-O-glucosylhamaudol significantly 
increased NQO1 protein levels.  Again, imperatorin (75μg/mL) co-treatment 
decreased HO-1 protein levels, whereas Sec-O-glucosylhamaudol co-treatment 
further significantly increased HO-1 protein levels. Although the authors do not 
offer an explanation for this apparent contradiction, they suggest that future 
studies should examine the significance of the downregulation of HO-1 mRNA 
and protein expression [113]. 
 
• Malus domestica apple peel extract 
 Malus domestica L. peel contains polyphenolic flavonoids such as 





domestica L. peel has been reported to inhibit arsenic trioxide-induced LDL 
oxidation, reduce ROS, exhibit antihypertensive properties, and protect against 
damaged DNA and mitochondria [118]. Vineetha et al. (2014) investigated 
aqueous and methanolic extract of apple peel (40μg/mL) against 5μM arsenic in 
H9c2 cells exposed for 24-hours (unless otherwise noted).   
Both aqueous extract and methanolic extracts demonstrated high phenolic 
and flavonoid content [118]. Co-treating H9c2 cardiomyocytes with apple peel 
extracts effectively increased cell viability, decreased LDH release, and reduced 
morphological indications of apoptosis induced by arsenic trioxide. Apple peel 
extracts decreased mitochondrial superoxide, ROS, and oxidants (H2O2, OH-, and 
ONOO-). Apple peel extracts also reversed arsenic induced alterations in GPx 
activity to near control levels, reversed short term (6-hour) increases in GSH 
content and longer term (>12-hour) decreases in GSH content.  
Arsenic exposure significantly decreased SOD and catalase activity, while 
apple peel extracts significantly reversed these trends [118]. Apple peel extracts 
decreased XO activity, caspase-3 activity, and calcium levels, and increased TR 







• Naringin  
 Naringin, a flavonoid antioxidant, is a polyphenolic compound found in 
citrus fruit that has anti-inflammatory, antioxidant, antihypertensive, and anti-
cancer activities [122].  
Adil et al. (2016) orally exposed Sprague-Dawley rats to 5mL/kg arsenic for 
28 days in the presence or absence of Naringin (20, 40, or 80mg/kg). Naringin (40 
and 80mg/kg) increased heart weight, body weight, and heart rate, and 
decreased QRS, QT, QTc, and RR interval compared to arsenic-only treated rats 
[122]. Naringin (40 and 80mg/kg) also significantly decreased systolic and 
diastolic blood pressures, and significantly decreased left ventricular end 
diastolic pressure (LVEDP) compared to arsenic-only treated rats [122].  
Naringin (40 and 80mg/kg) fully prevented edema, vacuolization, 
cytoplasmic eosinophilia, and inflammation, and partially reversed nuclear 
pyknosis, fibrosis, and collagen deposition in the myocardium of arsenic treated 
rats [122].  The higher concentrations of naringin significantly decreased serum 
levels of LDH, CK-MB, AST, ALT, ALP, total cholesterol, triglycerides, LDL and 
V-LDL, whereas serum HDL was significantly increased compared to arsenic-





increased SOD level, GSH level, and Na+/K+-ATPase activity, and significantly 
decreased MDA and NO content compared to the arsenic treated group [122]. 
Naringin co-treatment (40 and 80mg/kg) significantly increased the activity 
at mitochondrial complexes I-IV and reduced the appearance of swollen and 
degenerated mitochondria with dilated perinuclear membrane and vacuolization 
[122]. Co-treatment with naringin (40 and 80mg/kg) also restored arsenic-
induced alterations in cardiac Nrf2 and HO-1, Smad-3 and TGF-β mRNA 
expression. Naringin (40 and 80mg/kg) also decreased apoptosis and decreased 




 Phloretin is a polyphenolic flavonoid found in apples and other sources. 
Vineetha et al. (2015) exposed H9c2 cells to 5μM arsenic along with phloretin (2.5 
and 5μM). Both phloretin concentrations increased cell viability and decreased 
LDH release compared to arsenic exposed cells. Phloretin (2.5 and 5μM) also 
restored arsenic- mediated increases in ROS and oxidants (mitochondrial 
superoxide and combined H2O2, OH-, and ONOO-) and arsenic- mediated 





treatment with phloretin at both concentrations decreased Nrf2 to levels near 
control cells [58].  
Phloretin at both concentrations significantly restored arsenic-induced 
increases in XO and caspase-3 activity, and significantly restored arsenic-induced 
decrease in aconitase activity. Arsenic exposure significantly elevated calcium 
content and significantly reduced Ca2+-ATPase activity compared to control cells, 
whereas treatment with phloretin at both concentrations significantly restored 
these parameters [58].  
Phloretin co-treatment significantly decreased mitochondrial superoxide 
levels compared to arsenic exposed cells, and phloretin restored activity in 
mitochondrial complexes I, III, and IV. In this study, arsenic did not result in 
significant changes in mitochondrial complex II. Phloretin restored arsenic-
mediated decreases in ATP content, disruptions in transmembrane potential, and 
PTP pore opening, as well as arsenic-mediated reductions in oxygen 
consumption rate. Arsenic exposure also mediated mitochondrial swelling, 
which was restored with phloretin, and phloretin returned the percentage of 








 Resveratrol is a polyphenolic stilbene found in red wine. Zhang et al. 
(2013) studied the effects of resveratrol (8 mg/kg) against arsenic (3mg/kg) in 
Wistar rats exposed every other day over an 8-day period. Arsenic exposure led 
to increased arsenic content in the hearts of Wistar rats, whereas resveratrol 
significantly reduced this accumulation. Compared to arsenic treated rats, rats 
co-treated with resveratrol demonstrated a significant decrease in markers 
associated with myocardial injury including LDH, CK, CK- MB, and AST 
measured in plasma. In addition, resveratrol significantly reversed arsenic-
mediated increases in the levels of ROS species and markers of oxidation (H2O2, 
OH-, ONOO-, 8-OHdG, and GSH/GSSG ratio). Resveratrol significantly reduced 
Ca2+ content compared to the arsenic treated group [89]. Resveratrol co-treatment 
partially restored arsenic-mediated myofibril loss, cardiomyocyte necrosis, and 
decreased cAMP levels in the heart [89].  Arsenic also mediated down regulation 
in Nrf2 and HO-1 mRNA gene expression in the heart, both of which were 
restored with resveratrol. In this study, there was no significant change in NO 
concentration in arsenic-treated or resveratrol-treated groups, possibly due to the 





Another study conducted by Zhao et al. (2008) tested resveratrol (3mg/kg/) 
against arsenic (1mg/kg) exposure in BALB/c mice. Animals were exposed to 
arsenic intravenously on alternate days over a 6-day period. Mice co-treated with 
resveratrol received resveratrol injections 1-hour prior to arsenic exposure.  
In vivo, resveratrol reduced QT elongation, decreased LDH activity in 
plasma, and increased catalase, GPx, and SOD activities compared to arsenic 
treated mice. Structural abnormalities following arsenic exposure (cytoplasmic 
vacuolization, myofibrillar loss, and cardiomyocyte necrosis) were partially 
prevented with resveratrol co-treatment [124]. Additionally, TUNEL-positive 
cells were detected with a greater frequency in the hearts of arsenic treated mice 
compared to control mice and this parameter was dramatically decreased by 
resveratrol treatment [124].  
In vitro, H9c2 cardiomyocytes were pre-treated with 0.1, 1 or 10μM 
Resveratrol, followed 1-hour later by 10μM arsenic for 24-hours [124]. 
Resveratrol dose-dependently increased cell viability and dose-dependently 
reduced LDH release to the medium. Resveratrol dose-dependently reduced 
apoptosis and DNA damage, and pre-treatment with 10μM resveratrol returned 





Additionally, pre-treatment with 10μM resveratrol significantly restored arsenic-
induced increases in Ca2+ accumulation and Caspase-3 activity [124].  
 
• Resveratrol & genistein 
 Fan et al. (2014) investigated the effects of the flavonoid genistein (50μM) 
and the stilbene resveratrol (5μM) on primary neonatal rat left ventricular 
myocytes (NRLVMs) exposed to arsenic (5μM). Cardiomyocytes exposed to 5μM 
arsenic for 12-hours along with resveratrol or genistein demonstrated neutralized 
ROS and oxidants (H2O2, OH-, and ONOO-) generation and increased 
mitochondrial transmembrane potential. Resveratrol co-treatment reversed 
decreases in GSH while resveratrol and genistein co-treatment reversed the 
reduction in SOD activities induced with 24-hour arsenic exposure. Additionally, 
genistein and resveratrol enhanced autophagy in 24-hour arsenic treated 
cardiomyocytes. LC3, a marker of autophagy, was also measured due to the 
functional relationship between the mediators regulating oxidative stress and 
autophagy [154]. LC3 was elevated in resveratrol and genistein-arsenic groups 
compared to the arsenic treated group [117]. Therefore, an enhancement of 
autophagy in antioxidant-treated groups may represent a beneficial, 





organelles (mitochondria), whereas arsenic-treated groups demonstrated lower 
levels of autophagy and higher levels of apoptosis [117].  
Moreover, resveratrol and genistein protected against apoptosis, DNA 
fragmentation, and decreased cell viability induced by a 24-hour exposure to 
arsenic. When examined individually, a much lower dose of Resveratrol (5μM) 
was needed to achieve these effects in cardiomyocytes compared to genistein 
(50μM).  
Although not the focus of the present review, Fan et al. (2014) also 
investigated the effects of arsenic and resveratrol/genistein in NB4 cancer cells. 
Arsenic causes cancer cell apoptosis by binding to protein kinase M2 (PKM2), 
located on the surface of PML/RARA. PKM2 promotes aerobic glycolysis (the 
“Warburg effect”) leading to tumorigenisis and cancer cell proliferation. Arsenic 
reduces PKM2 activity, thus inhibiting cancer cell growth [64]. It is worth noting 
that resveratrol/genistein increased the anti-cancer effects of arsenic in NB4 
cancer cells by increasing ROS, enhancing mitochondrial transmembrane 
potential alteration, reducing GSH content and SOD activity, promoting 







• Silybum marianum  
 Silybum marianum (SB) is a polyphenolic flavonoid antioxidant of 
silymarin isolated from the seeds of milk thistle. SB has been used as a hepato-
protective agent against arsenic induced liver toxicity [155] and has membrane 
stabilizing, anti-inflammatory, antioxidant, metal chelation, and cardioprotective 
qualities [156].  
Wistar rats were exposed to 5μM arsenic, 75μM SB, or both for 4-weeks [155]. 
SB significantly decreased the activities of cardiac enzymes (CK-MB, LDH, AST, 
ALP), increased heart mitochondrial enzymes (ICDH, SDH, MDH, α-KDH, and 
NADH hydrogenase), decreased levels of plasma and cardiac lipids (cholesterol, 
triglycerides, and free fatty acids) and increased phospholipids compared to 
arsenic exposed rats [155]. Pre-treatment with SB significantly restored arsenic-
induced increases in LDL cholesterol and V-LDL cholesterol, and restored 
arsenic-induced decrease in the level of HDL cholesterol in plasma. Markers of 
oxidative stress in the heart were significantly reduced by SB-co treatment, 
whereas GSH content, SOD activity, catalase activity, GPx activity, GST activity, 
GR activity, and G6PD activity were significantly increased compared to the 
arsenic treated group. SB partially reversed arsenic-induced changes in 





in the membrane bound ATPases Na+/K+-ATPase, Ca2+-ATPase, and Mg2+-
ATPase. SB co-treatment decreased the NOX2 and NOX4 protein levels. NOX 
family proteins mediate ROS, including H2O2 and superoxide, thus decreased 
NOX expression should decrease anti-oxidant responses. Indeed, SB co-treatment 
normalized arsenic-altered protein expression of Nrf2, HO-1, and Keap-1 in 
arsenic treated liver [155].  
 
• Sorbus phnuashanesis (Hante) Hedl  
 Sorbus phnuashanesis (SPF) is a traditional Chinese herb with high 
flavonoid antioxidant activity. Yu et al. (2017) exposed BALB/c mice to 5, 10 or 
20mg/kg SPF by intraperitoneal injection followed one-hour later with 1mg/kg 
arsenic by intravenous tail injection for 14-days.  
Arsenic caused structural abnormalities in heart tissue including cytoplasmic 
vacuolization, myofibrillar loss, and cardiomyocyte necrosis compared to control 
animals, whereas SPF pretreatment significantly alleviated these alterations 
[114]. ECG analysis demonstrated that SPF prevented arsenic-induced alterations 
in ST-T wave change and QT-interval prolongation. All SFP concentrations 
significantly reduced serum cardiac enzymes (CK, CK-MB, and LDH) compared 





In vitro, H9c2 cells were pre-treated with 4μM arsenic or co-treated with 
arsenic and 20μg/mL SPF for 24-hours. SPF significantly maintained cell viability 
and reduced the release of LDH observed in cells exposed to arsenic for 24-hours. 
Arsenic reduced the activities of SOD, catalase, and GPx in vivo and in vitro 
following 24-hour exposure, whereas SPF significantly alleviated these oxidative 
stress responses [114]. In vitro, SPF significantly decreased arsenic mediated 
elevation in levels of H2O2, OH- and ONOO-. Pre-treatment with SPF prevented 
arsenic-induced apoptosis in vitro and arsenic-mediated increases in the 
expression of caspase-3, caspase-8, and caspase-9 both in vivo and in vitro [114]. 
SPF also restored arsenic-induced reductions in Bcl-2/BAX protein ratios.   
Akt plays a role in arsenic-induced apoptosis and can activate Nrf2. Arsenic 
significantly reduced the ratio of Akt phosphorylation to total Akt, but this was 
reversed by SPF co-treatment in H9c2 cells [114]. In agreement, Nrf2 expression 
was significantly reduced by arsenic, and significantly restored by SPF co-
treatment. The Nrf2/antioxidant responsive element (ARE) signaling pathway 
can induce phase II detoxification enzymes including HO-1. Treatment by SPF 







• Trichosanthes dioca 
 Trichosanthes dioca (T. dioica) is a dioecious climber found in northern 
and northeastern India [120]. All parts of the plant have been used for medicinal 
purposes. The roots contain flavonoids, alkaloids, reducing sugars, saponins, and 
steroids [120], and the fruit contains flavonoids, glucosides, and alkaloids [119]. 
Bhattacharya et al. (2014) evaluated the hydroalcoholic extract of T. dioica root 
(TDA) against arsenic toxicity in vivo, and Bhattacharya et al. (2013)  evaluated 
the aqueous extract of T. dioica fruit (AQTD) against arsenic toxicity in vivo.   
Although these experiments are reported in separate journals, the 
experimental design was identical. In both sets of experiments, Wistar rats were 
orally administered water or the respective antioxidant (TDA at 5 or 10mg/kg 
[120], or AQTD at 50 and 100mg/kg [119]) every other day for 20 days. On day 
21, sodium arsenite was orally administered at 10mg/kg for 8 consecutive days. 
Arsenic significantly reduced heart and body weight whereas pretreatment with 
TDA or AQTD dose-dependently ameliorated these effects [120]. White blood 
cell (WBC) count significantly increased and δ-aminolevulinic acid dehydratase 
(ALAD), red blood cell (RBC) count, and hemoglobin significantly decreased in 
arsenic exposed rats, whereas TDA or AQTD significantly and dose-dependently 





Pre-treatment with TDA or AQTD significantly and dose-dependently 
decreased CPK, LDH, and total serum cholesterol, and increased HDL 
cholesterol compared to arsenic treated rats [120]. TDA and AQTD pre-treatment 
reduced TBARS, increased GSH content and decreased GSSG content compared 
to arsenic treatment of myocardial tissues [120]. GST, GPx, GR, SOD, and 
catalase activities were significantly decreased in arsenic-treated rats and 
significantly modulated by TDA or AQTD in a dose related manner [120]. DNA 
fragmentation was prevented by TDA or AQTD treatment prior to arsenic 
exposure [120].  
While both the fruit and roots of T. dioca were effective against arsenic-
induced toxicity, it is worth noting that a significantly lower dose of TDA (5 or 
10mg/kg body weight) compared to AQTD (50 or 100mg/kg body weight) was 







Figure 5. Structure of non-polyphenol antioxidants 
 
iv.ii.ii. Other antioxidants (Figure 5) 
• α-lipoic acid 
 α-lipoic acid (LA) is an organosulfur compound derived from octanoic 
acid. LA contains two sulfur atoms connected by a disulfide bond and has 
antioxidant properties. Kumazaki et al. (2011) injected Wistar rats with 
5mg/kg/day arsenic for 8 weeks in the presence or absence of 35mg/kg/day LA 
administered orally. Two of the 4 arsenic-exposed rats died suddenly at days 25 





through the study [111]. Unexpectedly, LA did not prevent arsenic-induced 
decreases in body weight, decreased AST, or increased urinary excretion of 8-
OHDG-an indicator of oxidative stress. This led Kumazaki et al. (2011) to 
hypothesize that LA prevented death without reducing oxidative stress, possibly 
through preventing sudden cardiac death [111]. To test this hypothesis, the 
authors exposed Wistar rats to 0.15, 1.5 and 5mg/kg arsenic for 2-hours followed 
by 70mg/kg LA in order to assess the EKG profile [111]. Arsenic didn’t 
significantly alter QTc, but the highest arsenic dose caused transient ST-T wave 
change from 5-30 minutes post infusion, and prolonged the PQ interval [111]. LA 
prevented alterations in ST-T wave and PQ interval [111].  
In a subsequent study, Kumazaki et al. (2013) further explored the 
cardioprotective effects and chelation potential of LA against QT interval 
prolongation in a guinea pig model [110]. Hartley guinea pigs were exposed to 
1.5mg/kg arsenic intravenously in the presence or absence of LA (0.35, 3.5, or 
35mg/kg). The experiment was repeated with LA post-treatment occurring one-
hour after arsenic treatment. Both sets of experiments exposed guinea pigs for a 
2-hour time frame and ECG readings were taken in live guinea pigs [110].  
Continuous infusion with arsenic prolonged QTc interval as early as 60 





attenuated by LA co-treatment [110]. Post-treatment with LA also rapidly 
ameliorated QTc interval prolongation observed with arsenic exposure [110]. The 
authors suggest that arsenic may induce QT prolongation via the human ether-a-
go-go-related gene (hERG) channel, thus, Kumazaki et al. (2013) looked at acute 
exposure on the slowly activating delayed rectifier K+ current (IKs) in ventricular 
myocytes isolated for patch clamping.  
Cardiomyocyte exposure to 1μM arsenic inhibited IKs currents and reduced 
amperage, both of which were rapidly restored to basal levels with 10μM LA. 
After washout of LA, arsenic-induced IKs inhibition returned [110]. Decreased IKs 
current prolongs ventricular repolarization, and is one of the most important 
mechanisms involved in Torsades de Pointes [157].  
LA and its reduced form dihydrolipoic acid (DHLA) bind metal ions, thus 
the chelating potential of LA was investigated with electrospray ionization time-
of-flight (ESI-TOF) mass spectrometry analysis. When arbitrary concentrations of 
LA and arsenic trioxide were mixed, a peak at m/z 450.98 was detected 
indicating that one molecule of LA (MW 206.3) bound one molecule of As2O3 
(MW 197.8) with solvent molecules (formic acid (MW 46.0) and protons (MW 
1.0)). This peak was not present when the two molecules were analyzed 





• Flax seed oil 
 Flax seed oil (FSO) is a rich plant source of polyunsaturated fatty acid 
alpha-linolenic acid (ALA), a precursor to eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) which has anticancer, anti-inflammatory, and anti-
atherogenic effects [158]. Wistar rats were exposed to 4mg/kg/day arsenic in the 
presence or absence of 500mg/kg FSO for 45-days [105]. FSO decreased arsenic 
deposition in the heart and restored structural changes in cardiac tissue 
compared to arsenic-treated rats [105]. Importantly, FSO significantly reduced 
CK-MB levels, LDH levels, and TBARS, and significantly increased GSH level 
and the activities of SOD, GPx, GST, and Catalase compared to arsenic treated 
rats [105].  
 
• Morphine  
  Morphine, an opioid, has antioxidant effects including ROS scavenger 
capacity, NADPH oxidase activity, and increased glutathione levels [159].  Pre-
treatment with 1μM morphine protected H9c2 cardiomyocytes against 24-hour 
0.5, 1, and 2μM arsenic-induced decreases in cell viability, decreased activity at 
mitochondrial complex II, and increases in mitochondrial superoxide, and ROS 





DNA damage, while morphine pre-treatment significantly prevented this 
deleterious effect [112]. Morphine significantly decreased caspase-3 activity 
induced with 24-hour exposure to 1 and 2μM arsenic [112]. Forty-eight hour 
exposure to 2μM arsenic significantly increased the expression of pro-apoptotic 
BAX and PUMA genes, and significantly decreased the expression levels of anti-
apoptotic BCL-2, Survivin, CIAP1, CIAP2, XIAP, and BCL-XL, whereas 
morphine significantly reversed alterations in BAX, PUMA, BCL2, and Survivin 
[112]. Additionally, morphine pre-treatment significantly activated NF-κB 
compared to 0.5-2μM arsenic treated cells [112].  
Using morphine in clinical settings is controversial, particularly for chronic 
or non-cancer pain, based on concerns about addiction, safety, and efficacy [160]. 
Amini-Kohei et al. (2016) is the only report we are aware of using morphine to 
prevent arsenic induced cardiovascular toxicity, but it is worth noting that the 
antioxidant properties of morphine have been reported to protect against 
methyl-mercury intoxication in rat glioma cells [161] and reverse oxidative 
damage in neuroblastomas [162], astrocytes [163], and microglial cells [159]. 
Proposed mechanisms for the antioxidant properties of morphine include direct 
scavenger activity [159] recovery of GSH levels [162], and/or inhibition of 





morphine induces cardioprotection by preventing oxidative stress through 
mitochondrial Src tyrosine kinase at mitochondrial complex 1 [165].  
 
• Omega-3 fatty acid  
 Omega-3 fatty acids, found in abundance in fish oil, are long chain 
polyunsaturated fatty acids with a common chain length of 18, 20, or 22 carbon 
atoms containing a C=C bond at the third carbon from the end, a carboxylic acid 
(COOH) at one end and a methyl (CH3) at the other end [109]. Omega-3s 
influence oxidative stress by inhibiting the production of inflammatory proteins, 
decreasing NF-κB activation, and reducing MAPKs [166]. Consuming omega-3 
fatty acids, particularly eicosapentaenoic (EPA) and docosahexaenoic acid 
(DEA), decrease the risk of heart failure, and influence cardiac mitochondrial 
function by impacting membrane phospholipids [167]. Varghese et al. (2017) 
investigated the effect of omega-3 fatty acid (50mg/kg) in vivo in Wistar rats 
exposed to 4mg/kg arsenic for 45 days.  
Omega-3 co-treatment decreased arsenic deposition in heart tissues and 
decreased CK-MB [109]. Omega-3s also decreased lipid peroxidation, and 
increased GPx activity, GSH content, GST activity, SOD activity, and catalase 





reduced the observed frequency of micronuclei and the presence of abnormal 
cardiac structures such as swelling near the epicardium, endocardium, and 
interstitial edema [109].  DHA (100μM) protected against 24-hour, 10μM arsenic-
induced LDH release, lipid peroxidation, intracellular Ca2+ accumulation, and 
alterations in MMP in cardiomyocytes [109].  
 
• Selenium 
 Selenium is an essential trace element present in legumes at 
concentrations that vary based on soil selenium levels. Selenium and arsenic 
interact metabolically, resulting in biliary excretion as seleno-bis-S (glutathionyl)-
arsenium ion ([GS)2AsSe]-) [123]. Krohn et al. (2016) exposed APO E-/- mice to 
selenium deficient (0.009mgk/kg), selenium adequate (0.16mg/kg), or selenium 
fortified (0.3mg/kg) diets for 2 weeks, followed by 3 weeks of concurrent 
exposure to 200ppb sodium arsenite in drinking water [123]. Arsenic exposure 
significantly increased atherosclerotic plaque formation in the aortic arch of 
selenium deficient and selenium adequate mice, whereas arsenic exposed mice in 
the selenium-fortified group demonstrated reduced plaque formation that 
resembled selenium-fortified controls [123]. Arsenic exposure in conjunction 





indicating decreased plaque stability [123]. Arsenic also increased oxidative 
stress, measured as decreased concentration of hepatic GSSG, whereas selenium-
containing diets significantly restored hepatic GSSG [123]. Arsenic exposure in 
conjunction with a selenium-deficient diet decreased HDL to LDL ratio 
compared to the two other diets.  
 Krohn et al. (2016) report no significant effects of arsenic on total serum 
cholesterol, LDL cholesterol, triglyceride level, or TBARS. However, the authors 
report a significant effect of diet on numerous endpoints regardless of arsenic 
exposure. For example, selenium deficiency increased lesion area in control and 
arsenic exposed mice. Furthermore, total cholesterol, LDL, and triglycerides were 
increased in selenium deficient groups regardless of arsenic exposure. This study 
highlights the negative effects of selenium deficiency alone on cardiovascular 
health, which resulted in increased plaque formation, as well as the exasperation 
of plaque formation in the arsenic exposed and selenium deficient condition 
[123].  
 
• Taurine  
 Taurine is a sulfonic acid derivative of the amino acid cysteine, which is 





Rather, taurine is believed to serve as a regulator of mitochondrial protein 
synthesis, which enhances the electron transport chain and protects 
mitochondria against excessive superoxide generation [156,168]. Taurine is 
involved in ion channels, transporters, and enzymes, modulates intracellular 
calcium [169], and has antioxidant properties [170]. 
Zhao et al. (2008) exposed Wistar rats to 2 mg/kg arsenic for 5 weeks, or 
50mg/kg taurine for 2 weeks followed by 2mg/kg arsenic for 5 weeks. The in vitro 
component of this study involved exposing neonatal cardiomyocytes to 25mM 
taurine, 5μM arsenic, or 25mM taurine followed by 5μM arsenic (after 1-hour) 
for 24-hours. Overall, taurine increased SOD, catalase, GST, GR, and GPx 
activities, and increased GSH level and GSH/GSSG ratio compared to the arsenic 
treated group [121]. Taurine significantly decreased total cholesterol, MDA, and 
LDH compared to the arsenic treated group, and increased the level of HDL 
cholesterol to near control levels [121]. Taurine also improved cell viability and 
decreased apoptosis compared to arsenic-treated rats [121]. 
Taurine decreased NF-κB pathway phosphorylation [121]. Confirming the 
involvement of the NF-κB pathway in apoptosis, pre-incubation with the IKK 
inhibitor PS-1145 prevented arsenic-induced phosphorylation, caspase-3 





can activate MAP Kinases as well as NF-κB, as MAPKs are mediators of cell 
death due to apoptosis [121]. The protein content of the MAPKs p38 and p-JNK, 
and to a lesser extent PERK, were elevated in heart tissue and cardiomyocytes 
following arsenic exposure, and taurine significantly decreased these parameters 
[121]. Pre-treatment with p38 and p-JNK inhibitors prevented arsenic induced 
NF-κB activation, suggesting that MAPK activity contributes to NF-κB activation 
[121].  
Arsenic upregulated pro-apoptotic proteins BAX and Bad, and 
downregulated anti-apoptotic proteins Bcl2 and Bcl-xL, whereas taurine 
mitigated these effects [121]. Taurine increased mitochondrial membrane 
potential, reduced cytosolic cytochrome c content, and decreased intracellular 
Ca2+ compared to arsenic exposed groups [121].  
 
v. Discussion  
 Arsenic impairs all aspects of mitochondrial function and mitigates 
apoptosis by elevating ROS. The antioxidants presented in this review largely 
prevented arsenic-induced pathology in vivo and in vitro. Compared to arsenic 
treatment alone, co-treatment with phytonutrient antioxidants restored cardiac 





reduced calcium overload, restored ATP content, and restored the activity of 
mitochondrial complexes. While particularly toxic to mitochondria, arsenic 
exposure also led to structural abnormalities in the endoplasmic reticulum, 
lysosomes, and contractile proteins [125]. It is worth noting that antioxidants 
were reported to be partially effective at restoring arsenic-induced alterations in 
the morphology of mitochondria and other organelles [122].  
 
v.i. Identifying inconsistencies 
 Several inconsistencies are worth mentioning. In one study arsenic caused 
a short-term increase in GSH [118], yet arsenic decreased GSH in all other 
instances [122]. Since GSH was also reduced at 12 and 24-hours [118], the short 
term increase was likely a compensatory, beneficial mechanism in response to a 
specific arsenic dose and time.  
Similarly, one study reported increased GPx activity after exposing Wistar 
rats to 5mg/kg arsenic for 10 days [106]. This contrasts with the majority of 
studies in which arsenic decreased GPx activity [120]. It is possible that increased 
GPx activity reported by Hemmati et al. (2017) resulted from the relatively short 
exposure time (10 days) compared a much longer average exposure time of 25.4 





Additionally, one in vitro study reported arsenic-induced increase in Nrf2 
level in conjunction with increased HO-1 and increased NQO1 [113]. In contrast, 
the majority of studies used an in vivo model and reported decreased Nrf2 level 
and decreased level of HO-1 [122]. It is possible that a difference in the in vitro 
cell culture environment caused this variability in the Nrf2 pathway [113]. 
Interestingly, past research has demonstrated that arsenic-induced effects often 
fail to follow a typical dose-response pattern [171,172]. This supports the 
hypothesis that the increase in antioxidant-related pathways is not an 
inconsistency due to technical variations but a true bimodal response that is 
dependent on dose and time of exposure to arsenic that can lead to increased 
upregulation of compensatory pathways. In agreement, past studies of various 
cell types have reported arsenic-induced upregulation of the Nrf2 pathway [128-
132].  
In addition to testing antioxidants against arsenic, all of the studies included 
in this review reported on the impact of antioxidants in the absence of arsenic 
(untreated conditions) to examine any potential beneficial or detrimental effects 
on cells/animals exposed to antioxidants alone. As expected, no significant 
positive or negative effects of antioxidants were reported, with the notable 





Nrf2 pathway. This is likely a compensatory response to stimulate additional 
antioxidant responses, as the Nrf2 pathway contains electrophile DNA elements 
that can lead to upregulation in the presence of oxidative stress [173].  
 
v.ii. Study comparisons  
 Based on differences in cell type, experimental animal model, arsenic 
dose, duration, and experimental design, a direct comparison of antioxidants 
across studies is not possible in the present review. Only one study compared the 
effects of different antioxidants (resveratrol vs. genistein) in vitro and determined 
that resveratrol requires a lower dose for the same efficacy against 5μM arsenic 
[117]. We can make a similar comparison between TDA and AQTD, since the 
same experimental setup was used by Bhattacharya et al. (2013) and 
Bhattacharya et al. (2014), revealing that a 10x lower concentration of TDA was 
effective against 10 mg/kg arsenic. Additionally, studies conducted by Adil et al. 
(2016) and Muthumani et al (2014) used the same arsenic-dosing paradigm and 
numerous overlapping endpoints. Thus, we can conclude that 40mg/kg naringin 
was as effective as 75μM silybum marianum at reversing the effects of 5mg/kg 
sodium arsenite for the endpoints of total cholesterol, LDL, LDH, AST, ALT, CK-





mitochondrial morphology [122]. In order to improve our understanding of the 
capacity of antioxidants to prevent arsenic induced dysfunction, an in vivo 
investigation should be conducted on the pharmacokinetics of arsenic and 
antioxidants in the heart in relation to cardiotoxicity. 
In vitro, there was some overlap in experimental cell type, arsenic 
concentration, and endpoint, and we can categorize in vitro studies conducted on 
cardiomyocytes by low, moderate, and high arsenic exposure, defined as <2μM, 
2 to 5μM and >5-10μM. We suggest that a more extensive comparative study be 
conducted on H9c2 cardiomyocytes testing polyphenols at their optimized 
concentrations against an intermediate dose of 5μM arsenic.  
 
  v.iii. Limitations 
 Despite the overall strength of the studies included in this review, we 
acknowledge a level of variability in the strength of study design and data 
reporting of included studies (Table S1). All included studies were peer 
reviewed, had clearly stated experimental objectives, and all in vitro studies 
identified the source and/or isolation method of cells. Among in vivo studies, 92% 
fully disclosed the characteristics of the experimental model including animal 





analyzed in this review specified that animals were randomly assigned to 
experimental groups, and all studies used commonly accepted experimental 
methods.   
However, no studies specifically conducted a power analysis to justify the 
size of experimental groups or the number of technical replicates in experiments. 
Additionally, no studies reported effect sizes. In the absence of effect sizes, the 
relevance of antioxidant effects cannot be comparatively assessed.  
With regard to data assessment and reporting, 88% fully reported the 
statistical methods used, and 91% of these studies used appropriate methods.  
The average number of citations per article was 12.1 ± (20.5), and the average 
H index (a measure of productivity and citation impact) for journals in which 
articles were published was 86.8± (50.8). 
While several aspects of these studies are lacking, particularly in the area of 
complete data reporting, our results of the studies analyzed provide compelling 
evidence that antioxidants protect against arsenic-induced mitochondrial 
dysfunction, and make a strong case for performing additional studies that 
directly compare the efficacy of different antioxidants. 
A potential limitation for the applicability of this research in a real world 





defined and categorized based on the nature of their chemical skeletons. Major 
classes are phenolic acids, flavonoids, stilbenes, and lignins. Flavonoids are the 
most abundant polyphenol in our diets, and classes of flavonoids are based on 
the degree of oxidation of the oxygen heterocycle [145,174]. Flavonoid classes are 
isoflavones, flavonols, flavones, flavanols, proanthocyanidins, and anthocyanins 
[145]. 
Assessing polyphenol bioavailability is not straightforward. Measuring 
polyphenol antioxidant quantities is a useful way to compare food items, yet 
polyphenol content cannot necessarily be extrapolated to bioavailability or health 
claims [175]. For example, consuming flavonoid-rich food will only slightly 
increase the flavonoid content of plasma due to the process of polyphenolic 
metabolism, in which flavonoids are broken down into smaller phenolic acids, 
absorbed and metabolized to form glucuronides and sulfide conjugates [175]. 
Conjugated forms of polyphenols appear in circulation and can have altered 
bioactivity from the parent compound [175]. 
Individual variability in levels of the enzymes involved in polyphenol 
metabolism also impact overall bioavailability of polyphenols [175]. Some 
polyphenols are absorbed in the stomach or small intestine, while others are 





microbe populations further alter polyphenol bioavailability at the individual 
level [175]. 
Despite challenges predicting polyphenol bioavailability, studies have 
reported on concentrations of polyphenols circulating in plasma, or the amount 
of polyphenol measured in urine, even though these observations do not 
necessarily correlate with the amount of a compound that reaches a target site to 
exert a desired effect [175].  Although an indirect method to assess 
bioavailability, a more accurate measure of polyphenol bioavailability is to assay 
for markers of peroxidative damage in vivo following polyphenol consumption. 
However, a limited number of studies on polyphenol bioavailability have been 
conducted using this method in humans. The available data suggests that among 
flavonoids, isoflavones have the highest bioavailability, with absorption between 
33-100%, followed by flavonols (12-41%), and flavanones (11-16%) [174]. Tea 
catechins and anthocyanins are among the polyphenols with the lowest 
absorbability, while catechins have intermediate absorption characteristics 
(lower than isoflavones and higher than flavonols [175].)  
An additional potential limitation on applying these findings in arsenic-
affected regions relates to the ability to extrapolate in vitro and animal model 





ameliorative antioxidant treatments employed in the reviewed studies vary 
significantly. Although the doses of arsenicals used in these studies may be 
considered high, they are applicable in the context of human exposures. Humans 
have been acutely and chronically exposed to similar concentrations of arsenicals 
environmentally [176] and in the clinical treatment of acute promyelocytic 
leukemia [177]. Furthermore many epidemiological studies have demonstrated 
the pathological effects of long-term accumulation of arsenicals in human bodies 
at high doses [43,50]. 
We also acknowledge a lack of consensus in the research on the benefits of 
antioxidant supplementation in humans. Observational studies suggest that 
consuming greater amounts of antioxidant-rich foods decreases the risks of 
cardiovascular diseases, stroke, and cancer, but it is not entirely clear if these 
effects are due to antioxidants themselves, due to other substances in fruit and 
vegetables, or a result of other behaviors (such as exercise) among individuals 
who consume a higher volume of antioxidant-rich foods.  
While laboratory studies consistently demonstrate that antioxidants stabilize 
free radicals, many long-term clinical trials of antioxidant supplementation have 
failed to conclusively demonstrate a benefit of antioxidant supplementation. It is 





studies support the role of antioxidant amelioration of oxidative stress in 
humans. For example, 12-week supplementation with 100mg resveratrol 
significantly ameliorated arterial stiffness and decreased serum diacron-reactive 
oxygen metabolites (d-ROMS)-a measure of oxidative stress- in type 2 
diabetics [107], supplementation with 500mg/day resveratrol significantly 
decreased oxidative stress (measured as serum MDA) in subjects with ulcerative 
colitis [108], and supplementation with α-lipoic acid in type-2 diabetics 
significantly increased SOD and GPx, and decreased MDA in subjects compared 
to baseline measures and compared to the placebo-control group [109]. Thus, 
recent clinical trials provide evidence that antioxidant's ability to ameliorate 
oxidative stress translates to human subjects. Additionally, several clinical trials 
have reported mild benefits of selenium pill supplementation on measures of 
arsenic toxicity [178-180], and Krohn et al. (2016) are currently planning a clinical 
trial supplementing the diet of arsenic-exposed individuals in Bangladesh with 
selenium fortified lentils [181]. Also if interest, poor nutrient status and 
malnutrition among arsenic exposed individuals has been associated with 
increased rates of cardiovascular diseases [182], skin lesions [183], and Blackfoot 
disease [184]. This further supports the importance of consuming an adequate 





v.iv. Future directions 
 Given the limitation of low polyphenol bioavailability, research has been 
conducted on combining polyphenols to improve bioavailability. Evidence 
suggests that combined polyphenols can have a synergistic effect, particularly 
with regard to anti-cancer properties.  For example, combining EGCG and 
curcumin allowed for an 8-fold dose reduction in EGCG in the mixture for the 
same therapeutic effect [172]. Additionally, Fan et al. (2014) reported that the 
combination of resveratrol and genistein was more effective against NB4 cancer 
cells than either polyphenol alone [117]. Therefore, based on these 
aforementioned observations in cancer, it is conceivable that combination 
therapies involving more than one polyphenol can exert synergistic effects in 
reversing cardiovascular pathology following arsenic exposure. 
Another promising area of research is on improved polyphenol extraction 
and preservation techniques. Polyphenols are found in many natural sources 
complexed with sugars or proteins, or in polymerized derivatives [172]. To 
achieve effective isolation, proper selection of a solvent for extraction is 
necessary to maintain molecular integrity, and recovery depends on time and 
temperature (high temperature, long extraction times, and alkaline environment 





More recently, encapsulation and nanoformulation have been proposed as 
potential solutions, as these techniques can improve both stability and 
bioavailability of polyphenols [172]. Nanoformulations include nanosuspensions, 
solid lipid nanoparticles, liposomes, gold nanoparticles, micelles, and polymeric 
nanoparticles. Nanoencapsulaton can increase intracellular concentration and 
allow slow and sustained polyphenol release [185]. 
Nanoformulations have been developed for several polyphenols for use 
against cancer cells in pre-clinical trials. Ellagic acid encapsulated nanoparticles 
were developed for use in oral cancer with improved results [186]. In addition, 
EGCG nanoformulations have been used against human prostate cancer cells, 
human melanoma cells, mouse models of melanoma, breast cancer cell lines, and 
breast cancer cells isolated from patients [187]. Silibinin nanoparticles have been 
used against human hepatocellular cells and carcinoma cell lines [188], and 
resveratrol nanoformulations have been used against human prostate cancer cell 
lines [189], murine melanoma cells [190], rat glioma cells [191], human head and 
neck cancer cells [192], and human ovarian cells [193]. Importantly, resveratrol 
has also been developed into a mitochondrial targeting drug to improve anti-
cancer ability [194]. Sassi et al. (2014) linked resveratrol derivatives with an o-





selectively kill fast growing cells [194]. Additionally, a mitochondrial targeted 
prototype nanoformulation of genistein was developed by Pham et al. (2013) and 
is reported to increase cytotoxicity through the intrinsic apoptotic pathway 
against hepatic and colon carcinoma [195].  
Although not focused specifically on arsenic-mediated cardiovascular 
dysfunction, several recent clinical trials have assessed the benefit of polyphenols 
on general cardiovascular effects. For example, Richter et al. (2017) reported that 
isoflavone-containing soya protein supplementation significantly reduced 
brachial diastolic blood pressure compared to a lower dose of soya protein (but 
not compared to control) [196]. Even more compelling, Tenore et al. (2017) 
demonstrated that supplementation with microencapsulated annurca apple 
polyphenol extracts, trade-marked as 'AppleMetS' significantly decreased LDL 
cholesterol, significantly increased HDL cholesterol and significantly decreased 
total cholesterol compared to control subjects in a randomized parallel group 
placebo-controlled 2 week study [185].  
The present review identifies 21 compounds with antioxidant properties that 
are effective against arsenic-mediated mito-toxic effects in cardiovascular tissue. 
We believe that the current limitations in bioavailability of polyphenol 





mitochondrially targeted molecule designed as an antioxidant to block 
mitochondrial oxidative damage [197]. MitoQ selectively accumulates in 
mitochondria and is currently being pursued as a therapy for degenerative 
conditions such as Parkinson disease [198]. While MitoQ has not been tested 
against arsenic-induced cardiotoxiciy, it has demonstrated cardioprotective 
properties against Doxorubicin (DOX), which is used for treating various cancers 
despite severe cardiovascular side effects including congestive heart failure, 
arrhythmias, and cardiomyopathy [199]. Importantly, mitochondria-targeting 
nanoformulations represent a compelling avenue of research for preventing 
arsenic-induced cardiovascular toxicity in a clinical context and among 
individuals chronically exposed to arsenic through ground water or APL 
therapy. 
As a preliminary step, we suggest a pre-clinical approach of comparing 
antioxidant abilities of several combinations of polyphenol antioxidants to 
prevent arsenic-induced mito-toxic effects in H9c3 cardiomyocytes, while 
simultaneously increasing toxicity to NB4 cells. We suggest a focus on the 
mitochondrial endpoints of the Nrf2 pathway and associated antioxidants, 
caspase activation, apoptosis and associated Bcl-2/BAX expression, GSH activity, 





activity at mitochondrial complexes, OCR, and ATP generation. We believe the 
aforementioned proposed studies will give a comprehensive view of antioxidant 
capacity to prevent mitochondrial dysfunction. Following antioxidant selection, 
we recommend developing a mitochondrial-targeted nanoformulation for use in 
H9c3 and NB4 cell lines and Wistar rat models. As mitochondrial targeting 
nanoformulations of resveratrol and genistein have already been developed, 
adapting these formulations for use against arsenic-induced cardiotoxicity may 




Antioxidants have the potential to improve the cardiovascular health of millions of 
people chronically exposed to elevated arsenic concentrations through contaminated 
water supplies or used as lifesaving cancer treatments. While consuming foods 
containing antioxidants is a healthful and useful practice for the prevention of 
cardiovascular disease, additional research is needed on proper compounding, 
encapsulation and nanoformulations that prevent antioxidant degradation and 
improve polyphenol pharmacokinetics in order to counteract arsenic-induced 
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Chapter 3.  





 Arsenic methylation capacity is associated with metabolic syndrome and 
its components among highly exposed populations. However, this association 
has not been investigated in low to moderately exposed populations. We 
investigated arsenic methylation capacity, measured as urinary proportion of 
arsenic species and methylation indices, in relation to the clinical diagnosis of 
metabolic syndrome in a low arsenic exposure population. Additionally, we 
compared arsenic methylation patterns present in our sample to methylation 
patterns among more highly exposed populations.  
 Using linear regression models adjusted for relevant biological and 
lifestyle covariates, we report a positive association between increased arsenic 
methylation and metabolic syndrome among women with normal body mass 
index (BMI). Methylation patterns in our sample were similar to reports of 
methylation capacity among highly exposed populations. To our knowledge this 
is the first investigation of methylation capacity with respect to metabolic 
syndrome in a low exposure population. Additionally, we report that gender and 





syndrome. Future studies should evaluate the effectiveness of current arsenic 
standards on subclinical biomarkers of cardiovascular disease in a model that 
establishes causality.  
 
ii. Introduction  
 Exposure to arsenic has been epidemiologically linked to myriad health 
conditions including cardiovascular disease, diabetes, and cancer [200]. Exposure 
to inorganic arsenic occurs through the consumption of contaminated food and 
water sources, and arsenic biotransformations in the liver increase the presence 
of highly toxic methylated arsenic metabolites [27,57,139]. Methylated arsenicals 
increase (ROS) to a greater extent than inorganic arsenic, thus, arsenic 
methylation may be associated with increased disease prevalence [27]. 
 Although the World Health Organization (WHO) recommends a 
maximum contaminant level (MCL) for arsenic of 10 ppb, global arsenic 
concentrations in untreated waters can reach several hundred to several 
thousand ppb, contributing to as much as 21.4% of all causes of mortality in 
highly exposed regions of the world [34]. 
 Chronic exposure to arsenic has been associated with elevated risk of 





incidence and mortality in several American Indian populations with water 
sources measured up to 21 ppb arsenic [9] and among populations in 
Bangladesh, over half of which consume ground water that substantially exceeds 
50 ppb arsenic [34]. Increased rates of cerebrovascular disease prevalence have 
been observed among residents of Taiwan with water sources that can exceed 
300 ppb arsenic [201], and increased severity of atherosclerosis was observed 
among subjects in rural Taiwan with median arsenic concentrations in drinking 
water between 700 and 930 ppb [177]. Additionally, a recent meta-analysis 
demonstrated a positive association between arsenic exposure and hypertension 
among 11 cross-sectional studies of subjects with various levels of arsenic 
exposure [67]. 
 Arsenic exposure is also associated with a diagnosis of metabolic 
syndrome, a risk factor for CVD. Metabolic syndrome is defined as the presence 
of at least 3 out of 5 components including elevated fasting glucose, 
hypertension, elevated triglycerides, large waist circumference, and low HDL 
cholesterol [202]. Inorganic arsenic exposure was associated with a clinical 
diagnosis of metabolic syndrome, elevated plasma glucose, and elevated blood 
lipids among residents in an industrial region of Taiwan exposed to arsenic both 





association between arsenic and metabolic syndrome has not been investigated 
in a population exposed to low arsenic concentrations.  
 In addition to arsenic exposure, arsenic methylation capacity is a 
recognized risk factor for arsenic toxicity, and may contribute to CVD 
susceptibility. Inorganic arsenic (iAs) undergoes biotransformation through its 
monomethylated form (MMA) and dimethylated form (DMA), both of which are 
more toxic than the parent compound [27]. Arsenic methylation capacity is 
measured as the proportion of methylated arsenicals in urine or as a ratio of 
MMA:iAs (termed primary methylation index or PMI) and ratio of DMA:MMA 
(termed secondary methylation index or SMI). Arsenic methylation facilitates 
urinary excretion, yet also increases the bioavailability of toxic methylated 
arsenicals [27]. Interestingly, methylation capacity is not highly associated with 
inorganic arsenic exposure [203], but is influenced, by genetics, gender, age, and 
BMI [204,205].  
 Incomplete arsenic methylation is characterized by a pattern of higher 
urine proportion MMA, lower urine proportion DMA, increased PMI, and 
decreased SMI, whereas more complete arsenic methylation is characterized by a 
pattern of lower urine proportion MMA, higher urine proportion DMA, 





have investigated the impact of arsenic methylation on cardiovascular disease or 
metabolic syndrome, the available evidence suggests that complete methylation 
may be a contributing factor [53]. Importantly, this association has not been 
investigated in a relatively low arsenic-exposed population. Indeed, reports of 
adverse health outcomes associated with arsenic exposure and arsenic 
methylation have originated from regions where arsenic concentrations are 
unregulated or significantly under-regulated and thus exceed current safety 
guidelines. In contrast, we assessed the relationship between arsenic methylation 
and pre-clinical biomarkers of cardiovascular disease in a general sample of the 
U. S. where despite widespread compliance with current treatment standards for 
arsenic in food and water, appreciable concentrations of arsenic are still 
detectable in the blood and urine of U.S. residents [54,206-208].  
 The present study uses U.S. NHANES 2013-2014 data to investigate the 
association between urine %MMA, %DMA, and indices of primary methylation 
(PMI) and secondary methylation (SMI), with respect to a clinical diagnosis of 
metabolic syndrome.  
 
iii. Materials and Methods 





  Data for this study were acquired from the U.S. National Health and 
Nutrition Examination Survey (NHANES) website [209]. Complete protocols for 
sample selection are described elsewhere [210]. In brief, NHANES is a national, 
population-based, cross-sectional study representing the civilian, non-
institutionalized U.S. population. Demographic information is collected via 
survey and a physical examination is performed on all subjects. Biological 
samples are collected from nationally representative subsamples. The present 
study draws from subjects selected for the environmental subsample containing 
urinary arsenic concentrations which comprises approximately one third of the 
total U.S. NHANES population, and subjects selected to provide blood samples 
in the morning fasting session, comprising approximately half of the total U.S. 
NHANES population.   
 
iii.ii. Exclusion Factors 
  Pregnancy was an exclusion factor in the present study based on the 
influence of pregnancy on several measures used to assess metabolic syndrome 
(e.g. waist circumference, blood pressure, and cholesterol measures). Pregnancy 
status was determined by NHANES personnel using the Icon 25 hCG test kit 





excluded subjects under the age of 20 because arsenic metabolism is believed to 
differ between youth/adolescents and adults [211] and metabolic syndrome is 
rare among subjects under 20. We also excluded subjects who were missing data 
on metabolic syndrome components and covariates (age, gender, race/ethnicity, 
smoking status, poverty income ratio (PIR), urine creatinine, urine arsenobetaine, 
or BMI). Our final analytical sample contained 957 subjects.  
 
iii.iii. Speciated arsenicals 
  Concentrations of iAs(III), iAs(V), (MMA(III+V)), and (DMA(III+V)) were 
determined by NHANES personnel using high performance liquid 
chromatography (HPLC) to separate the species coupled to Multi-Element 
Inductively Coupled Plasma-Mass Spectrometry (ICP-DRC-MS) [212]. The lower 
limits of detection (LLOD) were 0.12μg/L (iAs(III)), 0.79μg/L (iAs(V)), 0.20μg/L 
(MMA(III+V)) and 1.91μg/L (DMA(III+V)). For our analysis, subjects with arsenic 
species below detection were assigned a concentration of LLOD/ √2, representing 
29.8%, 24.5%, and 26.9%, for iAs(III), DMA, and MMA, respectively. We 
eliminated iAs(V) from subsequent analysis as 98.3% of samples were below 





and indices of methylation were calculated for the present study using the 
following formulas: 
Total Arsenic = iAs+MMA+DMA 
% MMA = ((MMA/total arsenic)*100) 
%DMA = ((DMA/total arsenic)*100) 
PMI = MMA/iAs 
SMI = DMA/MMA 
PMI and SMI were right skewed and log adjusted for all subsequent analyses. 
Urinary % MMA and DMA were right skewed but non-log normal, thus 
untransformed values were used in subsequent analyses. Non-log adjusted 
values are presented for descriptive purposes.  
 
iii.iv. Metabolic syndrome components 
 Physical and biological data pertaining to metabolic syndrome were 
obtained from the NHANES website [213]. In the present study, a diagnosis of 
metabolic syndrome was given to subjects with at least 3 of the following 
conditions; fasting glucose >100 or medication to control glucose; systolic or 
diastolic blood pressure > 130/85mmHg or medication taken to control blood 





cm (females); and HDL-cholesterol < 40mg/dL (males) or <50mg/dL (females) 
[202].   
iii.v. Fasting glucose 
  Glucose concentrations were determined by NHANES personnel using 
the Beckman Unicel DxC800 Synchron method. The complete protocol is 
published elsewhere [212]. In brief, oxygen electron circuits determine the rate of 
oxygen consumption, which is directly proportional to the concentration of 
glucose in the sample. In the present study, subjects were classified as having 
elevated fasting glucose if their fasting serum glucose reached or exceeded 
100mg/dL, if they reported currently taking insulin, or if they reported currently 
taking a diabetic pill.  
 
iii.vi. Hypertension 
  After resting in a seated position for 5 minutes, 3 or 4 consecutive blood 
pressure measurements were taken by NHANES personnel. In the present study 
we eliminated the first measurement unless it was the only measurement 
available, and averaged the remaining blood pressure measurements in 
accordance with recommendations from the American Heart Association council 





reached or exceeded 130/85 mmHg were considered to have elevated blood 
pressure. Subjects currently taking blood pressure lowering medication were also 
classified in the high blood pressure group, as determined by questionnaire 
administered by NHANES personnel.  
 
iii.vii. Elevated triglycerides 
  Triglycerides were measured by NHANES personnel in refrigerated 
serum using the Beckman Unicel DxC800 Synchron timed-endpoint method 
[212]. 
 
iii.viii. Waist circumference.  
 Waist circumference measurement was determined by NHANES trained 
health technicians and was measured at the high point of the iliac crest at 
minimal respiration to the nearest 0.1 cm [215].  
 
iii.ix. Low HDL Cholesterol 
  The Roche Cobas 6000 chemistry analyzer method was used by NHANES 





measures HDL-cholesterol using an ion specific electrode (ISE) and photometric 
measuring system.  
 
iii.x. Covariates 
 Age, , gender, race/ethnicity and smoking status were determined by 
questionnaire during household interviews administered by trained and 
NHANES certified personnel [213]. In the present study, smokers were defined 
as subjects who responded in the affirmative to smoking cigarettes ‘every day’ or 
on ‘some days’. A measure of creatinine concentration was determined by 
NHANES personnel for each urine sample via the enzymatic method using the 
Roche Cobas 6000 Analyzer [212], and was considered as an independent 
variable [216]. Arsenobetaine, a measure of non-toxic arsenic from seafood, was 
measured by NHANES personnel via HPLC -ICP-DRC-MS [212]. Poverty 
income ratio (PIR) was calculated by NHANES personnel according to the 
Department of Health and Human Service (HHS) guidelines by dividing family 
income by the poverty guidelines specific to the survey year [212]. BMI 
measurements were collected by trained NHANES health technicians and are 
expressed as weight in kilograms divided by height in meters squared rounded 





(BMI<25.0), overweight (25.0<BMI<30.0), or obese (BMI>30.0). Complete 
protocols for all NHANES data collection methods are published elsewhere 
[212]. 
 
iii.xi. Statistical analysis 
 Descriptive and statistical analyses were conducted with SPSS v32. When 
combining data from more than one sample, using the sampling weight of either 
subsample is not recommended by NHANES as it could result in unreliable 
estimates [217]. Thus, the complex sampling design was ignored because the 
study population belonged to two subsamples (environmental subsample and 
fasting subsample).  
 We used logistic regression to assess the relationships between urine 
%MMA, urine %DMA, PMI, and SMI with metabolic syndrome. Covariates were 
evaluated in the literature and statistically using Mann-Whitney-U test, Kruskal 
Wallace test, χ2 test, or student-t test, and statistically relevant or biologically 
justified covariates were included in the final adjusted model. We investigated 
plausible interactions and stratified our models by BMI and gender. We 
considered using BMI as a dependent variable but based on statistical 





syndrome as our dependent variable and stratified by BMI category. A 
sensitivity analysis was conducted among subjects who exceeded baseline 
measures for arsenic species (MMA n=700, DMA n=732, PMI n=585, SMI n=681), 
and a subgroup analysis was conducted on non-diabetic subjects (n=871). We 
also considered the effect of controlling for total arsenic and/or arsenobetaine, 
and the inclusion of urinary creatinine as an independent variable in our main 
models. Urinary creatinine was considered as an independent variable rather 
than a covariate because adjusting for creatinine has been suggested to confound 
the relationship between total urinary arsenic and arsenic metabolism [216]. 
 
iv. Results 
 Table 1 provides study participant characteristics. The mean age of the 
study population was 47 years. Approximately 51% of subjects were male and 
46% of subjects were white. Three hundred and twenty six subjects (34.1%) met 
the clinical diagnostic criteria for elevated fasting glucose, 425 subjects (44.4%) 
had elevated blood pressure or were taking medication to lower blood pressure, 
261 subjects (27.3%) had elevated triglycerides, 526 subjects (55.0%) had large 
waist circumference, and 288 subjects (30.1%) had low HDL cholesterol. Overall, 





sample had 9.68% (±6.70), 11.69% (±9.94), and 78.63% (±9.94) urine iAs, MMA, 
and DMA, respectively (Table 1). The average total urinary arsenic in our sample 
of the U.S. NHANES 2013-2014 population was 15.67 μg/L. 
Table 1 
Study participant characteristics 
 




  Male 
 
Race/Ethnicity 
  Non-Hispanic White 
  Mexican American 
  Non-Hispanic Black 
  Non-Hispanic Asian 
  Other Race 
 
PIRa 





  Normal 
  Overweight 
  Obese 
 
Metabolic syndrome components 
Fasting glucose (mg/dL) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Serum triglycerides (mg/dL) 
Waist circumference (cm) 
HDL cholesterol (mg/dL) 
 
Urinary Arsenic Species 
iAs IIIc (μg/L) 
MMA III + Vd (μg/L) 


































































































Less than 2  











a Poverty Income Ratio was calculated according to the Department of Health and Human Service 
(HHS) guidelines by dividing family income by the poverty guidelines specific to the survey year 
[212], b Body Mass Index was calculated as weight in kilograms divided by height in meters squared 
rounded to one decimal place, c trivalent inorganic arsenic, d trivalent and pentavalent 
monomethylarsonous acid, e trivalent and pentavalent dimethylarsonous acid, f (iAs / 
(iAs+MMA+DMA)*100), g (MMA / (iAs+MMA+DMA)*100), h (DMA/ (iAs+MMA+DMA)*100), i 
MMA/iAs, j DMA/MMA. 
 
iv.i. Covariate association with arsenic measures and metabolic syndrome  
 We were interested in the relationship between biologically relevant, 
literature-justified covariates and our independent and dependent variables. We 
first examined the association between continuous and categorical covariates 
with measures of arsenic methylation (Table 2). Gender was significantly 
associated with all measures of arsenic methylation (p<0.05). Women had 
significantly lower %MMA, significantly higher %DMA, and significantly 
increased PMI and SMI compared to men. Race/ethnicity, BMI, smoking status 
and PIR were associated with at least one arsenic measure (Table 2). White 





White subjects had significantly lower %DMA compared to Black subjects, and 
White subjects had significantly higher PMI compared to Mexican-American and 
Black subjects.  
 Smokers had a significantly higher PMI compared to non-smokers, and 
subjects with a PIR < 1 had higher SMI compared to subjects with PIR > 1. 
Subjects with obese BMI demonstrated a pattern of increased arsenic 
methylation: significantly lower %MMA and significantly higher %DMA 
compared to subjects with normal BMI. Age was significantly associated with all 
measures of arsenic methylation and urine arsenobetaine was significantly 
associated with %MMA and SMI (Table 2). These data suggest that when 
considered independently, female gender, non-White race, poverty, obesity, 
increased age, increased seafood consumption (measured as arsenobetaine), and 
dehydration (measured as urine creatinine) were associated with increased 
arsenic methylation.  
Table 2 
Distribution of arsenic measures by covariate 
Arsenic Measures 
Mean (SD) 
 %MMAa %DMAb PMIc SMId 
 p-Valuee   p-Value p-Value p-Value 








         <0.001 
76.85(10.13) 
80.51(9.41) 
        0.003 
1.73(1.67)  
2.05(2.08) 
        <0.001 
10.13(27.32)  
10.76(9.81) 








































          0.141 
11.54(5.90)  
12.27(6.14) 
          0.962 
78.61(10.01)  
78.677(9.72) 
        0.009 
1.84(1.87)  
2.09(1.95) 


















































[B(Se) Beta p-Valuem] 
Age -0.04(0.01)-0.116 .002 0.15(0.02) 0.250  .001  0.00(0.00) 0.182 .001  0.00(0.00) 0.159 .001 
Creatininen  1.59(0.59) 0.078 .011 -2.74(0.97) -0.018 .002 -0.04(0.04)-0.037 .220 -0.07(0.03)-0.072 .008 
Arsenobetaineo -2.60(0.29)-0.252 .001 4.61(0.51) 0.267  .001  0.00(0.02) 0.000 .995  0.15(0.02) 0.292 .001 
a urine % of monomethylarsonous acid, burine % of dimethylarsonous acid, c primary methylation index, d 
secondary methylation index, e p-values obtained from Mann-Whitney U Test comparing two groups or 
Kruskal-Wallis Test comparing more than two groups (α=0.05), f post hoc analysis conducted with Tukey’s test,  
g Mexican American, h Significant difference compared to White race, (Tukey’s post hoc test), i Poverty Income 
Ratio – calculated by dividing family income by the poverty guidelines specific to the survey year [212], j 
BMI<25.0, k 25.0<BMI<30.0, l BMI>30.0,m p-values obtained from bootstrapped linear regression (α=0.05), n 
creatinine is used to normalize for hydration, o arsenobetaine is a non-toxic form of arsenic found in seafood  
 
Next we assessed the association between covariates and our dependent 
variable (metabolic syndrome). Clinical diagnostic cutoff levels differ for men 
and women, therefore, we stratified our sample by gender. Age, BMI, smoking 





men and women, whereas urinary creatinine and race/ethnicity were only 
significantly associated with metabolic syndrome in women (Table 3). 
Table 3 
Association between metabolic syndrome and covariates 
 Metabolic syndrome status Metabolic syndrome status 
  (No) 
N=334 
 (Yes)  
N=157 
p-Valuea (No)  
N=292 
 (Yes)  
N=174 
p-Value 
 Men  Women  











































































































Age 44.4(16.7) 53.6(15.0) <0.001 44.2(16.3) 53.3(15.0) <0.001 
 
Creatinineg 133.1(76.7) 134.1(73.4) 0.767 98.0(69.2) 109.4(70.1) 0.036 
 
Arsenobetaineh 7.9(19.4) 6.7(19.9) 0.266 10.4(37.2) 6.6(18.8) 0.477 
 
Notes:  a p-Values obtained from 2-way χ2 test or one-way ANOVA for categorical variables and Man 
Whitney U test for continuous covariates, b BMI<25.0, c 25.0 < BMI < 30.0, d BMI > 30.0, e Poverty Income 
Ratio – calculated by dividing family income by the poverty guidelines specific to the survey year 
[212], f Mexican American, g creatinine is used to normalize for hydration, h arsenobetaine is a non-toxic 






iv.iii. Logistic regression  
 Our crude analysis suggested that in men, decreased urine %MMA, 
increased urine %DMA, and increased SMI were significantly associated with 
increased odds of metabolic syndrome whereas in women, increased %DMA and 
increased SMI were significantly associated with increased odds of metabolic 
syndrome (data not shown).  
 Next we adjusted our gender stratified models for statistically relevant 
and literature justified covariates [22]. We adjusted gender-stratified models for 
age (continuous), race (White vs. non-White), poverty status (PIR < 1 vs. PIR > 1), 
and smoking status (dichotomous) (Table 4). In the gender stratified, adjusted 
model, decreased %MMA was significantly associated with increased odds of 
metabolic syndrome in men, whereas increased SMI was significantly associated 
with increased odds of metabolic syndrome in women.  
Table 4 
Binary logistic regression, fully adjusteda 
 Men Women 
IV R2 OR [95% CI] p-valueb R2 OR [95% CI] p-value 
%MMAc 0.079 0.960 [0.927, 0.994] 0.021 0.085 0.974 [0.940, 1.010] 0.153 
%DMAd 0.073 1.015 [0.995, 1.037] 0.150 0.087 1.020 [0.998, 1.044] 0.078 
PMIe 0.073 0.656 [0.358, 1.203] 0.173 0.081 0.956 [0.543, 1.683] 0.876 
SMIf 0.073 1.636 [0.834, 3.209] 0.152 0.090 2.148 [1.048, 4.402] 0.037 
a adjusted for age (continuous), poverty income ratio (PIR<1 vs. PIR>1) – calculated by dividing family 
income by the poverty guidelines specific to the survey year [212], race (white vs. non-white), and smoking 





urine % of monomethylarsonous acid, d urine % of dimethylarsonous acid, e primary methylation index, f 
secondary methylation index 
 
 Based on the significant overlap between subjects with metabolic 
syndrome and overweight/obese BMI [218], we stratified by BMI category rather 
than adjusting for BMI. (Table 5) provides the fully adjusted model among male 
subjects stratified for BMI category, and (Table 6) provides fully adjusted, BMI 
stratified values for women. The data suggest that BMI confounds the association 
between arsenic methylation and metabolic syndrome in men: our stratified 
regression model returned non-significant p-values for all associations of arsenic 
methylation and metabolic syndrome in men. In contrast, the data suggest that 
BMI modifies the effect of arsenic methylation on metabolic syndrome in 
women: reduced urine %MMA and increased SMI were significantly associated 
with metabolic syndrome in women with normal BMI, whereas the opposite 
trend occurred in women with overweight BMI (significantly increased %MMA 
and reduced SMI), and there was no significant association between arsenic 
methylation and metabolic syndrome in obese women. However, it should be 
noted that the sample size for women with normal BMI and metabolic syndrome 





 We next assessed the possibility of biologically plausible interactions in 
our gender-stratified model (age*smoking, age*PIR, and PIR*smoking) and 
report no significant interactions (data not shown).  
 Controlling for total arsenic, including urinary creatinine as an 
independent variable in logistic regression models [216] and excluding diabetic 
subjects had no significant impact on our results. In contrast, sensitivity analysis 
in which we excluded subjects below detection limits for arsenic species 
eliminated the significant effect of arsenic methylation on metabolic syndrome in 
subjects with overweight BMI, but did not alter the significance of results among 
subjects with normal BMI. Additionally, controlling for seafood consumption 
(measured as urine arsenobetaine), in obese subjects resulted in a significant 
association between increased SMI and increased odds of metabolic syndrome, 
whereas the association was not significant in the model prior to adjusting for 
arsenobetaine. This suggests that the role of arsenic methylation on metabolic 
syndrome may have been masked by the effect of seafood consumption, whereas 
controlling for seafood consumption revealed a true association between 










Binary logistic regression 
DV: Metabolic syndrome in women, fully adjusted modela 
 Normal BMIb Overweight BMIc Obese BMId 
IV R2 OR [95% CI] p-
valuee 
R2 OR [95% CI] p-value R2 OR [95% CI] p-value 
%MMAf 0.182 0.826 [0.701, 0.973]   0.022 0.219 1.113 [1.016, 1.218] 0.021 0.057 0.966 [0.919, 1.015]   0.174 
%DMAg 0.167 1.085[0.999, 1.178]   0.053 0.203 0.951 [0.903 1.003] 0.063 0.054 1.018 [0.986 1.052]   0.273 
PMIh 0.160 0.644 [0.365, 1.135]    0.128 0.187 1.149 [0.912, 1.446]  0.239 0.049 0.992 [0.879 1.120]    0.896 
SMIi 0.175 11.485 [1.371, 
96.196] 
  0.024 0.220 0.089 [0.011, 0.704] 0.022 0.064 2.590 [0.926, 7.243]   0.070 
a adjusted for age (continuous), Poverty Income Ratio (PIR<1 vs. PIR>1) – calculated by dividing family income by the poverty guidelines specific to the 
survey year [212], race (White vs. non-White), and smoking status (dichotomous), b BMI<25.0, c 25.0<BMI<30.0, d BMI>30.0, R2 represents Cox & Snell R2 value, e 
p-value obtained from binary logistic regression, f urine % monomethylarsonous acid, g urine % dimethylarsonous acid, h primary methylation index, i 
secondary methylation index 
Table 5 
Binary logistic regression 
DV: Metabolic syndrome in men, fully adjusted modela 
 Normal BMIb Overweight BMIc Obese BMId 
IV R2 OR [95% CI] p-valuee R2 OR [95% CI] p-value R2 OR [95% CI] p-value 
%MMAf 0.073 0.974 [0.888, 1.068] 0.577 0.101 1.019 [0.958, 1.083] 0.554 0.112 0.979 [0.913, 1.049] 0.549 
%DMAg 0.074 1.019 [0.963, 1.078] 0.519 0.102 0.986 [0.951 1.022] 0.429 0.110 1.007 [0.966 1.050] 0.728 
PMIh 0.072 1.179 [0.230, 6.043]  0.843 0.099 0.926 [0.312, 2.748]  0.890 0.110 0.995 [0.333, 2.979]  0.993 
SMIi 0.072 1.470 [0.238, 9.081] 0.678 0.106 0.477 [0.129, 1.757] 0.266 0.110 0.929 [0.275, 3.144] 0.906 
a adjusted for age (continuous), Poverty Income Ratio (PIR<1 vs. PIR>1) – calculated by dividing family income by the poverty guidelines specific to the 
survey year [212], race (White vs. non-White), and smoking status (dichotomous), b BMI<25.0, c 25.0<BMI<30.0, d BMI>30.0, R2 represents Cox & Snell R2 value, e 
p-value obtained from binary logistic regression, f urine % monomethylarsonous acid, g urine % dimethylarsonous acid, h primary methylation index, i 






Ours is the first study to investigate the association between arsenic 
methylation and metabolic syndrome in a population with relatively low arsenic 
exposure. We report that increased arsenic methylation is associated with 
increased odds of metabolic syndrome among women with normal BMI.  
 
v.i. Oxidative stress and inflammation 
  Metabolic syndrome is associated with a clustering of abnormalities that 
lead to increased cardiovascular risk. Inflammation is an important cellular 
mechanism that links metabolic syndrome to cardiovascular disease [218]. For 
example, obesity (a central component of metabolic syndrome) is associated with 
overexpression of tumor necrosis factor α (TNF-α), a cell signaling protein 
involved in systematic inflammation [219], and high fat intake contributes to 
increased oxidative stress and nuclear factor (NF-κB) activation, a 
proinflammatory signaling pathway [220]. Additionally, the inflammatory 
marker C-reactive protein (CRP) statistically enhances the relationship between 
metabolic syndrome and coronary heart disease events [221]. Furthermore, 
oxidative stress is believed to contribute to metabolic syndrome [222], 





Oxidative stress has also been convincingly linked with exposure to arsenic. 
Indeed, exposure to inorganic arsenic and its metabolites can generate ROS and 
free radicals, hydroxyl radicals, nitric oxide, and superoxide anion in a variety of 
cell lines [57,226]. Additionally, a human study conducted among a highly 
arsenic exposed population in China reported that arsenic-exposed subjects 
demonstrated higher oxidative stress compared to control subjects (measured as 
increased serum levels of lipid peroxide) [227]. Importantly the same study 
reported a significant correlation between oxidative stress and methylated 
arsenic metabolites [227].  
 
Thus, there is evidence for an association between arsenic and oxidative 
stress, as well as evidence of a link between oxidative stress and metabolic 
syndrome. Furthermore, our outcome of a positive association between increased 
arsenic methylation and metabolic syndrome is consistent with past 
investigations conducted among populations with higher overall arsenic 
exposure. Indeed, in regions of Taiwan with exposure to industrial arsenic as 
well as water sources measured up to 16 ppb, Wang et al. (2007) reported a 
positive association between total arsenic and metabolic syndrome [49] and Chen 





with a higher risk for metabolic syndrome in a population exposed to median 
arsenic concentrations of 700-930ppb [53]. Although a minority of findings 
suggest that incomplete methylation (high urinary proportion of MMA) is a 
stronger contributor to cardiovascular disease [51] and hypertension [228], this 
may result from differences in the valence state of measured arsenicals. For 
example, studies demonstrating elevated toxicity of complete methylation have 
included trivalent and pentavalent species in calculations of urinary arsenic 
proportion, whereas  studies reporting the opposite trend measured only the less 
toxic pentavalent species [51] or failed to specify the valence states of measured 
arsenicals [228]. In the present study, we report that increased arsenic 
methylation is associated with increased odds of metabolic syndrome in specific 
subgroups. 
 
v.ii. Increased toxicity of methylated species 
 Following ingestion and tissue distribution, a series of biotransformations 
in the liver reduce arsenate (iAs(V)) to arsenite (iAs(III)) and arsenic 
methyltransferase enzymes mediate the sequential addition of methyl ions from 





ingested inorganic arsenic is sequentially converted to its mono- and di- 
methylated forms and removed through the urinary system (Figure 1). 
  
 
Figure 1. Arsenic biomethylation 
 
Once considered a detoxification reaction, a growing body of evidence 
demonstrates that arsenic methylation significantly increases toxicity and that 
trivalent species are more toxic than pentavalent species [25,57]. Individual 
variability in arsenic biotransformation is measured as the proportion of each 
arsenic species in urine, or by calculating PMI and SMI. Variation in urine 





[51,229] and may reflect differential bioavailability of arsenicals across 
individuals [230].  
 
v.iii. Arsenic distribution patterns 
  Other notable findings from the present study are the similarities in 
arsenic methylation patterns in our sample of the U.S. compared to regions with 
higher exposure, as well as similarities with respect to individual variation in 
methylation capacity [203]. Urinary proportions of arsenic species found in the 
present study are consistent with reports that most individuals have 10-30% iAs, 
10-20% MMA, and 60-80% DMA, regardless of their arsenic exposure level [203]. 
Our sample had 9.68% (±6.70), 11.69% (±9.94), and 78.63% (±9.94) urinary iAs, 
MMA, and DMA, respectively. The average total urinary arsenic in the U.S. 
NHANES 2013-2014 population was 15.67 μg/L, considerably lower than the 
total urinary arsenic reported in the aforementioned studies of pre and post-
clinical CVD outcomes, where total mean urinary arsenic has ranged from 53.6 
μg/L among women from southwest U.S. and northwest Mexico [231] to 580 
μg/L among a northern Chile population [203]. Relative consistency in average 
arsenic methylation capacity among different populations irrespective of arsenic 





subtle (2-3%) differences in mean urine proportion of MMA and DMA between 
populations exposed to inorganic arsenic at levels differing by 500ppb [203].  
In contrast to the relative consistency of arsenic methylation patterns 
between study populations, considerable variability has been reported in 
methylation capacity between individuals in the same population [22]. For 
example, subjects in San Pedro ranged from approximately 40% to over 90% 
urinary DMA and from 7% to 40% urinary MMA [203]. In the present study, 
urine percent MMA ranged from below detection limits to 34.22%, and urine 
percent DMA ranged from 41.16% to 98.74%. 
 
v.iv. Gender and BMI 
  Past studies suggest that variability in methylation capacity is due, in part 
to variations in genetic polymorphisms, as well as age, BMI, and gender 
[204,205]. Our results also demonstrate an effect of gender and BMI on arsenic 
metabolism. In the present study, we report that increased arsenic methylation is 
associated with increased odds of metabolic disorder in gender and BMI 






Our finding that gender modified the effect of arsenic methylation on the 
odds of metabolic syndrome is supported by previous research conducted by 
Lindberg et al. (2007), who reported that women in Bangladesh had higher 
methylation efficiency than men during childbearing ages (20 to 60 years) [204]. 
Similarly, European women between the ages of 20 and 60 had an increased rate 
of arsenic methylation [205]. The authors of these studies speculate that sex 
hormones are partially responsible for increased rates of methylation in women, 
as it is specific to women of childbearing age [204,205]. This is a plausible 
explanation for some of the observed differences in metabolic syndrome 
outcomes based on gender in the present study, as 79% of women in our sample 
were between the ages of 20-60.   
The present study also demonstrated a significant effect of BMI on arsenic 
methylation. Subjects with obese BMI expressed a pattern of increased arsenic 
methylation: significantly lower %MMA and significantly higher %DMA 
compared to subjects with normal BMI. Since increased arsenic methylation is 
generally associated with increased disease status, we expected to see a 
significant association between arsenic methylation and metabolic syndrome in 





between increased arsenic methylation and metabolic syndrome in women with 
normal BMI.  
We were interested in which clinical symptoms characterized metabolic 
syndrome in subjects who had metabolic syndrome and normal BMI. Among 
these 16 women, we found that 13 had elevated fasting glucose, 11 had elevated 
triglycerides, 14 had elevated blood pressure, and 12 had low HDL cholesterol. 
The most common combination of symptoms were elevated blood pressure and 
elevated glucose in combination with low HDL cholesterol (n=7) or elevated 
triglycerides (n=6). Despite the small sample size, ours is the first report of BMI 
as an effect modifier of in the association between arsenic methylation and 
metabolic syndrome.  
v.v. Selection of adjustment factors 
 It is worth noting that we adjusted for covariates similar to those used in 
other studies assessing the relationship between arsenic exposure or arsenic 
methylation and various aspects of metabolic syndrome. These varied somewhat 
based on the specific research question, but generally included age, gender, BMI, 
smoking status, alcohol use, diabetes, waist to hip ratio, serum lipid levels, urine 
creatinine, and urine arsenobetaine [9]. In the present study, we adjusted for age, 





category. These covariates are used in comparable studies with biological 
relevance verified in the literature [232]. Additionally, we report no significant 
effect of controlling for urine creatinine, total arsenic, or eliminating diabetic 
subjects. We did, however, determine that limiting our analysis to subjects above 
detection limits for MMA eliminated the statistical significance between low 
arsenic methylation and metabolic syndrome in overweight subjects. This 
suggests that the apparent protective effect of overweight BMI was not a true 
effect, but rather, was due to a large number of subjects in the overweight BMI 
group with undetectable arsenic levels. Although we used a commonly accepted 
practice by assigning a value of the LLOD/ √2 to subjects below detection limits, 
this erroneously resulted in an apparent protective effect of overweight BMI, 
which we deemed implausible. Sensitivity analysis revealed that this was likely 
an artifact of our statistical method, and not a true effect.  
We also probed our model by controlling for arsenobetaine and found that in 
women with obese BMI, the role of arsenic methylation on metabolic syndrome 
was masked by the effect of seafood consumption. By re-evaluating our final 
model after controlling for seafood consumption (i.e. adjusting for 
arsenobetaine), we detected a significant association between increased arsenic 





seafood is a significant determinant of urine concentrations of total arsenic and 
arsenic species. Arsenobetaine is a non-toxic organic form or arsenic present in 
high levels in seafood that is excreted unchanged via the kidneys. Navas-Acien et 
al. (2011) also propose eliminating subjects who have consumed seafood in the 
last 24-hour from statistical analyses as a further safeguard from misclassifying 
arsenic exposure. In the present study, statistically controlling for arsenobetaine 
altered the statistical significance of results among female subjects with obese 
BMI, whereas controlling for arsenobetaine in women with normal BMI did not 
alter the significant association between decreased urine %MMA and increased 
SMI with increased odds of metabolic syndrome. While arsenic concentrations 
from seafood are an important consideration for statistical analysis, the most 
important source of arsenic exposure in terms of health outcomes is 
contaminated water sources.  
  
v.vi. Policy implications 
An important implication of our study is the relevance of public water testing 
and treatment. The U.S. follows EPA recommendations for a MCL of 10 ppb 
inorganic arsenic in public water. The EPA is responsible for regulating 





the Safe Drinking Water Act (SDWA) of 1974, which requires the EPA to define 
and set legal limits for contaminants, develop a testing schedule, and determine 
appropriate testing methods and techniques [233]. Under this act more than 90 
contaminants are regulated at specified MCLs [233]. The SDWA requires that an 
MCL be reliably testable, achievable by the best technology available, and result 
in health risks deemed acceptable, defined as 1 cancer death per 10,000 persons 
or less [233]. Based on the findings of the National Academy of Sciences (NAS), 
the current MCL is estimated to result in 5 deaths per 10,000 persons, failing to 
meet EPA safety standards. The current MCL is justified based on a 1996 
amendment to the SDWA, which allows for a recommended MCL to be revised 
in light of a benefit-cost analysis [233]. The NAS initially supported an MCL of 3 
ppb based on their analysis of relevant toxicology and epidemiology research 
[234]. Using the NAS recommendations and a cost-benefit assessment, the EPA 
originally proposed an MCL of 5 ppb inorganic arsenic, which was later revised 
to 10 ppb inorganic arsenic. Unfortunately the current MCL fails to consider 
cardiovascular outcomes, diabetes, and preclinical indictors of CVD that are 
associated with arsenic exposures below 10 ppb, as demonstrated in the 
literature. The present study suggests that the current MCL may not be 





association between arsenic methylation and metabolic syndrome, even when 
adjusting for total arsenic exposure (Table S1 and S2). Further study is needed to 
assess the adequacy of current water standards for arsenic in the U.S. in terms of 
preclinical biomarkers of CVD. 
 In addition to the possibility that current standards fail to protect 
individuals in the U.S. from arsenic related diseases, not all waters are subject to 
EPA standards, potentially placing an unequal health burden on regions with 
naturally higher arsenic concentrations and greater reliance on unregulated 
water sources. For example, rural areas of the U.S. with a higher proportion of 
un-piped water report much higher concentrations for groundwater arsenic. A 
survey of 102 homes using domestic wells in rural areas of Nevada averaged 356 
μg/L arsenic pre-treatment and 87 μg/L arsenic following reverse osmosis 
treatment [8], and arsenic concentrations were measured between 10 and 61 ppb 
on rural reservation lands in Arizona [9]. Even populations using piped water on 
Reservation lands are at risk of consuming high concentrations of arsenic. 
Indeed, health-related violations relating to one or more substance above the 
MCL, were reported among 46% of public water systems on Reservations, 
compared to just 7% in public water systems in the remainder of the U.S. [233]. 





rural areas represent a small fraction of the total U.S. population and are thus 
unlikely to represent a large proportion of the U.S. NHANES sample used in the 
present study.   
 Looking beyond the U.S., global arsenic regulations range from 6 ppb in 
Sweden to 50 ppb in Bangladesh, though there is vast disparity in regional 
infrastructure that supports water testing, reporting, and remediation for arsenic. 
For example, despite regulations, a 2009 survey of 15,000 randomized 
households in Bangladesh estimated that 22 million people consume water 
exceeding 50 ppb and 5.6 million people consume water exceeding 200 ppb [235]. 
However, there is no reliable estimate of the global scope of arsenic exposure due 
to delayed health effects, poor reporting, and low levels of awareness in some 
regions [236]. Based on findings from the present study we cannot rule out the 
possibility that exposure to water meeting the MCL of 10 ppb inorganic arsenic 
does not contribute to metabolic syndrome. 
 
v.vii. Limitations  
Important limitations in the present study include reliance on secondary data 
and the use of self-reported data for several measures (e.g. diabetes, smoking 





two different subsamples, we were unable to use the U.S. NHANES weighting 
factors and are thus unable to apply our findings to the general population. 
Finally, our study design allows for an interpretation of correlation but not 
causation. Despite these limitations, this is the first study to examine urinary 
arsenic methylation with respect to metabolic disorder in the U.S. We also 
acknowledge that our stratified sample sizes were small, and these outcomes 
should be assessed in a larger population.  
vi. Conclusion 
In summary, in a country where arsenic levels are regulated at 10 ppb in 
public drinking water, we report a significant association between increased 
arsenic methylation capacity and metabolic syndrome in women with normal 
BMI. Our sample represents a relatively low exposure population, and the 
association between arsenic methylation to metabolic syndrome may be 
significantly greater in regions of the world that lack the infrastructure for water 
testing and treatment and in regions of the U.S. that remain highly exposed to 
arsenic, such as American Indian reservations and rural communities relying on 
untreated waters from private domestic wells. We emphasize the need for 
studies that highlight the impact of policy enforcement on urinary arsenic, and 





gender, BMI, and other factors that may modify the association of arsenic 
methylation to pre- and post-clinical cardiovascular disease status in a model 






Subgroup and sensitivity analyses in fully adjusteda binary logistic regression model of women  
IV: %MMAb 
DV: Metabolic Syndrome 

























0.177 0.747 [0.588, 0.950] 
 
 


















































































0.965 [0.917, 1.014] 
 
0.161 
Notes: a adjusted for age (continuous), gender, race (dichotomous, White vs. non-White) smoking status (dichotomous), and poverty status (PIR<1 vs. PIR>1), 
b Urine % monomethylarsonous acid, c BMI<25.0, d 25.0 >BMI<30.0, e BMI>30.0, R2 represents Cox & Snell R2 value, f p-value obtained from binary logistic 













Subgroup and sensitivity analyses in fully adjusteda binary logistic regression model of women  
IV: SMI 
DV: Metabolic Syndrome 

























0.220 8.309 [1.065, 64.850] 
 








0.188 12.244 [1.324, 
113.201] 




0.180 12.550 [1.440, 109.76] 0.022 0.229 0.119 [0.014, 0.999] 0.050 0.083 3.115 [1.080, 8.960] 0.035 
Adjusted for 
creatinineh 
0.175 11.635 [1.370, 98.791] 0.025 0.220 0.090 [0.011, 0.715] 0.023 0.073 2.663 [0.938, 7.560] 0.167 
Notes: a adjusted for age (continuous), gender, race (dichotomous, White vs. non-White) smoking status (dichotomous), and poverty status (PIR<1 vs. 
PIR>1), b Secondary methylation index, c BMI<25.0, d 25.0 >BMI<30.0, e BMI>30.0, R2 represents Cox & Snell R2 value, f p-value obtained from binary 








Chapter 4. Monomethylarsonous acid, but not inorganic arsenic, is a 
mitochondria-specific toxicant in vascular smooth muscle cells 
 
i. Abstract 
 Arsenic exposure has been implicated as a risk factor for cardiovascular 
diseases, metabolic disorders, and cancer, yet the role mitochondrial dysfunction 
plays in the cellular mechanisms of pathology is not fully elucidated. To 
investigate arsenic-induced mitochondrial dysfunction in vascular smooth 
muscle cells (VSMCs), we exposed rat aortic smooth muscle cells (A7r5) to 
inorganic arsenic (iAs(III)) and its metabolite monomethylarsonous acid 
(MMA(III)) and compared their effects on mitochondrial function and oxidative 
stress. Our results indicate that MMA(III) is significantly more toxic to 
mitochondria than iAs(III). Exposure of VSMCs to MMA(III), but not iAs(III), 
significantly decreased basal and maximal oxygen consumption rates and 
concomitantly increased compensatory extracellular acidification rates, a proxy 
of glycolysis. Treatment with MMA(III) significantly increased hydrogen 
peroxide and superoxide levels compared to iAs(III). Exposure to MMA(III) 
resulted in significant decreases in mitochondrial ATP, aberrant perinuclear 
clustering of mitochondria, and decreased mitochondrial content. 





peroxide contribute to mitochondrial toxicity, as treatment of cells with MnTBAP 
(a mitochondrial superoxide dismutase mimetic) and catalase significantly 
reduced mitochondrial respiration deficits and cell death induced by both arsenic 
compounds. Overall, our data demonstrates that MMA(III) is a mitochondria-





 Exposure to arsenic has been associated with cancer, diabetes, 
cardiovascular disease, and metabolic syndrome [200,237-239]. It has been 
suggested that arsenic alters common pathways such as those involved in 
oxidative stress and inflammatory signaling, which underlie a variety of arsenic-
associated diseases [237,240-242]. The generation of ROS in particular is a major 





of cancer [243], insulin resistance [244], metabolic syndrome [245], and 
cardiovascular disease [242].  
 Arsenic has been shown to induce oxidative stress in numerous cell lines, 
including human vascular smooth muscle cells (VSMCs) [246-249,250 ], by 
causing the release of iron from ferritin [251], or by altering antioxidant activity 
and increasing inflammation [252]. Additional tissue pathology in the vascular 
endothelium caused by exposure to arsenic includes an increase in oxidative 
stress caused by increased NADPH oxidase activity in VSMCs and endothelial 
cells, leading to an increase in superoxide and hydrogen peroxide levels [246], 
and a vicious cycle of dysregulated calcium and nitric oxide signaling. Arsenic-
induced ROS couples with nitric oxide (NO) producing peroxynitrite [253] and 
decreases the bioavailability of NO to vascular endothelium and smooth muscle, 
which likely contributes to cardiovascular complications. ROS have also been 
shown to result in cell damage and cell death in numerous cell lines and models 
of arsenic-induced disease pathology [254-256].  
 Inorganic arsenic (iAs(III)) undergoes biomethylation in the liver to form 
the toxic intermediate metabolites monomethyl-arsonous acid (MMA(III)) and 
dimethylarsonous acid (DMA(III)). These trivalent organic arsenic species have 





and may be responsible for many of arsenic’s pathological effects. Indeed, cells 
with higher rates of arsenic metabolism show increased susceptibility to 
oxidative damage to DNA and induction of tumorigenesis [27,258]. These 
organic arsenic species can also promote cytotoxicity and tissue pathology by 
decreasing the levels of several antioxidants. For instance, in comparison to 
iAs(III), much lower concentrations of MMA(III) over shorter periods of time can 
alter the activity of glutathione peroxidase and catalase, induce expression of 
stress proteins and metallothioneins, and increase ROS levels [139]. Other 
proposed mechanisms for the enhanced toxicity of MMA(III) include greater 
rates of cell permeation and accumulation [259], differences in subcellular 
distribution, and selective toxicity towards subcellular compartments such as the 
mitochondria  [250].  
Several studies have investigated the effects of arsenic on VSMCs, which 
comprise the medial cell layer of vascular arteries and are known to be exposed 
to arsenic through contact with blood plasma. In vivo, it has been reported that 
iAs(III) increases blood pressure through calcium sensitization in VSMCs [260], 
and that exposure to MMA(III) at high doses induces VSMC dysfunction by 
impairing voltage-sensitive Ca2+ channels and reducing vascular reactivity to 





arsenic trioxide has been shown to induce apoptosis in human coronary smooth 
muscle cells [262], microvascular cells [263], human umbilical vein endothelial 
cells [255], and intestinal endothelial cells [139]. However, some studies have 
demonstrated a proliferative effect of arsenic on VSMCs [264] and endothelial 
cells [265], presumably by activating mitogenic signals and inducing the release 
of vascular endothelium growth factor. Bimodal effects of MMA(III) have also 
been demonstrated. Lim et al., (2011) reported that MMA(III) elicited higher 
vasopressor responses at low doses while suppressing vasoconstriction at high 
doses in vivo [138]. Collectively these data suggest that the variable effects of 
these arsenical species may be caused by differences in concentrations and 
exposure duration, differences in cell culture conditions, tissue preparations of ex 
vivo models of arsenic toxicity, and cell type analyzed in each study.   
As previously mentioned, mitochondria may be a primary target of 
arsenic in several tissues. Indeed, exposure to arsenic is associated with loss of 
mitochondrial membrane potential in human pulmonary cell lines [143], and 
reduced ATP content in rat liver mitochondria [266]. In addition, MMA(III), but 
not iAs(III) can selectively target and inhibit mitochondrial complexes II and IV 
in isolated mitochondria from rat liver [250], and induce ROS levels in intact 





mitochondrial structure/function and mechanisms of toxicity in VSMCs however, 
remain to be elucidated.  
Our study is the first to comparatively analyze the effects MMA(III) and 
iAs(III) on mitochondrial structure and function in immortalized rat aortic 
smooth muscle A7r5 cells, a tissue culture model of VSMCs. The doses of iAs(III) 
and MMA(III) used in this study are in accordance with environmental 
exposures of at-risk populations reported in several studies [176,177,267,268] and 
have been used in previously published studies [27,139,250]. In this study, we 
report that MMA(III), but not iAs(III), promotes mitochondrial dysfunction, 
metabolic and morphological alterations, and oxidative stress compared to 
untreated VSMCs. We also found that MMA(III)-mediated induction of ROS 
preceded loss of mitochondrial content and cell death. Overall, our data supports 
a conceptual model that suggests that MMA(III) impairs mitochondrial function 
by eliciting mitochondrial and non-mitochondrial sources of ROS that contribute 
to cytopathology of VSMCs. 
 
iii. Materials 
 Dulbecco’s Modified eagle’s media (DMEM), trypsin-EDTA solution 





(ABAM) (100X), and Amplex® Red Hydrogen Peroxide/ Peroxidase Assay kit 
were purchased from Invitrogen (Carlsbad, CA). Trypan Blue solution (0.4%), 
RIPA buffer, inorganic arsenic (As2O3) (iAs(III)), 4′,6-diamidino-2-
phenylindole (DAPI) nuclear stain, sodium pyruvate solution, sodium 
hydroxide pellets, methyl iodide, hydrochloric acid, sulfur dioxide, protease 
inhibitor cocktail, adenosine 5’ -triphosphate (ATP) disodium salt hydrate, 
dithiothreitol (DTT), catalase from bovine liver, and Bradford Assay Kit were 
obtained from Sigma-Aldrich (St. Louis, MO). GlutaMax (GIBCO) and MitoSOX 
(Molecular Probes) were purchased from Thermo Fisher Scientific (Waltham, 
MA). MnTBAP chloride hydrate was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). The CellTiter-Glo® Luminescent Cell Viability Assay kit and 
the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit were 
obtained from Promega (Madison, WI). The XF Cell Mito Stress Test Kit was 
purchased from Seahorse Biosciences (Billerica, MA). The broad-spectrum 
caspase inhibitor Z-VAD-FMK was purchased from Enzo Life Sciences, Inc. 
(Farmingdale, NY). 
The following antibodies were used: mouse anti-OXPHOS (Abcam), rabbit 
anti- β-tubulin (Abcam), rabbit anti-Tom20 (Santa Cruz Biotech), rabbit anti-





secondary antibodies conjugated to horse radish peroxidase (GE Healthcare Bio-
Sciences, Pittsburgh, PA), and Alexa 568-conjugated donkey anti-rabbit IgG 
secondary antibody (Molecular Probes, Eugene, CA).  
Diiodomethylarsine (CH3AsI2), a precursor of monomethylarsonous acid 
(MMA(III)), was synthesized in the Angermann lab as described by Millar et al 
(1960). In brief, arsenic(III) oxide (As2O3) and sodium hydroxide were combined 
in a solution, to which ethyl alcohol and 1.6M methyl iodide were added. The 
resulting solution was cooled in an ice bath under continuous stirring for 20h, 
and evaporated to dryness under vacuum. A fraction of the solid generated was 
diverted, reconstituted in ethanol, and recrystallized 2x from ethanol as 
disodium methanearsonate (Na2(CH3AsO3); ‘MMA(V)’), which presented as 
white crystals melting at 161°C. The remainder of the residue was dissolved in 
water, to which concentrated hydrochloric acid, sulfur dioxide, and potassium 
iodide (KI) were added, generating a precipitate which was then filtered out, 
washed twice, and discarded; the lower layer of diiodomethylarsine (the diiodo- 
salt of MMA(III)) was subsequently separated from the filtrate and recrystallized 
2x from methanol. The final product was washed with ice water, vacuum dried, 
and the resultant yellow crystals were verified as diiodomethylarsine by 





further confirmed via 400 MHz 1H NMR spectroscopy on a Varian 400-MR 
instrument (Figure S1). Diiodomethylarsine crystals were stored at -80°C. 
MMA(III) working solutions were made fresh as needed by dissolving 
diiodomethylarsine in ultrapure water, storing at 4°C, and using within 24 hours. 
Arsenic compounds (iAs(III) and MMA(III)) are carcinogens and skin irritants. 
Health Precautions: Proper precautions should be taken to avoid inhalation or 
direct skin contact by wearing proper laboratory attire including a laboratory 
coat, safety goggles, and nitrile gloves when handling these compounds. 
 
iv. Methods 
iv.i. Vascular smooth muscle cell cultures 
  Immortalized rat aortic smooth muscle cells (A7r5) were generously 
provided by Dr. Dean Burkin (Department of Pharmacology, University of 
Nevada School of Medicine). Cells were seeded in polystyrene tissue culture 
treated T-75 flasks (Sigma-Aldrich) in DMEM containing 4500 mg/L glucose and 
100 mg/mL sodium pyruvate supplemented with 10% FBS and 1% ABAM. Cells 
were maintained at 37°C / 5% CO2 and passaged at 80% confluency. All 






iv.ii. Bright field microscopy  
A7r5 cells were seeded at 30,000 cells per well in tissue culture treated 24-well 
plates and adhered for 24 hours prior to treatment with increasing concentrations 
of iAs(III) (0.1μM, 1μM, 10μM) or MMA(III) (0.1μM, 1μM , 10μM). Live cells 
were imaged under bright field phase for morphological changes 24 hours post 
exposure to arsenic species at a magnification of 10X or 20X on an AxioVert 200M 
microscope (Zeiss) or with an EVOS-FL microscope at the same magnification 
(Life Technologies).  
 
iv.iii. Trypan Blue exclusion assay for cellular mortality 
  Cells were plated at 30,000 cells per well in a 24-well plate for 24 hours, 
after which cells were treated with increasing concentrations of iAs(III) or 
MMA(III) for 24 hours. Cells were then trypsinized with 0.25% trypsin to obtain 
aliquots of cell suspension. Active measurements of cell death induced by arsenic 
toxicity were conducted by manually counting aliquots of cell suspension by 
using a 1:1 dilution of Trypan Blue Exclusion dye. The lethal concentrations at 
50% (LC50) for MMA(III) and iAs(III) at 24 h were determined using Origin 
software (version 6.0). To complement our Trypan Blue Exclusion assays, cell 





cells treated with increasing concentrations of arsenicals by using a ZTM series-
Coulter Counter (Beckman Coulter) (Figure S3).  
 
iv.iv. Cell survival assays  
 To measure the effects of iAs(III) and MMA(III) on cell viability of VSMCs, 
cells were seeded in opaque-walled, clear bottom 96 well plates at 10,000 cells per 
well. Twenty-four hours after seeding, cells were treated with either 0.5μM 
MMA(III) or 10μM iAs(III) for 24 hours, with or without the broad spectrum 
caspase inhibitor Z-VAD-FMK at 40μM, followed by incubation with the 
CellTiter 96® AQueous One Solution MTS reagent for 1hour per manufacturer’s 
instructions. Absorbance was measured at 490 nm with a Multi-mode 
SpectraMax M4 96 well plate reader (Molecular Devices, Sunnyvale, CA). It is 
important to note that the amount of iodide present in MMA(III) stocks does not 
significantly affect cell viability compared to water-treated cells or untreated cells 
as determined by performing the MTS assay (Figure S2A) or DAPI counts (data 
not shown), nor does it impact mitochondrial content (data not shown). Hence, 







iv.v. Mitochondrial respiration assay 
  Cellular respiration was analyzed in cells seeded in a XF24 V7 Cell 
Culture Microplate by using an XFe24 Extracellular Flux Analyzer (Seahorse 
Biosciences, North Billerica, MA). In brief, A7r5 cells were plated at a density of 
10,000 cells per well for 24 hours prior to analysis of mitochondrial respiration. 
The oxygen consumption rates (OCRs) and extracellular acidification rates 
(ECARs) were measured in quadruplicate wells for basal respiration by 
performing four measuring cycles (~30 minutes) followed by injecting the wells 
with vehicle or arsenic compounds to analyze for toxic effects of arsenic species 
on mitochondrial respiration. Cells were then sequentially treated with 1μM 
oligomycin to measure ATP-linked mitochondrial respiration, 1μM carbonyl 
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) to measure the maximal 
respiratory capacity, and with 1μM rotenone/antimycin-A to measure 
mitochondria-specific respiration as previously described [270,271]. We also 
performed concentration-dependent studies of MMA(III) to measure the lowest 
dose at which MMA(III) induces a deficit in mitochondrial respiration in A7r5 
cells. Following each assay, OCRs and ECARs were normalized to protein 
concentration by using the Bradford Assay. The line trace of the oxygraph for 





standard errors of the mean (SEM) were calculated by using the WAVE 2.0 
software (Seahorse Biosciences). All cells not exposed to MMA(III) were treated 
with water. However, it is worth noting that the iodide contained in stocks of 
MMA(III) did not significantly contribute to a decrease in mitochondrial 
respiration, suggesting negligible potential for MMA(III) solution-derived iodide 
toxicity in this model (Figure S2B). 
 
iv.vi. Intracellular detection of hydrogen peroxide levels 
 A7r5 cells were seeded at 30,000 cells per well in 6-well plates for 24 hours 
prior to analysis of extracellular levels of hydrogen peroxide by using the 
Amplex Red kit. On the day of the assay, the media was replaced with fresh 
media containing a dilution of 1:1000 Amplex Red, 1:100 horseradish peroxidase 
(HRP), and iAs(III) (1μM) or MMA(III) (100nM, 1μM, 10μM) and incubated at 37 
°C for 2 hours. A Tecan Ultra microplate reader (Männedorf, Switzerland) was 
used to measure absorption and fluorescence emission at 530 nm and 590 nm, 
respectively. The data was plotted as the mean fluorescence derived from at least 







iv.vii. Mitochondrial superoxide assays 
  To measure the effect of arsenic species on the levels of mitochondria-
derived superoxide at different time points, cells were stained with MitoSOX 
(Molecular Probes) as described previously [270,272]. As a control for induction 
of mitochondrial superoxide, cells were treated with 1μM rotenone for 2 or 4 
hours. We used Image J (version 1.44, Bethesda, MD) to calculate the mean 
fluorescence intensity of MitoSOX per cell for at least 30 cells per condition as 
previously described [270,271]. 
 
ii.viii. Western blot analysis 
 Cell lysates were prepared by harvesting cells in lysis buffer (1.0% Triton X-100 
with phosphatase inhibitors sodium orthovanadate and sodium pyrophosphate, 
and protease inhibitors E64 and PMSF). Twenty-five micrograms of cell lysates 
were resolved on 10% SDS-PAGE Tris-buffered polyacrylamide gels by using the 
mini-gel BioRad system as previously described [273]. At the end of the SDS-
PAGE run, the proteins were transferred onto methanol pre-activated PVDF 
membranes by using the Transblot SD Semi-Dry Transfer electrophoresis system 
(BioRad, Hercules, CA). The PVDF membrane was then blocked in either 2% 





0.1% Triton X-100 (PBST), and incubated overnight at 4°C with primary 
antibodies specific for the outer mitochondrial membrane (OMM) -localized 
protein TOM 20 (1:2000), for subunits of various mitochondrial-encoded 
mitochondrial complexes (OXPHOS) (1:2000), and for β-tubulin (1:10,000) as a 
loading control. PVDF membranes were incubated with the appropriate 
secondary antibodies conjugated to horseradish peroxidase (1:5,000) in PBST and 
immunoreactive bands were imaged by chemiluminescence by using a BioRad 
Imager available at the Nevada Proteomics Center.  
 
iv.ix. Immunofluorescence 
  To image mitochondria, VSMCs were fixed in 4% paraformaldehyde, 
permeabilized in PBST containing 0.1% Triton X-100 and stained for 
mitochondria by exposing cells to rabbit-anti-human TOM 20 antibody overnight 
at 4°C. The cells were then washed extensively in PBST and incubated with 
Alexa 568-conjugated donkey anti-rabbit IgG (1:1,000), and counterstained with 
1.25 µg/ml DAPI to stain for nuclei. Immunolabeled cells were imaged at 25°C by 
using an EVOS-FL Cell Imaging System equipped with EVOS Light cubes 





628/692) and at a magnification of 20X (0.45NA) or 40X (0.60NA). NA: numerical 
aperture. 
 
iv.x. Fluorescence-based image analyses of cell density and active cell death 
 To determine whether MMA(III) induces caspase-3 mediated apoptosis, 
we assessed cell density and cell death in VSMCs that were treated with LD50 
concentrations of arsenicals by performing image analyses of caspase-3 and 
DAPI-stained cells. To assess cell density, the number of nuclei per 
epifluorescence micrograph was manually counted blind to the observer for at 
least 300 cells per condition. By using the semi-automated Apoptosis Cell 
Density Image J macro, 
(http://imagejdocu.tudor.lu/doku.php?id=plugin:morphology: 
apoptosis_and_cell_count_macro:start), we also analyzed for cell death induced 
by arsenicals by counting the percentage of cells containing fragmented, 
pyknotic, or irregular-shaped nuclei per epifluorescence micrograph, 
morphological hallmarks of cell death (Figure S4). Arsenical-treated cells were 
also stained for cleaved caspase-3 to determine the extent by which MMA(III) or 
iAs(III) promote late stage apoptosis in A7r5 cells. Immunolabeled cells were 





The percentage of cells that stained for caspase-3 per epifluorescence micrograph 
was determined to assess the ability of MMA(III) or iAs(III) to induce apoptosis. 
 
iv.xi. Mitochondrial morphology 
  To analyze the effects of arsenic species on mitochondrial morphology 5 
hours post treatment, the average area/perimeter ratio per cell was measured as 
an index of mitochondrial interconnectivity in arsenic-treated VSMCs by using 
the “Mitochondrial Morphology Macro” (available for free on the Wiki site 
http://imagejdocu.tudor.lu/) on Image J software (v1.39) as previously described 
[274].  We chose 5 hours as this is the longest duration of treatment with iAs(III) 
or MMA(III) for functional and non-cytotoxic assays done in this study. 
 
iv.xii. ATP assay 
  Mitochondrial ATP concentrations were measured by using the CellTiter-
GloR Luminescent Cell Viability Assay (Promega, USA) and a SpectraMax 
Microplate Reader (Molecular Devices, Sunnyvale, CA) as previously described 
[270,271]. In brief, cells were plated at 10,000 cells per well in opaque-walled 96-
well microplates and cultured in DMEM containing 10mM galactose, 2mM 





with arsenic. Under these media conditions, the cells predominantly rely on 
mitochondrial oxidative phosphorylation for ATP production [275]. Cells were 
exposed to iAs(III) (1μM, 10μM) or MMA(III) (0.5μM, 1μM) for 6 hours. To 
assess for mitochondrial ATP levels, one half of the wells containing cells were 
treated with the ATP synthase inhibitor oligomycin for 1hour at 1μM. The 
luminescence readings were converted to ATP concentrations (μM) based on a 0 
-10μM standard curve and normalized to protein concentration by using the 
Bradford assay. Mitochondrial and cytosolic (non-mitochondrial) ATP levels 
were determined based on the following equation: Mitochondrial steady-state 
ATP levels= (Total cellular steady-state ATP levels) – (oligomycin-resistant 
steady state ATP levels, cytosolic ATP).  For some experiments, cells were 
cultured in high glucose media to induce glycolysis to assess the effects of iAs(III) 
or MMA(III) on cytosolic ATP levels in glycolytic conditions.   
 
iv.xiii. Toxicity reversal studies with antioxidants 
 To determine whether mitochondrial superoxide and/or hydrogen 
peroxide play a role in arsenic-mediated mitochondrial dysfunction, A7r5 cells 
were plated at 10,000 cells per well in a XF24 V7 Microplate and either pre-





superoxide dismutase mimetic- at 100μM for 24 hours prior to the addition of 
MMA(III) (0.5μM, 2hours), or co-treated with 10 units/ml of catalase for the 
duration of MMA(III) treatment (0.5μM, 2hours) to scavenge hydrogen peroxide. 
This specific dose of MMA(III) consistently decreases mitochondrial respiration 
(Figure 6). Following treatments with anti-oxidants, the baseline, maximal, and 
ATP-linked mitochondrial respiration were measured as described above 
(Mitochondrial respiration assay section). It is worth noting that the brown color in 
the media formed in cells co-treated with MnTBAP impaired the ability of the 
XF24e Analyzer to read OCRs, which precluded an analysis of the effects of co-
treating cells with MnTBAP and arsenic compounds on mitochondrial function. 
Hence, for this reason, it was necessary to pretreat (not co-treat) VSMCs with 
MnTBAP for 24 hours prior to reading OCRs in arsenic-treated cells. 
 To study the effects of antioxidants on arsenic-induced cell death, cells 
were plated in opaque-walled 96-well plates at 10,000 cells per well. Following 
an adherence time of 24 hours, cells were co-treated with 0.5μM MMA(III) or 
10μM iAs(III) in the presence of either 100μM of MnTBAP or 10 units/ml of 
catalase for 24 hours. Following a 24 hour exposure, cells were incubated with 
One Solution MTS reagent for 1 hour and absorbance was measured at 490 nm 





The absorbance of wells containing cells and treatments were subtracted from 
wells lacking cells but containing the respective backgrounds. It is worth noting 
that cells were treated with the above concentrations of arsenicals for 24 hours in 
order to elicit a consistent, measurable and significantly consistent decrease in 
cell viability (~50% cell death) prior to assessing for potential significant reversal 
of cytotoxicity with antioxidants.  
 
iv.xiv. Statistical analysis 
 All statistical analyses were performed by using the SPSS software (IBM) 
(v 23). Unless indicated otherwise, most experiments were performed at least 
three times and the results are presented as means ± standard errors (SE). By 
applying an α of 0.05, One-Way ANOVAs followed by the post hoc Tukey’s HSD 
tests were conducted for all experiments to account for multiple comparisons in 
data interpretation.  
 
v. Results 
v.i. Viability of A7r5 Cells following exposure to iAs(III) and MMA(III) 
  We conducted several cell survival assays to compare the cytotoxic 





cell morphology revealed that exposure of cells to iAs(III) induced 
morphological changes associated with necrosis while MMA(III) induced 
morphological changes consistent with apoptosis (pyknosis and cell blebbing) 
(Figure 1A).  Consistent with the observation that MMA(III) promotes apoptosis, 
we observed that treating cells with MMA(III), but not iAs(III), robustly elicited 
the activation of caspase-3 and nuclear fragmentation, pathological hallmarks of 
apoptosis (Figure S4A-B). Furthermore, co-treating cells with the pan-caspase 
inhibitor Z-VAD-FMK conferred partial protection against MMA(III)-mediated 
cell death suggesting that factors other than caspases also contribute to cell death 
(Figure S4C-D). This data is in agreement with other reported studies that show 
that MMA(III) and iAs(III)-mediated cell toxicity is associated with the activation 
of apoptosis and necrosis respectively [138-140]. The LC50s at 24 hours for 
MMA(III) and iAs(III) were determined to be 0.50μM and 10.0μM respectively as 
assessed by three independent methods: the trypan blue exclusion assays (Figure 
1B,C), and further corroborated by the MTS assay, a more quantitative and non-
biased method for assessing cell viability (Figure 1D), and by performing cell 
counts using a Coulter counter apparatus (Figure S3). Collectively, these data 
show that MMA(III) is 20x more toxic than iAs(III) to VSMCs at 24 hours. Based 





morphological analyses were done using sublethal exposures of arsenical that do 
not result in significant cell death (Figure S4).
  
Figure 1. Differential morphological and toxicological effects of MMA(III) and 
iAs(III) in A7r5 cells.  
 
A. Representative images of live A7r5 cells treated with the indicated concentrations of toxicants 
or vehicle control (Control) for 24 hours. Cells were imaged with an AxioVision (Zeiss) 
microscope at 10X magnification. Representative micrographs of cells with MMA(III) show 
pyknosis and blebbing, consistent with apoptosis.  
 
 B, C. Cell mortality curves were assessed by performing the Trypan Blue Exclusion Dye assay 
for cells treated with iAs (panel B) or with MMA(III) (panel C). The percent mortality was 
calculated as follows: [Cell mortality= Trypan Blue stained cells/total cells * 100]. The 24 hour 
lethal concentrations at 50% (LC50s) were determined to be 0.5μM for MMA(III) and 11.3μM for 
iAs(III) as indicated by red-hatched lines. Dose dependent graphs are representative of three 
experiments (*:p<0.05 vs. untreated, Means ±SE, n=3 samples per condition). One-way ANOVA, 
Tukey’s HSD. 
 
D. Viability of A7r5 cells was assessed via the MTS assay following 24 hour exposure. Cells 





(*:p<0.05 vs. untreated, Means±SE, n=18 wells/condition). One-way ANOVA, Tukey’s HSD. Data 
was compiled from 3 independent experiments.  
 
v.ii. Effects of iAs(III) and MMA(III) on mitochondrial respiration 
  We measured the effects of both inorganic and organic arsenic species on 
mitochondrial function by using an Extracellular Flux XF24e Analyzer, a well-
characterized system for measuring real-time oxygen consumption in live cells. 
In brief, we found that prelethal exposure of cells to 0.5μM of MMA(III), but not 
iAs(III) at 10μM, progressively induced a significant decrease in the basal 
respiration of VSMCs within 3 hours of treatment (Figure 2A,B). For comparative 
purposes, other OCR traces show consistency and little variability in the 
temporal dynamics of MMA(III)-mediated decrease in OCRs across experiments 
(Figure S5). It is worth noting that treating cells with MMA(III), but not with 
iAs(III), led to a progressive reduction in baseline OCR that plateaued by 100 
min. of treatment (Figure 2A, Figure S5). In addition, we observed a significant 
decrease in maximal oxygen consumption rates (OCRs) in cells exposed to 0.5μM 
MMA(III), but not with 10μM iAs(III) (Figure 2 A, Fig. S6). MMA(III) is a 
mitochondria-specific toxicant since treating cells with MMA(V) at similar 






Figure 2. Effect of arsenic species on mitochondrial respiration. 
 
A. Representative mitochondrial respiration profile (oxygraph) of three experiments 
demonstrates that VSMCs treated with 0.5μM MMA(III), but not with 10μM iAs(III) show a 
progressive decrease in baseline OCRs followed by a reduction in maximal OCRs compared to 
control (untreated). The oxygraph is representative of three experiments with similar results and 
all other traces have been uploaded as supplemental information (Figure S5). 
 
B. Comparative analysis of basal respiration, measured as a percentage relative to time 0, 
demonstrates that VSMCs treated with 0.5μM MMA(III) for 3 hours showed a significant 
decrease in baseline OCRs relative to untreated cells or cells treated with 10μM iAs(III) (*:p<0.05 
vs. untreated cells, **:p<0.05 vs. 10μM iAs(III) treated cells, Means, ±SE, n=10-16 wells/condition). 
One-way ANOVA, Tukey’s HSD. Data was compiled from three independent experiments.  
 
C . Comparative analysis of maximal mitochondrial respiration, measured as a percentage 





significantly reduced maximal OCRs compared to untreated cells or cells treated with 10μM 
iAs(III). To measure maximal mitochondrial respiration, cells were treated with 1μM FCCP and 
OCRs were measured for three consecutive time points (*:p<0.05 vs. untreated cells,**:p<0.05 vs. 
10μM iAs(III) treated cells, graph shows means, ±SE, n=10-16 wells/condition). One-way 
ANOVA, Tukey’s HSD. Data was compiled from three independent experiments. 
 
D. Comparative analyses of extracellular acidification rate (ECAR) show that treating VSMCs 
with 0.5μM MMA(III) or with 10μM iAs(III) for 3 hours leads to a significant increase in ECARs 
(*:p<0.05 vs. untreated cells, Means, ±SE, n=10-16 wells/condition). Treatment with 0.5μM 
MMA(III) resulted in a non-significant increase in ECAR relative to treatment with 10μM iAs(III). 
One-way ANOVA, Tukey’s HSD. Data was compiled from three independent experiments.  
 
E. Comparative analyses of maximal ECARs show that treating VSMCs with 0.5μM MMA(III) 
leads to a significant increase in maximal ECARs compared to untreated cells or cells treated with 
10μM iAs(III). (*:p<0.05 vs. untreated cells, **:p<0.05 vs. 10μM iAs(III) treated cells, Means, ±SE, 
n=10-16 wells/condition). One-way ANOVA, Tukey’s HSD. Data was compiled from three 
independent experiments.  
 
F. Dose-dependent analyses show that baseline OCRs were significantly reduced in VSMCs 
treated with MMA(III) in a dose dependent manner. (*:p<0.05 vs. untreated, Means, ±SE n=8-14 
wells/condition). One-way ANOVA, Tukey’s HSD. Data was compiled from three independent 
experiments.  
 
G. Dose-dependent analyses show that baseline ECARs were significantly reduced in VSMCs 
treated with MMA(III) in a dose dependent manner (*:p<0.05 vs. untreated, Means, ±SE n=8-14 
wells/condition). One-way ANOVA, Bonferroni adjusted Tukey’s HSD. Data was compiled from 
three experiments.  
________________________________________________________________________ 
 
Interestingly, treating VSMCs with MMA(III) led to a significant increase 
in basal and maximal extracellular acidification rates (ECARs), a proxy of 
glycolysis. This data suggests that MMA(III) toxicity leads to a compensatory 
increase in glycolysis when mitochondrial function is impaired, also known as 
the Warburg effect [276] (Figure 2D,E). Treatment with iAs(III) led to a robust 
increase in basal ECARs (Figure 2D) but maximal ECARs were not significantly 





partial upregulation of ECAR. Next, we wanted to assess the minimal 
concentration of MMA(III) that can induce alterations in mitochondrial 
respiration and glycolysis in VSMCs. Dose-dependent analysis of OCRs and 
ECARs revealed that MMA(III) can induce a significant decrease in basal OCRs 
and ECARs at concentrations as low as 0.5μM. A non-significant decrease in 
OCRs was observed in cells exposed to 0.25μM of MMA(III). (Figure 2F, G). 
Overall, these data suggest that treating A7r5 cells with sublethal doses of 
MMA(III), but not iAs(III), selectively impair mitochondrial respiration while 
concomitantly upregulating glycolysis, possibly as a protective mechanism to 
compensate for mitochondrial dysfunction.  
 
v.iii. Effects of Arsenic compounds on mitochondrial ATP levels  
  Given that oxidative phosphorylation drives the synthesis of 
mitochondrial ATP, we then investigated whether MMA(III)-mediated deficits 
on mitochondrial respiration are associated with a decline in mitochondrial ATP 
levels. We observed that exposing VSMCs to 0.5μM MMA(III) for 6 hours led to 
a significant decrease in mitochondrial ATP levels, while 1μM MMA(III) 
significantly decreased cytosolic ATP levels (Figure 3). To further corroborate the 





prelethal exposure to MMA(III), but not iAs(III), contributed to a modest but 
significant decrease in cytosolic ATP levels in cells grown in high glucose-
containing media (Control: 2.98μM ±0.12; MMA(III): 2.21 μM ±0.06, p<0.00001). 
On the other hand, treatment with 1μM or 10μM iAs(III) had no significant effect 
on either mitochondrial, cytosolic, or total ATP levels compared to control cells 
in no-glucose media (Figure 3) or under glycolytic conditions (Control: 2.98μM  
±0.12; iAs(III): 2.43 μM ±0.18, p=0.25). It is worth noting that treating cells with 
these doses of arsenicals for 6 hours does not cause significant cell death which 
rules out the possibility that any observed decreases in ATP levels is due to 
cytotoxicity (Figure S4). These results suggest that MMA(III) significantly 
decreases mitochondrial respiration and ATP levels while iAs(III) does not.  
 






Compiled quantification of ATP levels in VSMCs treated with the indicated concentrations of 
MMA(III) and iAs(III) for 6 hours. Mitochondrial ATP levels were determined by subtracting the 
levels of ATP not affected by electron chain complex inhibitors rotenone and antimycin-A 
(cytosolic ATP) from total ATP levels. Total, mitochondrial or cytosolic ATP levels shown in the 
compiled quantification was normalized to its respective untreated control within each group 
(total, mitochondrial or cytosolic).Treatment with 0.5μM MMA(III) resulted in a significant 
decrease in mitochondrial ATP levels relative to untreated cells, while treatment with 1μM 
MMA(III) resulted in a significant decrease in cytosolic ATP relative to untreated cells. (*:p<0.05 
vs. untreated cells, Means, ±SE, n=18 wells/condition) One-way ANOVA, Tukey’s HDS. Data was 
compiled from three independent experiments.  
Please note that in media conditions that do not have glucose but is supplemented with pyruvate 
and galactose, we observe that cells produce 50-60% of ATP from mitochondria whereas cells 
grown in high glucose media, which stimulate glycolysis, predominantly produce non-
mitochondrial (cytosolic) ATP (~80-90% of total ATP). 
 
v.iv. Effects of arsenic compounds on ROS levels 
 Given that MMA(III) can significantly suppress mitochondrial respiration, 
we then wanted to identify mechanisms of MMA(III)-mediated mitochondrial 
dysfunction in VSMCs. Arsenic compounds are known to stimulate the 
production of hydrogen peroxide in myriad cell types [277,278]. Hence, we 
surmised that an elevation in the levels of hydrogen peroxide may be correlated 
with mitochondrial dysfunction induced by MMA(III). In brief, we indirectly 
measured the levels of hydrogen peroxide in cells exposed to arsenic species by 
using the Amplex Red assay. We observed that increasing concentrations of 
MMA(III) induced a significant elevation of hydrogen peroxide levels compared 





elevated hydrogen peroxide levels induced by MMA(III) may contribute to 
mitochondrial and cellular pathology (Figure 4A).  
 
v.v. Generation of Superoxide 
  Arsenic toxicity has been associated with increased levels of 
mitochondrial superoxide in other cell lines [250]. Given that hydrogen peroxide 
is derived from mitochondrial superoxide, we investigated the extent to which 
arsenic species can induce the production of mitochondrial superoxide by 
staining live cells with the red-fluorescent, cell permeable superoxide indicator 
MitoSOX. Image analyses of mean MitoSOX fluorescence suggests that treating 
cells with 0.5μM or 1μM MMA(III) can significantly elevate mitochondrial 
superoxide levels at 4 hours compared to control cells or cells treated with 1μM 
or 10μM iAs(III) (Figure 4B). MMA(III)-mediated elevation in superoxide is 
commensurate with oxidative stress induced by exposure to the complex I 
inhibitor rotenone. Neither arsenic species significantly elevated mitochondrial 
superoxide levels at 2 hours, while only a non-significant increase in superoxide 
was induced by iAs(III) at 4 hours (Figure 4B). However, at longer exposures of 6 
hours, we found that iAs(III) can significantly increase mitochondrial superoxide 





another study that showed a stronger induction of ROS in MMA(III) compared 
to iAs(III) in liver cells [250]. Collectively, this data suggests that MMA(III) is a 
more efficient inducer of mitochondrial superoxide compared iAs(III) in VSMCs. 
 
Figure 4. Effects of arsenic species on hydrogen peroxide and mitochondrial 
superoxide levels. 
 
A. Mean hydrogen peroxide levels, as assessed by the Amplex red assay, were significantly 
elevated in cells exposed to 1μM or 1μM MMA(III) for 2 hours compared to untreated cells or 
cells treated with 1μM iAs(III) (*:p<0.05 vs. untreated cells, **:p<0.05 vs. 1μM iAs(III) treated cells, 
graph shows means, ±SE, n=4 wells/condition). One-way ANOVA, Tukey’s HSD. Data is 
representative of one of three experiments.  
 
B. The average intensity of MitoSOX fluorescence was quantified in untreated cells, and in cells 
exposed for 2 or 4 hours to the indicated concentrations of MMA(III), iAs(III) or with the complex 
I inhibitor rotenone as a positive control for mitochondrial superoxide induction. Mitochondrial 
superoxide was significantly elevated among cells treated for 4 hours with 0.5μM or 1μM 
MMA(III) compared to untreated cells, or cells treated with iAs(III) at a concentration of 1μM or 
10μM (*:p<0.05 vs. untreated, **:p<0.05 vs. iAs(III), Means, ±SE, n=25-46 cells/condition). One way 








v.vi. Effects of Arsenic compounds on mitochondrial morphology and content  
 Next, we surmised that the decreased mitochondrial respiration and ATP 
levels induced by MMA(III) leads to a decrease in mitochondrial content in 
VSMCs. To address this hypothesis, we quantified mitochondrial content in 
VSMCs by using image-based analysis of mitochondrial content in VSMCs 
immunostained for mitochondria and by immunoblotting for the total cellular 
levels of various mitochondrial markers. Western blot analyses of mitochondrial 
markers revealed that treating VSMCs with 1μM MMA(III) for 5 hours, a 
concentration that is sufficient to induce mitochondrial damage and oxidative 
stress but not cell death (Figure 2, 4 and S4), significantly decreased the levels of 
mitochondrial markers localized either to the outer mitochondrial membrane 
(TOM20) or the inner mitochondrial membrane (ATP synthase V) (Figure 5A-C). 
On the other hand, treating cells with 1μM iAs(III) for 5 hours caused a non-
significant decrease in mitochondrial protein levels (Figure 5A-C). This data is 
consistent with the effects of MMA(III) on mitochondria-derived ATP levels 
(Figure 3). In further agreement with our Western blot data, image analyses of 
VSMCs immunostained for mitochondria revealed that cells treated with 1μM 
MMA(III) or 1μM iAs(III) for 5 hours led to a significant decrease in 





Given that mitochondrial content is regulated by mitochondrial turnover 
through the autophagosomal-lysosomal pathway (mitophagy) and the fact that 
mitochondrial fragmentation precedes mitophagy [279-281], we then surmised 
that treating cells with both arsenic species causes mitochondrial fragmentation. 
Unexpectedly, we observed that 1μM MMA(III), but not 1μM iAs(III), promoted 
perinuclear clustering of mitochondria and a significant increase in 
mitochondrial interconnectivity at 5 hours post exposure (Figure 5 E-F). 
However, treatment of cells with longer exposure of 10μM iAs(III) can decrease 
mitochondrial content eventually and fragment mitochondria (Figure S9). 
Overall, our immunofluorescence data highlights significant differences in the 










Figure 5. Effects of arsenic species on mitochondrial content and morphology. 
 
A. Representative Western blot analyses of the total cellular levels of mitochondrial markers 
(TOM20 and ATP synthase V) and of β-tubulin in cell lysates from untreated cells (lanes 
indicated by a), and cells exposed for 5 hours to 1μM MMA(III) (lanes indicated by b) or exposed 
to 1μM iAs(III) (lanes indicated by c). 
 
B. Densitometric analyses of the immunoreactivity of the outer membrane localized protein 
TOM20 as assessed by Western blot of cell lysates from cells treated with indicated 
concentrations of MMA(III) and iAs(III) and normalized to untreated cells. (*:p<0.05 vs. 
untreated, Means, ±SE, n=5 lanes/condition). One-way ANOVA, Tukey’s HSD. Data was 
compiled from three independent Western blot experiments.  
 
C. Densitometric analyses of the immunoreactivity of the inner membrane localized protein ATP 
Synthase V as assessed by Western blot of cell lysates derived from cells treated with indicated 
concentrations of MMA(III) and iAs(III) and normalized to untreated cells. (*:p<0.05 vs. 
untreated, Means, ±SE, n=5 lanes/condition). One-way ANOVA, Tukey’s HSD. Data was 
compiled from three independent Western blot experiments.  
 
D. Image-based quantification of mitochondrial content in paraformaldehyde-fixed cells 
immunolabeled for TOM20 as assessed by measuring the percentage of the cytosolic area 
occupied by fluorescently-labeled mitochondria-specific pixels and normalized to untreated cells. 
(*:p<0.05 vs. untreated cells, Means, ±SE, n=44-57 cells/condition). One-way ANOVA, Fishers LSD 
Tukey’s HSD. Data was compiled from three independent experiments.  
 
E. Mitochondrial interconnectivity, defined as the ratio of the average area to the perimeter of 
mitochondria per cell (Dagda et al. 2009), was measured in untreated cells and in cells treated 
with the indicated concentrations of iAs(III) and MMA(III). Cells treated with MMA(III) had 





(*:p<0.05 vs. untreated, **:p<.05 vs. 1μM iAs(III), Means, ±SE, n=44-57 cells/condition). One-way 
ANOVA, Fishers LSD Tukey’s HSD. Data was compiled from three independent experiments.  
 
F. Representative epifluorescence micrographs of paraformaldehyde-fixed cells immunolabeled 
for TOM20 (red) and counterstained with DAPI to visualize mitochondria and nuclei 
respectively. Epifluorescence micrographs were acquired at a magnification of 20X. While 
untreated VSMCs showed a normal mitochondrial morphology (tubular to interconnected), cells 
treated with MMA(III), but not iAs(III), showed the presence of aberrant mitochondrial clusters 




v.vii. Mitochondrial and non-mitochondrial sources of ROS contribute to arsenic 
toxicity in VSMCs  
 Given that MMA(III), but not iAs(III), selectively promotes mitochondrial 
dysfunction and is a more efficient inducer of ROS than iAs(III), we then 
surmised that mitochondrial superoxide and hydrogen peroxide induced by 
MMA(III) contributes to mitochondrial dysfunction in VSMCs. To address this 
hypothesis, we co-treated VSMCs with catalase or pretreated them with the 
superoxide dismutase mimetic MnTBAP- two anti-oxidants that can scavenge 
hydrogen peroxide and mitochondrial superoxide, respectively. Following 
exposure to antioxidants, VSMCs were treated with 0.5μM MMA(III) and 
assayed for mitochondrial respiration by employing a XF24e Extracellular Flux 
Analyzer. We observed that MnTBAP treatment partially but significantly 
ameliorated MMA(III)-mediated deficits in basal OCRs but was unable to reverse 





was able to reverse the increase in maximal ECARs induced by MMA(III) (Figure 
6F). Treating VSMCs with catalase, on the other hand, completely reversed 
MMA(III)-mediated decreases in basal and maximal OCRs and was able to block 
the increase in ECARs (Figure 6A, C-F). Next, we generated “phenograms” -
visual representations of the cell’s energy profile derived by plotting OCRs vs. 
ECARs- to further understand the metabolic rescue mediated by catalase and 
MnTBAP treatment in cells exposed to MMA(III). We observed that treating cells 
with catalase not only reversed mitochondrial dysfunction induced by MMA(III), 
but it also significantly reversed the energy profile of VSMCs back to a more 
aerobically active and less glycolytic phenotype compared to MMA(III)-treated 
cells (Figure 7A) whereas treating VSMCs with MnTBAP had a partial effect 










Figure 6. Antioxidant rescue of MMA(III)-induced deficits in mitochondrial 
respiration.  
 
A. Representative mitochondrial respiratory profile (oxygraph) demonstrates that co-treating 
cells with catalase rescued cells against 0.5μM MMA(III)-mediated decreases in baseline OCRs 
and maximal respiratory capacity. The oxygraph is representative of one of three experiments 
showing similar results. 
 
B. Representative mitochondrial respiratory profile (oxygraph) demonstrates that pre-treating 
cells with MnTBAP rescued cells against 0.5μM MMA(III)-mediated decreases in baseline OCRs 
but not the maximal respiratory capacity. The oxygraph is representative of one of three 
experiments showing similar results. 
 
C. Graph showing average baseline OCRs compiled from three experiments in cells treated with 
MMA(III) and co-treated with catalase or pretreated with MnTBAP for 24 hours at the indicated 
concentrations for 3 hours. (*:p<0.05 vs. 0.5μM MMA(III), Means, ±SE, n=25-29 wells/condition). 
One-way ANOVA, Tukey’s HSD. 
 
D. Graph showing average maximal OCRs compiled from three experiments in cells treated with 
MMA(III) and co-treated with catalase or pretreated with MnTBAP for 24 hours at the indicated 
concentrations for 3hours. (*:p<0.05 vs. 0.5μM MMA(III), Means, ±SE, n=25-29 wells/condition). 
One-way ANOVA, Tukey’s HSD. 
 
E. Graph showing average basal ECARs compiled from three experiments in cells treated with 
MMA(III) and co-treated with catalase or pretreated with MnTBAP for 24 hours at the indicated 
concentrations for 3hours. (*:p<0.05 vs. 0.5μM MMA(III), Means, ±SE, n=25-29 wells/condition). 
One-way ANOVA, Tukey’s HSD. 
 
F. Graph showing average maximal ECARs compiled from three experiments in cells treated 
with MMA(III) and co-treated with catalase or pretreated with MnTBAP for 24 hours at the 
indicated concentrations for 3 hours. (*:p<0.05 vs. 0.5μM MMA(III), Means, ±SE, n=25-29 
wells/condition). One-way ANOVA, Tukey’s HSD. 
 
Finally, we investigated whether the reversal in mitochondrial 
dysfunction mediated by anti-oxidants was associated with increased cell 
survival against MMA(III) and iAs(III)-mediated toxicity. As proof of principle of 
the ROS quenching effects of antioxidants in cells are cytoprotective, we 





enhancing cell survival against both MMA(III) and iAs(III) whereas MnTBAP 
had a partial protective effect against MMA(III) highlighting the differential 
contribution of different sources of ROS on cytopathology and the ability of 
antioxidants to confer protection (Figure 8). 
 
Figure 7. Antioxidants reverse the metabolic alterations induced by MMA(III).  
 
A. Representative phenogram from one of three experiments (baseline OCRs vs. baseline ECARs) 
showing a robust glycolytic shift in cells treated with 0.5μM MMA(III) for 200 min. compared to 
control (untreated) but reversed by co-treatment with catalase (*:p<0.05 vs. 0.5μM MMA(III), 
Means, ±SE, n= 4-6 wells per condition). One-way ANOVA, Tukey’s HSD. The decreased OCR 
observed in control group relative to its first time point likely reflects a modest induction of 
oxidative stress in cells incubating for 3 hours required to do the oxygen consumption assay. 
 
B. Representative phenogram from three experiments showing (baseline OCRs vs. baseline 





(untreated). MnTBAP pre-treatment was only able to partially reverse the glycolytic shift 
(*:p<0.05 vs. 0.5μM MMA(III), Means, ±SE, n= 4-6 wells per condition). One-way ANOVA, Fishers 
LSD. The decreased OCR observed in control group relative to its first time point likely reflects a 
modest effect oxidative stress in cells incubating for 3 hours required to do the oxygen 
consumption assay.   
 
Figure 8. Antioxidants reverse cell death induced by MMA(III) and iAs(III). 
 
Compiled quantification of cell viability as measured by the MTS assay in cells treated with the 
indicated concentrations of MMA or iAs(III), and either pretreated with MnTBAP or co-treated 
with catalase. (*:p<0.05 vs. 10μM iAs(III) or 0.5μM MMA(III) of their respective groups, **:p<.05 
comparing MnTBAP to catalase treatment in respective groups, Means, ±SE, n=6-21 
wells/condition). One-way ANOVA, Tukey’s HSD. Data was compiled from three experiments.  
________________________________________________________________________ 
 
vi. Discussion  
Although it is widely accepted that arsenic species can produce various 
degrees of mitochondrial dysfunction in myriad cell types, the effects of 





in VSMCs have not been elucidated. In this study, we demonstrate for the first 
time that MMA(III) promotes mitochondrial dysfunction and oxidative stress in 
VSMCs, and that these deficits stem from the generation of mitochondrial and 
non-mitochondrial ROS following exposure to MMA(III). 
 
vi.i. MMA(III) induces cytotoxicity in VSMCs 
  Our findings on the cytotoxicity of arsenic to VSMCs are in agreement 
with a majority of studies demonstrating arsenic’s capacity to induce apoptosis 
in various cell lines including aortic, coronary, and mesenteric vascular smooth 
muscle [139,255,261-263]. Our data shows that MMA(III), but not iAs(III), 
promotes caspase-dependent apoptosis in A7r5 cells consistent with other 
studies [138-140], whereas iAs(III) predominantly elicits necrosis [140] (Figure 1, 
S4). Furthermore, several studies suggest that apoptosis of smooth muscle cells 
may play a pathological role in cardiovascular disease progression [256,282,283], 
suggesting that cell death of vascular smooth muscle cells may underlie 








vi.ii. Arsenic targets mitochondria 
 Organic species of arsenic demonstrate higher toxicity compared to iAs in 
a variety of cell types. For instance, MMA(III) can induce apoptosis in the human 
intestinal epithelial cell line Caco-2 by elevating ROS, inducing a reduction in 
intracellular GSH, and increasing peroxidation of lipids. MMA(III) also alters the 
antioxidant activities of glutathione peroxidase and catalase and concomitantly 
induces expression of heat shock proteins and metallothioneins [139]. There is a 
wealth of evidence that supports selective toxicity of arsenic species towards 
mitochondria. Previous studies have shown that arsenic induces widespread 
mitochondrial dysfunction via loss of mitochondrial membrane potential, 
generation of ROS, diminution of cytochrome c oxidase function, and 
suppression of oxygen consumption via depletion of mtDNA copy number 
[143,144]. Consistent with the toxic effects of MMA(III) on mitochondria in many 
cell types, our data also show that MMA(III) is a mitochondria-specific toxicant 
in VSMCs. Our study is the first to show an interplay and temporal dynamics of 
MMA(III) exposure, generation of mitochondrial superoxide and non-
mitochondrial ROS, and alterations in mitochondrial function and metabolism in 





Our mitochondrial functional assays suggest that MMA(III) is a stronger 
inducer of mitochondrial dysfunction upstream of cell death compared to iAs(III) 
or to MMA(V) at equimolar concentrations that are sufficient to induce 
significant mitochondrial superoxide levels but not high enough to induce 
cytotoxicity (Figure 2, Figure S4). Although some doses of arsenicals used in this 
study may be considered high, humans have been acutely and chronically 
exposed to similar concentrations of arsenicals environmentally [176] and in the 
clinical treatment of acute promyelocytic leukemia [177]. Furthermore many 
epidemiological studies have demonstrated the pathological effects of long-term 
accumulation of arsenicals in human bodies at high doses [43,50]. Nevertheless, 
our study raises the possibility that mitochondrial dysfunction/metabolic 
alterations induced by MMA(III), at the prelethal doses used, may contribute to 
pathology and metabolic alterations in humans exposed to arsenic. Indeed, 
MMA(III)-induced perturbations of glycolytic flux, as discussed in the following 
section, are particularly relevant to vascular smooth muscle function due to the 
observation that ATP generated from glycolysis may have a separate 'metabolic 
purpose' (e.g., provision of energy for the Na+/K+ antiporter) than ATP derived 
from oxidative phosphorylation, which has been demonstrated to provide 





in ATP generation may therefore have profound consequences for VSMC 
function, especially since these cells are reliant on phosphocreatine (PCr) for 
short-term, instantaneous metabolic demands and PCr is resynthesized mainly 
via oxidative phosphorylation [285]. Overall, our data strongly suggest that 
MMA(III) is a highly selective arsenic metabolite that targets mitochondrial 
function at sublethal concentrations and time points. However, we do not rule 
out the possibility that iAs(III) may also contribute to mitochondrial pathology, 
albeit less efficiently than MMA(III), in VSMCs in instances of prolonged 
exposure to iAs(III).  
 
vi.iii. Selective toxicity of MMA(III) to mitochondria activates metabolic 
compensation in VSMCs 
  Our results show that treatment of VSMCs with MMA(III) led to 
significant decreases in basal and maximal OCRs while concomitantly enhancing 
basal and maximal ECARs compared to cells treated with iAs(III) (Figure 2). The 
ECAR values detected by the XF24e analyzer are a reliable measure of glycolytic 
rate. Hence, a decrease in the ratio of the mean OCR to ECAR associated with 
MMA(III) exposure (Figure 7) is an indicator of a compensatory upregulation of 





known to adversely affect the functioning of the electron transport chain (ETC) 
[250], an increase in glycolysis may be a compensatory mechanism to ensure 
cellular survival, somewhat akin to the Warburg effect [276] due to 
mitochondrial impairment. However, it is worth noting that this increase in 
ECARs caused by MMA(III) exposure does not lead to an increase in cytosolic 
ATP levels under conditions that favor mitochondrial ATP production (Figure 3), 
or in glycolytic conditions (data not shown), suggesting that either MMA(III) 
elicits a futile upregulation of glycolysis or that non-mitochondrial sources of 
ROS (e.g. hydrogen peroxide from ER) shut down compensatory glycolysis as 
suggested by our ATP assays that show a significant decrease in cytosolic ATP at 
1μM MMA(III). Toxic stimuli that elicit classical apoptosis (e.g. staurosporine) 
can significantly elevate cytosolic ATP levels to promote cell death [286]. 
Although MMA(III) elicits apoptosis as evident by increased active caspase-3 
levels and nuclear fragmentation (Figure S4 A-B), our luminescence-based ATP 
assays show that MMA(III) does not elicit an increase, but modestly decreases, 
cytosolic steady-state ATP levels at 2 or 6 hour of exposure (data not shown). 
This observation suggests that MMA(III) may promote apoptosis through 
distinct mechanisms that do not involve a transient rise in cytosolic ATP levels 





mitochondrial ROS may prevent an upregulation of cytosolic ATP levels by 
inactivating glycolytic enzymes. 
Our data also suggests that the decline in mitochondrial respiration 
resulting from MMA(III) is an early event that occurs in response to elevated 
mitochondrial superoxide levels and precedes the loss of mitochondrial ATP and 
content (Figures 2-5). Although iAs(III) toxicity does not lead to early 
mitochondrial dysfunction, prolonged exposure of VSMCs with iAs(III) can lead 
to a reduction in mitochondrial content, fragment mitochondria, and elevate 
mitochondrial superoxide levels suggesting that iAs(III) induces delayed 
mitochondrial toxicity without inducing significant cell death (Figure, S4, S7-9).  
 
vi.iv. What are the mechanisms by which arsenic decreases mitochondrial 
content in VSMCs? 
  We observed that treating VSMCs with MMA(III) was associated with 
robust aberrant perinuclear aggregation (clustering) of mitochondria in a 
subpopulation of cells (Figure 5F) and significant loss of mitochondria (Figure 
5B-E). The effects of MMA(III) on mitochondrial aggregation (clumping or 
perinuclear clustering) is consistent with another study which reported 





glioblastoma cells [287]. In yet another study, chronic treatment of AL human-
hamster hybrid CHOK1 cells with arsenic resulted in an abnormal distribution of 
mitochondria that varied considerably between cells including increased 
mitochondrial fusion or filamentous morphology. This effect was associated with 
decreased mitochondrial function [144].  
   In mammalian cells, the E3 ubiquitin ligase Parkin is known to promote 
perinuclear clustering of damaged mitochondria to facilitate mitophagy [288]. 
Indeed, Watanabe et al., (2014) recently reported that ubiquitin proteasome 
system activity is increased by arsenic trioxide and the autophagy lysosomal 
system is increased in mouse atrial cardiomyocytes suggesting that the 
elimination of dysfunctional mitochondria is enhanced by the E3 ubiquitin ligase 
Parkin in arsenic-treated cells [289]. Based on our morphological analyses of 
perinuclear clustering and mitochondrial loss, it is conceivable that the process of 
elimination of mitochondria induced by both MMA(III) and iAs(III) may involve 
Parkin-mediated mitophagy. Hence, our study warrants future investigations to 








vi.v. Contribution of different sources of ROS induced by arsenic 
 There is significant evidence in the scientific literature indicating that 
arsenic exposure results in increased production of ROS in different cell types 
including Neuro-2a cells, β- pancreatic cells, human hepatocellular carcinoma 
HepG2 cells, and human breast and lung carcinoma cell lines [290,291]. 
However, little is known regarding the subcellular sources of ROS induced by 
arsenic compounds. In our study, MMA(III) induced a significant elevation of 
mitochondrial superoxide and hydrogen peroxide levels (Figure 4A-B). At 4 
hours post exposure to MMA(III), the levels of superoxide generated are similar 
to levels achieved in cells treated with the complex I inhibitor rotenone. iAs(III) 
treatment also induces a modest increase in mitochondrial superoxide 
production at 4 and 6 hours post treatment suggesting that MMA(III) is a more 
potent inducer of mitochondrial ROS in VSMCs.  
Although it is clear that mitochondrial superoxide induced by MMA(III) 
contributes to mitochondrial dysfunction in VSMCs (Figure 2 and 3), our data 
suggest that non-mitochondrial sources of hydrogen peroxide also contribute to 
mitochondrial dysfunction (Figure 8). While pretreating VSMCs with catalase 
was sufficient to reverse MMA(III)-mediated decreases in basal and maximal 





rescuing all aspects of mitochondrial function (e.g. maximal respiration) (Figure 
6B and D). Unexpectedly, although MnTBAP pretreatment partially rescued 
basal OCRs, it worsened the reduction in maximal OCRs induced by MMA(III) 
treatment (Figure 6D). Thus, treating VSMCs with catalase, but not MnTBAP, 
reversed the energy profile from a predominantly glycolytic to normal 
phenotype as untreated cells (Figure 6A).  
It is worth noting that mitochondria may be the primary target of different 
arsenic compounds, but are not the sole contributors to ROS production. Indeed, 
the endoplasmic reticulum and peroxisomes have a greater capacity to produce 
ROS than mitochondria in liver tissue [292]. Additionally, arsenic has been 
shown to induce ROS by deregulating NADH/NADPH oxidase activity in 
VSMCs and endothelial cells, leading to an increase in superoxide and hydrogen 
peroxide levels [246], and arsenic-induced ROS couples with nitric oxide (NO) to 
produce peroxynitrite [253]. Thus, in addition to mitochondrially derived ROS, 
non-mitochondrial ROS induced by iAs(III) and MMA(III) likely elicit oxidative 
damage in other organelles in our experimental model. Hence, our work 
warrants future studies that identify all mitochondrial sources of ROS, and verify 
non-mitochondrial sources of ROS induced by MMA(III) that contribute to 





A major limitation of the present study is the use of an immortal cell line 
for linking pathological effects of arsenic toxicity with chronic effects of arsenic 
toxicity as related to toxicity in humans. However, the benefits of using the 
immortalized A7r5 cell line as an in vitro model of arsenic toxicity in smooth 
muscle cells are to unveil mechanisms of arsenic toxicity in VSMCs using an 
acute dosing paradigm include robust consistency, reproducibility of results, a 
high availability of biomass to do in vitro studies in lieu of primary cells which 
precludes the need to sacrifice animals, and a lack of phenotypic change due to 
sub-selection in passaging. Thus, given the mitochondrial-toxic effects of 
MMA(III) as shown in this report, our studies warrant future experiments that 
analyze the toxic effects of MMA(III) vs. iAs(III) in a chronic cell culture model of 
arsenic exposure to elucidate the role that MMA(III) plays in VSMC toxicity.  
 
vii. Conclusion 
In summary, our study is the first to show that MMA(III) can induce 
concomitant mitochondrial dysfunction, mitochondrial ROS and metabolic 
alterations in VSMCs. Our study suggests that MMA(III) elicits mitochondrial 
and non-mitochondrial ROS to promote early mitochondrial dysfunction by 





morphology resulting in a pathology that precedes the loss of mitochondrial 
content. Our work warrants future studies that probe for molecular mechanisms 
by which MMA(III) selectively targets mitochondria and elicits the release of 
superoxide in VSMCs. 
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Figure S1. Identity and purity of MMA(III) as verified by 1H-NMR. 
5.8mg CH3AsIIII2 was dissolved in 0.7mL (CDCl3 + 0.05% TMS) and the 1H-NMR experiment was 
conducted on a Varian 400-MR liquid state NMR. The NMR spectrum indicates the expected shift 
for CH3AsIIII2 at =3.1 ppm (Styblo et al, 1997) and the absence of a proton shift at =2.0 ppm, 
demonstrating the absence of any contaminating dimethylated product (DMA(III)). TMS: 










Figure S2. Effects of iodide on cell viability and mitochondrial respiration. 
A) A7r5 cells seeded in 96 well plates were treated with increasing concentrations of iodide as 
found in 0.5μM or 1μM MMA(III) or with water alone (control, Ctrl) for 24 h. Cell viability was 
assessed by using the MTS assay. The bar graph shows that increasing concentrations of iodide 
does not significantly affect cell viability. Means ± SD, n=8 wells per condition). No significant 
differences found by One-Way ANOVA for any time points, followed by Fisher’s LSD. B) 
Representative OCR trace of A7r5 cells treated with either vehicle control (water) or with 
increasing concentrations of iodide for two h. prior to being sequentially exposed to oligomycin, 
FCCP and antimycin-A/rotenone to measure baseline, ATP-linked, maximal, and non-
mitochondrial respiration respectively. The OCR trace shows that iodide does not significantly 




























Figure S3. Cell density counts verify the 24hour- LC50s observed by MTS and 
Trypan Blue assays. Quantification of cell viability of A7r5 cells treated with increasing 
concentrations of either iAs(III) (A) or of MMA(III) (B) as assessed by performing cell counts with 
a Coulter counter. The mean cell count per dose of arsenical was plotted as the logarithmic line 
graph and the LC50s at 24 h. (0.5μM for MMA(III) and 10μM for iAs(III)) are indicated by dashed 



















Figure S4. A 6 hour treatment of cells with 0.5μM or 1μM MMA(III) and 1μM or 
10μM iAs(III) does not significantly promote cell death. 
A7r5 cells were treated with 1μM concentrations of MMA(III) or iAs(III) (Upper left graph) or 
10μM iAs (Lower left graph) for 6 h. prior to fixation with paraformaldehyde and counterstaining 
with DAPI to visualize nuclei. The average number of DAPI-stained nuclei per epifluorescence 
micrograph was counted as an index of cell density. The percentage of cells containing 
fragmented or pyknotic nuclei per epifluorescence micrograph was counted as an index of active 
cell death. The data shows that a 5 hour treatment of cells with arsenicals does not significantly 
induce cell death or reduce cell number ruling out that the pathological/cytotoxic effects of 
MMA(III) on mitochondrial content and morphology (Figure 5) is a result of cytotoxicity.  (NS: 
not significant vs. untreated, Means, ±SD, n=500-600 cells/condition). One-way ANOVA, Tukey’s 
HSD.  Data was compiled from three independent experiments for 1μM concentrations, and data 










































































Figure S5.  Other representative oxygraph traces showing that MMA(III) but not 
iAs(III) reduces OCRs in A7r5 cells. 
Representative mitochondrial respiration profiles (oxygraph) of two other representative 
experiments showing that 0.5 μM MMA (III) (top profile), but not 10μM iAs(III) (bottom profile) 
progressively decreases OCRs and this effect plateaus by 100 minutes of treatment. In addition, 









Figure S6.  MMA(III) but not MMA(V) decreases the OCRs in A7r5 cells. 
Quantification of the average OCRs in A7r5 cells treated with a 2 h. dose of the indicated 
compounds. A decrease in baseline mitochondrial respiration was observed in cells treated with 
MMA(III) but not MMA(V), (*:p<.05 vs. 1μM MMA(V)), Means ± SD, n=3-4 wells per condition). 





















Figure S7.  iAs(III) can induce a significant increase in mitochondrial superoxide 
levels in A7r5 cells at 6 hours of treatment. Quantification of the average intensity of 
MitoSOX fluorescence in untreated cells or in cells exposed for 6 h. with 10μM iAs. A significant 
elevation in MitoSOX intensity was detected among cells treated for 6 h. with 10μM iAs, (*:p<.05 
vs. untreated, Means ± SD, n=26 cells/condition). Independent t-test. Data is representative for 





















        
 
 
Figure S8 iAs treatment induces a decrease in mitochondrial content in A7r5 
cells at 5 h of treatment. Imaged-based quantification of mitochondrial content as 
determined by measuring the percentage of the cytosolic area occupied by fluorescently labeled 
mitochondrial specific pixels in cells treated for 5 h. with iAs and immunolabeled for 
mitochondrial marker TOM20. A significant decrease in mitochondrial content was detected 
among cells exposed to 10μM iAs(III) vs. untreated cells (*:p<0.05 vs. untreated, Means, ±SD, n=26 










Figure S9. iAs fragments mitochondria in A7r5 cells at 6 hours of treatment. 
Mitochondrial interconnectivity, defined as the ratio of the average area to the perimeter of 
mitochondria per cell (Dagda et al. 2009), experienced a significant decrease among cells treated 
for 6 h. with an LC50 of iAs(III) vs. untreated cells (*:p<0.05, Means, ±SD, n=27-28 cells/condition). 














Chapter 5. Summary, conclusions and recommendations 
 
 This dissertation, methodologically structured as a review of published 
data, a secondary data analysis, and an original study of experimental data, 
contributes to the literature on arsenic and cardiovascular disease. Chapter 2 
identifies 22 compounds with antioxidant properties that are effective against 
arsenic induced mito-toxic effects in cardiovascular tissue and cells. These data 
suggest that antioxidants have the potential to improve the cardiovascular health 
of millions of people chronically exposed to elevated arsenic concentrations 
through contaminated water supplies or lifesaving cancer treatment. We 
recommend future studies comparing antioxidant ability to prevent arsenic 
induced mito-toxic effects in H9c3 cardiomyocytes and vascular smooth muscle 
cells.  
 Additionally, we recommend developing mitochondrially targeted 
nanoformulation for improved antioxidant pharmacokinetics for use in vivo and 
in vitro. Although substantial preliminary research is necessary, we suggest that 
antioxidants have a potential for pharmaceutical development into products to 
counteract arsenic-induced cardiovascular toxicity in a real-world context.   
 Chapter 3 is the first study to examine urine arsenic methylation with 





between arsenic methylation capacity and metabolic syndrome women with 
normal BMI in a country where inorganic arsenic is regulated at 10 ppb. This 
suggests that current MCL should be evaluated in terms of cardiovascular 
outcomes using a model that establishes causality.  
In chapter 4 we demonstrate increased toxicity of the arsenic metabolite 
MMA(III) relative to iAs(III) in VSMCs.  We report that MMA(III) promotes 
mitochondrial dysfunction and oxidative stress in VSMCs, and that these deficits 
stem from the generation of mitochondrial and non-mitochondrial ROS 
following exposure to MMA(III). This work warrants future studies that probe 
for molecular mechanisms by which MMA(III) selectively targets mitochondria 
and elicits the release of superoxide in VSMCs. 
  Increased toxicity of methylated arsenic species (demonstrated in chapter 
4) support the outcome that increased arsenic methylation is associated with 
increased odds of metabolic syndrome (demonstrated in chapter 3), this may be 
due to the elevated presence of toxic methylated species that result from 
increased arsenic methylation. These data supports the concept that increased 
arsenic methylation increases the concentrations of toxic methylated arsenic 
species in the body, resulting in increased rates of ROS production, and 





amelioration of arsenic-induced cardiovascular dysfunction) provide suggestions 
for research on the prevention of arsenic-induced cardiovascular dysfunction.  
 It is worth noting that in chapter 4 we found that MMA(III) induced 
apoptosis, while iAs(III) primarily induced necrosis [57]. This finding is 
supported by a variety of other studies, however, our literature review (chapter 
2) includes reports that iAs(III) induces both apoptosis and necrosis. In addition, 
in chapter 4, we report that in a study conducted by Naranmandura et al. (2011) 
MMA(III), but not iAs(III) selectively targeted and inhibited mitochondrial 
complexes II and IV in isolated mitochondria from rat liver [250], however, 
chapter 2 included two studies that reported a decreased activity at 
mitochondrial complexes I, III, and IV that was induced with iAs(III) [122]  and 2 
studies that reported decreased activity at mitochondrial complex II that was 
induced with iAs(III) [122]. We believe these are examples of the varying effects 
of arsenic that depend on dose and duration of exposure as well as cell/tissue 
type. These apparent contradictions highlight the need for additional study, 
given that the effects of arsenic are often non-linear.  
 In light of evidence that trivalent arsenic species are selectively toxic to 
mitochondria, and that arsenic biotransformation is mediated by methylation 





genetic polymorphisms on arsenic metabolism in relation to pre- and post-
clinical cardiovascular disease status. 
 Improved knowledge of genetic polymorphisms that contribute to 
methylation capacity, namely, AS3MT and GST, could play a critical role in 
understanding the relationship between arsenic toxicity, oxidative stress, and 
cardiovascular disease /metabolic syndrome. Therefore, we suggest that future 
studies investigate the role of arsenic exposure and genetic polymorphisms that 
contribute to arsenic methylation capacity on cardiovascular disease outcomes 
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